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Altered metabolism is a well-defined characteristic of established cancers. 
Metabolic changes have been observed in various pathways, including glycolysis, 
oxidative phosphorylation, lipid metabolism and amino acid metabolism. Alterations 
can also be seen in cancer cell mitochondria, where many of these metabolic 
processes take place. Mitochondrial fission above normal levels has been shown to 
be important for the proliferation of transformed cells. While these phenotypes are 
described in established cancers, their role in tumour initiation and development is 
less well understood. The aim of this project is to begin to describe the metabolic 
phenotype of developing pre-neoplastic cells (PNCs) and investigate how metabolic 
adaptations may act synergistically with host inflammatory responses to regulate the 
developing tumour microenvironment at the very earliest stages of tumour initiation. 
Recently, the zebrafish (D. rerio) has become an important and dynamic 
model for in vivo investigations. Our group has used the genetic tractability and in 
vivo imaging potential of zebrafish to develop a novel model in which tumour 
development can be monitored in real time. This model allows for precise spatial and 
temporal induction of epithelial cellular transformation in larval zebrafish, giving rise 
to mosaic PNCs which can be monitored in vivo as they develop over time. Early work 
for this project involved characterisation of this model under the control of the 
superficial skin epithelial layer specific keratin 4 promoter driven human HRASG12V 
induced PNC initiation.  
The project then began to define the metabolic phenotype for human 
HRASG12V driven PNCs at the earliest stages of development. Data reveal that PNCs 
acquire a hyper-fragmented mitochondrial phenotype, which appears to be 
associated with altered mitochondrial function and enhanced proliferative capacity. 
Interestingly, while PNC bearing embryos display enhanced glycolytic flux, PNCs 
themselves do not show such alterations in glycolytic intermediates or end-products. 
This suggests that complex metabolic adaptations are taking place at early stages of 
PNC development and that broad spectrum, unbiased approaches are required to 
fully understand the complexity of metabolic adaptations in PNCs.   
 ii 
Here, I present data which point to an altered metabolic phenotype in PNCs 
during tumour initiation and development. These findings, as well as a number of 
new tools and techniques developed during the project, will help to enhance our 
understanding of cancer initiation and development and provides a basis for further 









































Cancer is a progressive disease that affects millions worldwide each year. 
While our understanding of cancer has vastly increased in recent times, our 
knowledge of the earliest stages of cancer development remains relatively limited. 
Metabolism is the complex process by which cells in the body break down various 
energy inputs, such as sugar, protein and fat in the food we eat, to generate the 
energy and building blocks they need to grow. Research has shown that these 
processes change in cancer cells, though our understanding of when and how these 
changes occur remains relatively limited. The aim of this project is to identify when 
and how changes to metabolic processes occur at the very earliest stages of cancer 
development.  
In recent times, the zebrafish has become an important model for studies of 
various human diseases. These freshwater fish are easily genetically engineered and, 
as they are transparent, can be used for monitoring cells interacting in a realistic 
environment as they grow. Our group has developed a new zebrafish model which 
allows monitoring and manipulation of the development of cancer from very early 
stages.  
The primary aim of this project was to identify changes to the complex 
metabolic processes that occur at early stages of cancer development. A number of 
the chemical reactions of metabolism take place in a specific part of the cell called 
the mitochondria, which is often referred to as the powerhouse of the cell. Data 
shows that early cancer cells have altered the shape and function of mitochondria, 
which in turn alters the ability of these early cancer cells to grow. Complex changes 
have also been detected in specific metabolic processes occurring very early in cancer 
development, suggesting that alterations to these chemical reactions could be an 
important event for cancer development.   
Here, I present data which begins to define how metabolism is altered during 
the earliest stages of cancer development and provide a basis for further studies of 
cancer cell metabolism. 
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1.1 Cancer: The Basics 
Cancer is a group of diseases characterised by uncontrolled proliferation, 
leading to metastasis of abnormal cells to distant organs of the body. The 
development of cancer is a multi-step process referred to as carcinogenesis and 
results from the accumulation of genetic mutations. Initially, mutations arise in a 
single cell, giving that cell a proliferative and survival advantage. The cell proceeds to 
proliferate in an uncontrolled manner, acquiring additional genetic mutations over 
time and ultimately giving rise to a heterogenous mass of cells called a tumour (Figure 
1.1). As cellular proliferation and genetic mutation continues tumours are infiltrated 
by cells of other types, including inflammatory cells, while some cancer cells may 
acquire invasive properties and leave the tumour mass, disseminating and 
metastasizing to distant areas of the body [1].   
While the mechanistic cause of all cancers is known to be genetic mutation, a 
variety of risk factors are known to play a role in initiating these genetic lesions. Only 
a small proportion of cancers are strongly hereditary [2], with the vast majority 
caused by acquired mutations. There are many risk factors associated with cancer 
development. As disease results from accumulation of mutations over time, the risk 
of developing cancer increases with age, with 36% of all newly diagnosed patients in 
the UK over the age of 75 [3] and 87% of all newly diagnosed patients in the United 
States over the age of 50 [2]. Other risk factors include smoking, excessive sun 
exposure, physical inactivity, obesity and poor diet. Some infectious agents are also 
associated with cancers, such as the human papillomavirus (HPV) associated with 
cervical cancer, hepatitis B virus (HBV) associated with liver cancer and Helicobacter 
pylori infection is associated with gastric cancers [4]. In fact, it is estimated that 
approximately 40% of cancers in both the UK [5] and the United States [2] are 
potentially preventable, should risk factors be controlled.  
Cancers can arise in many organs of the body, but some tissues are more 




Figure 1.1: Cancer 
development is a multi-step 
process. Cancer initiation 
begins when a single cell 
acquires genetic mutation 
leading to cellular 
transformation (grey cell). 
This cell gains a proliferative 
and survival advantage over 
its neighbours and begins to 
proliferate excessively. As 
transformed cells continue to 
proliferate they acquire 
further mutations, ultimately 
leading to a heterogenous 
mass of cells called a tumour. 
Vascularisation by endothelial 
cells and infiltration by 
inflammatory cells aids 
tumour growth and helps to 
establish metastatic disease.   
 3 
males and females [3], cancers of epithelial origin are most common in both sexes, 
accounting for approximately 80% of total human cancer cases [6][7]. Cancer survival 
varies depending on the combination of genetic mutations and tissue type involved. 
Cancer outlook is often assessed by the five-year survival rate, this reaching as high 
as 90% for breast cancer [2] and 98% for testicular cancer [8] but remains at just 1% 
for pancreatic cancer [8]. These figures highlight the diverse complexity associated 
with cancer and the necessity for continued research. Early detection is vital for 
increasing survival rates [9]. Screening programs have been developed for a number 
of cancer types, including breast [10], cervical [11] and bowel cancers [12], 
meanwhile cancer vaccines have been developed to protect against cancers caused 
by some infectious agents [13]. However, early detection of cancer remains a 
challenge as our understanding of the very earliest stages of initiation and 
development remains relatively limited [9]. Typically, by the time patients present to 
the clinic the tumour is already well established. While scientific research has 
excelled in recent times, issues detecting and monitoring very early oncogenic 
processes in vivo persist.   
As genetic mutations accumulate, cells acquire a number of phenotypic 
characteristics which confer a proliferative and survival advantage on mutated cells. 
These features were famously described as “The Hallmarks of Cancer” in a seminal 
paper by Hanahan and Weinberg [14], who then updated their analysis in 2011 to 
reflect ongoing research by including additional “Enabling Characteristics” [15], and 
these are now commonly discussed under the same title as the original features. The 
phenotypic hallmarks of cancer described are “evading growth suppressors, 
activating invasion and metastasis, enabling replicative immortality, inducing 
angiogenesis, resisting cell death, sustaining proliferative signalling, deregulating 
cellular energetics, evading immune destruction, tumour promoting inflammation 
and genome instability and mutation” [14][15] (Figure 1.2). Considerable research 
has been completed on each of these features and work continues in an effort to 
further our understanding of cancer and develop effective therapies. Research has 
revealed the sheer complexity of cancer development and progression, with these 
 4 
hallmarks of cancer working both independently and synergistically to enable 
disease. While it is known that these features are present and necessary in 
established tumours, when they arise and how they contribute to the early stages of 






Figure 1.2: The Hallmarks of Cancer. Established cancers have a number of 
defining features that were famously summarised as “The Hallmarks of Cancer” 
by Hanahan and Weinberg. These features aid tumour growth and help establish 
metastatic disease. Figure adapted from [15]  
 5 
1.2 Cancer Initiation and Development 
The multi-stage process of cancer development is initiated when a genetic 
lesion arises in a cell and is not sufficiently repaired. Cancer-causing mutations 
generally arise in genes that control processes essential for cellular homeostasis, such 
as DNA repair, the cell cycle, proliferation and cell death pathways [1]. Some genetic 
mutations are commonly seen in a variety of cancers, while others are characteristic 
to certain tissues. For instance, the cell cycle regulator TP53 is mutated in many 
cancer types, but mutations in the receptor tyrosine kinase HER-2 gene are 
characteristic of breast cancer and are seen in over 25% of cases [7].  
There are two classes of commonly mutated genes in cancer; oncogenes and 
tumour suppressor genes. Oncogenes typically control pro-tumourigenic processes 
such as cell growth and proliferation, with activating gain-of-function mutations 
leading to constitutive activation of downstream signalling processes. There are over 
60 known oncogenes including RAS, c-MYC, v-SRC and HER-2 [1]. Tumour suppressor 
genes govern anti-tumourigenic functions such as cellular repair, growth and 
proliferation inhibition and cell death; processes which are often down-regulated due 
to loss-of-function mutations. Common examples of tumour suppressors include 
TP53, Rb and APC [1]. The examples provided here represent prototypical, well 
defined cancer-causing genes and while there are a great number of oncogenes and 
tumour suppressor genes [16], the functions they control generally converge to 
regulate a much smaller number of key pathways within a cell [17]. These pathways 
include the Myc, PI3K, Ras, Notch and Hippo pathways, all of which are frequently 
altered in cancer and have been shown to play vital roles in regulation of the cell 
cycle, apoptosis, growth and proliferation [18]. Due to the importance of these genes 
in regulating cancer initiation processes, they are often referred to as cancer “driver 
genes” [16].  
It has been known for a long time that cancers develop from a single cell which 
expands clonally to generate a heterogenous population with mutations 
accumulating over time [19]. Mutation in one of the driver genes is insufficient to 
cause cancer. In fact, up to seven independent genetic mutations are thought to be 
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required for progression to metastatic disease [20][21]. Mutation events initiate pre-
neoplastic processes such as enhanced proliferation and evasion of growth controls, 
conferring a selective advantage on the mutant cell. Acquisition of subsequent 
mutations is coupled with emergence of further features of tumourigenesis and 
ultimately leads to the establishment of a tumour [19]. The specific mechanisms of 
tumour development and order of hallmark acquisition varies depending on the 
combination of genetic mutations and tissue type involved. Consequently, our 
knowledge of the very early interactions of oncogenesis following spontaneous 
cellular transformation in vivo remains relatively limited. Intensive research on how 
each of the oncogenes and tumour suppressor genes, and the pathways they control, 
contribute to oncogenic processes, both independently and synergistically, has vastly 
enhanced our understanding. Recent advances in lineage tracing confirms that clonal 
expansion of mutated cells leads to tumour formation and gives indications of how 
cellular transformation occurs in situ [22][23]. However, difficulty detecting these 
very early stages of cellular transformation in vivo remains a limiting factor for full 
elucidation of cancer initiation processes.     
Transformed cells continue to acquire genetic mutations as a tumour 
develops leading to considerable heterogeneity among tumour cells. Heterogeneity 
increases further as the developing tumour is infiltrated by other cell types [24]. 
Interactions between transformed cells and their developing microenvironment have 
been shown to be vital for tumour progression [25][26]. Developing tumours release 
a variety of factors that alter the surrounding extracellular matrix (ECM) to promote 
further development [27]. Fibroblasts and endothelial cells have active roles during 
tumour initiation, providing pro-tumourigenic signals and forming new blood vessels 
to supply the growing tumour with oxygen and nutrients [28]–[31]. Meanwhile, links 
between inflammatory cells and cancers have been proposed since the mid 19th 
century and have since been shown to be important for providing signalling 
molecules for a developing tumour (for further details see Section 1.7). Growth 
factors, MMPs, cytokine and chemokines are all produced by both the tumour cells 
and the cells of the developing tumour microenvironment to promote tumour 
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progression and help establish metastatic disease [26]. Again, the exact signalling 
molecules involved is dependent on tumour genotype and tissue involved, 
highlighting the complexity of cancer signalling.  
 
1.3 RAS Signalling and Its Role in Cancer 
The RAS family of proteins are a set of membrane-associated GTPases that act 
as molecular switches for several intracellular signalling pathways that regulate a 
wide variety of cellular functions. In humans, there are three RAS genes; HRAS, NRAS 
and KRAS which encode four protein isoforms [32].  
 The activation state of RAS is regulated by two classes of proteins called GEFs 
and GAPs, which determine the binding of GTP and GDP, respectively. RAS proteins 
are active when GTP is bound and inactive when GDP is bound [33][34]. The extent 
and duration of RAS activation has drastic downstream effects on cellular fate and 
function, so the balance of GEF and GAP activity is vital for regulation of cellular 
homeostasis [35].  
Given that it is a relatively simple molecule that merely cycles between GTP- 
and GDP-bound states, RAS controls a remarkable variety of cellular processes and is 
considered a focal point for signal transduction. Different RAS isoforms have different 
cellular function [36], but all are involved in signal transduction for pathways that 
control cell growth, proliferation, survival and differentiation [32]. The best described 
RAS interaction is with the MAPK pathway, where RAS acts as the first intracellular 
effector of the pathway by recruiting Raf-1 to the plasma membrane. Signal 
transduction ultimately leads to ERK activation and nuclear translocation causing 
activation of transcription factors that regulate a vast number of cellular processes 
including proliferation and the cell cycle [37]. While this may be the most established 
RAS signalling pathway, it is by no means the only. Other RAS effector pathways 
include the phosphoinositide 3-kinase (PI3K) pathway [38]–[40], phospholipase C𝜀 
pathway [41] and the RAS-related Ral protein pathway [42] (Figure 1.3), to name a 
few. This broad range of effector pathways  
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Figure 1.3 RAS 
effector signalling 
pathways RAS 
proteins have a 
number of effector 
signalling pathways 
that control a vast 
number of cellular 
processes. The best 
characterised is the 
MAPK pathway 
(green), which is 
important for 
proliferation and 
control of the cell 
cycle. Other effector 
pathways include the 
PI3K pathway (blue), 
the RAL protein 
pathway (orange) and 




mean RAS plays vital 
roles in regulation of 
proliferation, the cell 
cycle, apoptosis, gene 
expression, and cell 
migration.	
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means that RAS plays important regulatory roles in a vast number of processes, from 
proliferation and the cell cycle, to apoptosis and cell migration.     
The RAS genes are the most frequently mutated genes in human cancers [43], 
with approximately 20% of all human tumours showing activating RAS mutations 
[44]. RAS isoforms appear to show tissue variation, with some isoforms more likely 
to be mutated in certain tissues. KRAS mutations, the most common of the RAS 
mutations in cancer[45], are commonly seen in colorectal, lung and pancreatic 
cancers [45][46]. NRAS mutations are associated with haematological malignancies 
[45][47], while HRAS mutations frequently occur in skin and head and neck cancers 
[45][48]. Common oncogenic alterations are seen in the G12, G13 and Q61 residues 
of all isoforms [45]–[48], which retain the protein in the GTP-bound active state 
causing continuous activation of downstream effectors [32].  
Given the wide array of functions that are downstream of RAS, constitutive 
protein activation has significant impact on cellular function and results in several 
features characteristic of cancer cells [32]. RAS signalling has been shown to enhance 
proliferative capacity through a number of mechanisms, including driving cells into 
the cell cycle; upregulating growth factors including TGF-𝛼, HBEGF and AREG and 
enhancing expression of growth factor receptors [49]–[51]. Oncogenic RAS initiates 
pro-survival mechanisms by activating RAF and PI3K pathways to down-regulate pro-
apoptotic molecules such as BAK1 and BAD [52]–[54] and upregulate anti-apoptosis 
mediators [55][56]. RAS can also have non-cell-autonomous functions to influence 
cancer development. Expression of endothelial growth factors, including VEGF [57]–
[59], is enhanced to promote angiogenesis, increased expression of pro-
inflammatory cytokines, including IL-8, IL-6 and CXCL1, leads to inflammatory cell 
recruitment [60]–[63], while upregulation of MMPs promotes vascularisation and cell 
migration [64][59]. This vast array of cellular alterations places oncogenic RAS as a 
major signalling junction in a cell, with great potential to direct cellular 
transformation.  
As research continues to further our understanding of this oncogene and how 
its downstream effectors coordinate cancer initiation, development and progression, 
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a number of oncogenic RAS models have been developed. These include in vivo 
transgenic mouse and fish models, which allow in-depth studies of Ras oncogenes 
and the processes they control. In mice, RAS models have been used for decades as 
a leading system to help understand all stages of cancer development, progression, 
regression and response to treatment [65], by primarily expressing mutant forms of 
HRAS or KRAS to induce neoplasms in tissues including lung [66], pancreas [67], skin 
[68] and breast [69]. Meanwhile, zebrafish RAS systems have been developed to 
model melanoma [70], rhabdomyosarcoma [71] and pancreatic cancer [72], as well 
as inducible systems that can be used in different tissue types [73][74]. These in vivo 
models have greatly enhanced our understanding of oncogenic RAS signalling and, as 
they continue to evolve, allow targeted and specific studies of the role of RAS in 
tumourigenic processes.  
 
1.4 Glucose Metabolism 
Cellular metabolism involves a remarkably complex series of interconnected 
pathways that break down organic molecules to produce energy and metabolic 
intermediates for cellular processes. Broadly speaking, carbohydrates, fatty acids and 
amino acids are the primary fuel sources in a cell [7], and each of these are utilised in 
a variety of highly regulated mechanisms to ensure cellular homeostasis. 
Glucose is the central carbohydrate in cellular metabolism, acting both as a 
vital fuel source and a versatile supplier of a vast array of biosynthetic 
intermediates[75]. Within a cell, glucose can have four fates; storage as 
polysaccharides, synthesis of complex polysaccharides for structural functions, 
oxidation via the pentose phosphate pathway to generate nucleic acids, or oxidation 
via glycolysis to generate pyruvate for energy production [76]. Cells generate energy 
in the form of ATP via the complete oxidation of glucose to carbon dioxide and water 
via the glycolytic and oxidative phosphorylation pathways [76].   
The glycolytic pathway (Figure 1.4) is a series of chemical reactions that take 
place in the cytoplasm of a cell to breakdown a single glucose molecule into two 
three-carbon pyruvate molecules, with the concomitant production of ATP [77]. The  
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Figure 1.4: The Glycolytic 
Pathway. A single 
molecule of glucose is 
broken down into two 
molecules of pyruvate via 
the glycolytic pathway 
with the concomitant 
production of ATP. Early 
reactions of the pathway 
require energy input in 
the form of two ATPs 
(blue arrows), but later 
reactions generate four 
ATPs (orange arrows), 
resulting in net generation 
of two ATP molecules per 
molecule of glucose. The 
important regulatory 
steps of the pathway 
include conversion of 
glucose to glucose-6-
phosphate by hexokinase 
(blue star), conversion of 
fructose 6-phosphate to 
fructose 1,6-bisphosphate 
by PFK (orange star) and 
conversion of 
phosphoenolpyruvate to 
pyruvate by pyruvate 
kinase (yellow star). 
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pathway involves 10 tightly regulated enzymatic reactions (Figure 1.4), resulting in 
the net production of two ATP molecules and multiple biosynthetic intermediates. 
Glycolysis requires energy investment at the early stages, with ATP acting as a 
phosphoryl group donor for the conversion of glucose to glucose-6-phosphate and 
fructose-6-phosphate to fructose 1,6-bisphosphate (Figure 1.4, blue arrows). 
However, later stages of the pathway release four ATP molecules as two molecules 
of 1,3-bisphosphoglycerate are converted to two molecules of pyruvate (Figure 1.4, 
orange arrows), leading to the net production of two molecules of ATP per molecule 
of glucose [76]. The later reactions of glycolysis also involve the generation of two 
molecules of the co-enzyme NADH, which are subsequently utilised in the oxidative 
phosphorylation pathway (discussed below). Therefore, the overall equation for the 
glycolytic pathway under aerobic conditions is: [76]  
 
Glucose + 2 NAD+ + 2 ADP + 2 Pi  
®  2 Pyruvate + 2 NADH + 2 H+ + 2 ATP + 2 H2O 
 
In order to maintain homeostasis, the reactions of glycolysis are tightly 
regulated. While all of the reactions of the pathway are controlled, there are three 
regulation points of particular importance. Hexokinase irreversibly catalyses the 
conversion of glucose to glucose-6-phosphate as the first glycolytic reaction (Figure 
1.4, blue star). Hexokinase is inhibited by its product, glucose-6-phosphate. Should 
glucose-6-phosphate rise above equilibrium levels, inhibition of hexokinase will 
reduce production to allow the cell to return to homeostasis. [78] Arguably the most 
important regulatory step of the glycolytic pathway is the irreversible conversion of 
fructose-6-phosphate to fructose 1,6-bisphosphate by phosphofructokinase (PFK) 
(Figure 1.4, orange star) as it commits glucose utilisation to the glycolytic pathway. 
Given its importance, PFK has multiple regulatory sites. PFK is reversibly inhibited by 
ATP and citrate [79], allowing the pathway to remain responsive to cellular energy 
requirements. H+ ions inhibit PFK, preventing acidosis as a result of excessive lactate 
production in anaerobic conditions (see below). PFK is regulated by fructose 2,6-
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bisphosphate [80], a metabolic intermediate involved in the reciprocal regulation of 
glycolysis and gluconeogenesis. Finally, pyruvate kinase, which catalyses the 
conversion of phosphoenolpyruvate to pyruvate at the final stage of glycolysis (Figure 
1.4, yellow star), is inhibited by ATP, acetyl-CoA, fatty acids and certain amino acids 
[81]. This, again, ensures responsiveness to the energy requirements of the cell as 
glycolysis is inhibited when energy levels are sufficient.   
The glycolytic pathway generates two molecules of pyruvate per molecule of 
glucose. Under aerobic conditions, pyruvate is primarily converted to acetyl-CoA by 
pyruvate dehydrogenase (PDH) [82]. Acetyl-CoA then enters the citric acid cycle for 
further oxidation and ATP production (discussed below). However, if ATP levels are 
in excess, acetyl-CoA can be utilised for fatty acid or ketone body synthesis [83]. 
Under anaerobic conditions, pyruvate can be converted to lactate by lactate 
dehydrogenase (LDH) with concomitant regeneration of NAD+ to allow glycolysis to 
continue [84]. This is a reversible reaction and is an important metabolic process for 
varying oxygen conditions and energy requirements.  
In order to complete the breakdown of glucose into CO2 and H2O the pyruvate 
generated from glycolysis is converted to acetyl-CoA by PDH which then enters the 
citric acid cycle (Figure 1.5). This cycle, also known as the tricarboxylic acid cycle and 
the Krebs cycle, takes place in the mitochondria and is also used for the oxidation of 
acetyl-CoA from the breakdown of fatty acids and amino acids [76]. The eight stages 
of the citric acid cycle (Figure 1.5) result in the generation of three NADH and one 
FADH2 [85], which are subsequently re-oxidised by oxidative phosphorylation for 
energy production (discussed below). In addition to cellular energy production, the 
citric acid cycle is of central importance to provide pre-cursors for a variety of cellular 
pathways, including synthesis of fatty acids, amino acids and nucleotides as well as 
replenishing glucose by gluconeogenesis [76].  
The oxidation of glucose and other fuel sources that feed into the citric acid 
cycle to CO2 and H2O is completed by the oxidative phosphorylation pathway (Figure 
1.6), which is the process of ATP synthesis coupled to the oxidation of NADH  
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and FADH2 [76]. Transfer of electrons from NADH and FADH2 to oxygen occurs via a 
series of electron carriers in the mitochondrial inner membrane referred to as the 
electron transport chain (ETC). This chain consists of four large electron carriers, 
referred to as complex I – IV, linked by two smaller electron carriers [76][86]. The 
flow of electrons through this chain also results in the generation of a proton 
gradient, as H+ is pumped from the mitochondrial matrix across the mitochondrial 
inner membrane to the intermembrane space [87][88] (Figure 1.6). This proton 
gradient links electron transport to ATP synthesis. The protons in the intermembrane 
space flow back to the mitochondrial matrix through the ATP 
Figure 1.5: The Citric Acid Cycle. Pyruvate from glycolysis can be converted to acetyl-
CoA which enters the citric acid cycle for further oxidation. The eight steps of the 
citric acid cycle generate three NADH (orange arrows) and one FADH2 (yellow arrow) 
which are subsequently re-oxidised by oxidative phosphorylation.  
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synthase complex in the mitochondrial inner membrane, which drives the synthesis 
of ATP [89]. This process results in the generation of three ATP molecules per 
molecule of NADH and two ATP molecules per molecule of FADH2 [76].  
The flow of electrons through the ETC is also associated with the generation 
of reactive oxygen species (ROS). Electron transfer through complex I and complex III 
involves a partially reduced ubiquinone radical (•Q-) which can donate an electron to 
molecular oxygen (O2) to generate the superoxide free radical (•O2-) [90]. Up to 4% of 
oxygen used for respiration forms superoxide radicals [76] and this can be damaging 
to the cell if not dealt with appropriately. Cells have various mechanisms for ROS 
detoxification, including the conversion of superoxide to hydrogen peroxide via the 
action of superoxide dismutases (SODs), which is subsequently reduced to H2O via 
glutathione peroxidase [91].  
Figure 1.6: Oxidative Phosphorylation. Electrons flow from NADH and FADH2 
through the four complexes of the electron transport chain to form H2O which 
generates a proton gradient across the mitochondrial inner membrane. 
Protons flow back into the mitochondrial matrix via the ATP synthase complex 
with concomitant generation of ATP. Figure Adapted from [88] 
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The complete oxidation of glucose via glycolysis, the citric acid cycle and 
oxidative phosphorylation to CO2 and H2O generates approximately 30 - 32 molecules 
of ATP per molecule of glucose, depending on cytosolic NADH shuttle systems [76]. 
Additionally, numerous important biosynthetic intermediates are generated. By 
comparison, under anaerobic conditions just two ATP molecules per molecule of 
glucose are generated via glycolysis [76]. Therefore, complete oxidation of glucose 
via cellular respiration is vital for providing sufficient energy and biosynthetic 
precursors to meet cellular requirements.  
Given the central importance of these metabolic processes in a cell, 
perturbation of pathways can be harmful. A myriad of human diseases are now 
recognised to include metabolic components, including type 2 diabetes, obesity and 
cardiovascular disease, in addition to cancers, as discussed below.   
 
1.5 Metabolic Alterations in Cancer. 
In 1956 Otto Warburg put forward a model of aerobic glycolysis in 
transformed cells [92]. Since termed “The Warburg Effect”, this model proposes a 
metabolic switch from oxidative phosphorylation to glycolysis for ATP production, 
even in the absence of a hypoxic environment, leading to increased uptake of glucose 
and excessive lactate production. This led Warburg to conclude that cancers arise as 
a result of mitochondrial dysfunction. While this conclusion has since been disproven, 
many aspects of Warburg’s original theory have been verified and “The Warburg 
Effect” is now a well-established feature of cancers [93].  
In the late 20th century interest in cancer metabolism faded. However, a 
recent resurgence and realisation of its central role in cancer has led to an explosion 
of research into the metabolic features of cancer and how they could potentially be 
targeted for cancer treatment. Increased glycolytic metabolism in established 
tumours has been co-opted for diagnosis and monitoring purposes. Positron 
emission tomography (PET) involves uptake of 18fluorodeoxyglucose (FdG), a glucose 
analogue used as a tracer and allows quantifiable imaging of tumours in patients [94]. 
This technique has permitted verification of enhanced glucose uptake in human 
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tumours and enabled both diagnosis and monitoring of tumour development and 
response to treatment [95]–[99]. It has repeatedly been reported that increased 
glucose uptake correlates with increased aggressiveness and metastasis and is 
associated with poor prognosis for patients [100]–[103]. It is now accepted that 
cancer cells alter glucose utilisation by channelling pyruvate towards lactate 
production both as a response to hypoxia as the tumour develops and as a 
mechanism to generate biosynthetic intermediates to fuel proliferation [104], as 
discussed further below. Also, it is now recognised that The Warburg Effect is not the 
only means of metabolic alteration in cancers. Change is also seen in a number of 
other metabolic pathways including the citric acid cycle, oxidative phosphorylation, 
the pentose phosphate pathway, glutaminolysis and 𝛽-oxidation of fatty acids [105]. 
Functional alterations in these pathways are commonly the result of a genetic 
mutation in vital enzymes, leading to altered enzyme activity. Oncogenic processes, 
including oncogene and/or tumour suppressor gene activation, have been shown to 
alter activity of hexokinase [106]–[108], pyruvate kinase [109], pyruvate 
dehydrogenase [110], lactate dehydrogenase [111][112], fumarate hydratase [113], 
succinate dehydrogenase [114] and isocitrate dehydrogenase 1 and 2 [115]–[119] in 
various contexts leading to dysregulation of normal metabolic processes. These 
changes can manifest in a variety of ways which often converge to provide increased 
energy and biosynthetic intermediates for cell growth and ultimately aid tumour 
progression [105][118]. Downstream of these changes, acidosis, hypoxia, increased 
reactive oxygen species (ROS) and altered metabolic end-products are all features 
that arise in the tumour microenvironment [120], often in conjunction with other 
hallmarks of cancer [14][15]. These features can have profound effects on 
surrounding cells, from decreasing survival potential to allow the tumour cells to 
thrive, to changing cellular signalling to aid tumour growth. 
The purpose of metabolic switching was not understood for some time. 
Aerobic glycolysis is approximately 18-fold less efficient at ATP production than 
oxidative respiration [15]. Furthermore, metabolic pathways are intrinsically linked 
to maintain adequate supply of metabolic intermediates by a process called 
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anaplerosis. Disruption to these processes alters flux between these pathways and 
leads to metabolic imbalance and increased ROS production. However, while less 
efficient for energy production, the metabolic alterations seen in cancers are highly 
efficient for generating biosynthetic intermediates [121]. For example, altered 
regulation of hexokinase funnels glucose-6-phosphate into the pentose phosphate 
pathway for generation of ribose-5-phosphate, required for the synthesis of nucleic 
acids for cellular proliferation [76]. This increased generation of biosynthetic 
intermediates allows for the highly increased growth, proliferation and survival of 
tumour cells and drives tumour progression. While tumour cells are required to 
increase consumption of fuels such as glucose and glutamate to sustain these 
processes [122], they also generate sufficient energy to survive and drive increased 
proliferative processes, despite the reduced efficiency. 
As previously mentioned, oncogenic RAS can alter cellular metabolism in 
cancer cells. Through the upregulation of HIF-1𝛼 via MAPK-PI3K-mTOR signalling, RAS 
can stimulate the metabolic switch to aerobic glycolysis and enhance glucose uptake 
by upregulating expression of glucose transporters [123]–[125]. RAS also upregulates 
expression of glycolytic enzymes including hexokinase and lactate dehydrogenase 
[126][32]. Therefore, RAS signalling drives the cell towards glycolytic metabolism and 
contributes to the metabolic signature that is characteristic of established cancer 
cells.  
While our knowledge of altered metabolism in cancer has vastly increased as 
a result of the recent resurgence in attention, the complexity of cancer mechanisms 
intertwined with metabolic intricacies still leaves many unanswered questions. It 
remains to be determined how and why some of these changes occur and 
mechanisms of how they contribute to tumour progression remain poorly 
understood. Further insights into when these features arise during tumour 
development and how they interact with tumourigenic processes could enhance our 
understanding of established tumours and provide potential targets for cancer 
prevention and/or therapy.   
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1.6 Mitochondrial Dynamics in Health and Disease 
Mitochondria are double-membraned cellular organelles that are specialised 
for energy production [127] (Figure 1.7). The smooth outer mitochondrial membrane 
encases the organelle and is freely permeable to small molecules and ions. The inner 
mitochondrial membrane forms extensive convolutions called cristae which hold the 
four electron carriers of the electron transport chain and the ATP synthase complex 
for ATP production by oxidative phosphorylation. These cristae provide a large 
surface area on which oxidative phosphorylation can occur and the degree of 
convolution is linked to the bioenergetic requirements of the tissue. The 
mitochondrial matrix encased within the inner membrane is the site of numerous 
metabolic reactions including the citric acid cycle, 𝛽-oxidation of fatty acids and 
amino acid oxidation [76]. Given this vital role for generation of cellular energy, the 
mitochondria are often referred to as “The Powerhouse of the Cell”. However, in 
addition to energy generation, mitochondria also have important functions in calcium 
homeostasis, regulation of the cell cycle, regulation of apoptosis and control of ROS 
signalling [128]–[130]. Mitochondria also contain their own genome, referred to as 
mtDNA, which primarily encodes components of the respiratory network [131].  
Within a cell, mitochondria form dynamic networks that are in constant flux 
depending on the requirements of the cell. This mitochondrial network undergoes 
continuous cycles of fusion and fission (Figure 1.8) that are inextricably linked to 
functional requirements [132][133]. These cycles are vital for maintenance of a 
healthy mitochondrial population in the cell [132] and perturbation of this cycle can 
lead to cellular dysfunction and disease. Mitochondrial fusion is associated with 
increased oxidative phosphorylation, mtDNA stability and sufficient distribution of 
mtDNA among the mitochondrial network in a cell [134]–[136]. Meanwhile, fission is 
associated with organelle biogenesis and clearance of damaged mitochondrial 
fragments by mitophagy [137][138]. Mitochondrial morphology alters with the cell 
cycle. Mitochondria are highly inter-connected at 
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early stages of the cell cycle to ensure sufficient energy production for proliferative 
processes, as fused mitochondria are associated with increased oxidative 
phosphorylation and ATP production. However, fission increases at later stages of the 
cell cycle to ensure equal distribution of mitochondria to daughter cells [139]–[141]. 
Fragmentation is also associated with apoptosis, as fission is coordinated with 
mitochondrial outer membrane permeabilization to release matrix components into 
the cytoplasm to induce the programmed cell death cascade [142]. Mitochondrial 
ROS, generation of which increases with fragmentation [143], further contribute to 
induction of apoptosis. Differentiation and functional activation of a cell can also be 
governed by the fusion/fission state. For instance, the activation state of T 
lymphocytes is determined by mitochondrial dynamics [144] and mitochondrial 
dynamics have been shown to be indispensable during development [145]. 
 
Figure 1.7: Mitochondrial Structure. Schematic cross-sectional view of the 
structure of mitochondria. The organelle is surrounded by the smooth 
mitochondrial outer membrane. The mitochondrial inner membrane forms 
extensive folds called cristae to increase the surface area for oxidative 
phosphorylation, as the electron carriers of the electron transport chain and the 
ATP synthase complex are embedded in this membrane. The mitochondrial 
matrix is the site of numerous metabolic reactions including the citric acid cycle.   
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Given these important impacts on cellular function and fate, the cycle of 
mitochondrial fusion and fission is tightly regulated and is controlled by a number of 
GTPases highly conserved throughout evolution (Figure 1.8). Fusion of the outer  
membrane is facilitated by the action of mitofusin 1 and mitofusin 2, while Opa1 
facilitates fusion of the inner membrane [146]. Fission is orchestrated by the cytosolic 
protein Dnm1 (also called Drp1) which translocates to the mitochondrial outer 
membrane on activation and constricts the organelle, leading to division [147]. The 
mitochondrial membrane potential also has an important impact on the 
fusion/fission state of the mitochondria. Intact membrane potential is essential for 
Figure 1.8: Mitochondria undergo cycles of fusion and fission. Mitochondria 
form dynamic networks within a cell and are in a constant cycle of fusion and 
fission, determined by cellular requirements. Fused mitochondria are associated 
with mtDNA stability and increased ATP production by oxidative phosphorylation. 
Fragmented mitochondria are linked with biosynthesis, mitophagy, apoptosis and 
ROS production. These processes are regulated by a number of highly conserved 
GTPases, as shown in red. Figure adapted from [133] 
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mitofusin 1, mitofusin 2 and Opa1 function for fusion [148][149] and, therefore, 
reduction of membrane potential leads to fragmentation.  
Mitochondrial alterations are seen in a variety of diseases [150]. 
Mitochondrial fragmentation is a well-established feature of neurodegenerative 
disorders, particularly Parkinson’s disease where loss of PINK1 and parkin proteins 
leads to accumulation of Dnm1 [151]. Charcot-Marie-Tooth disease is a peripheral 
neuropathy caused by mitofusin 2 mutations [152], while Opa1 mutations are 
associated with optic atrophy [153]. Meanwhile, alterations to mitochondrial 
morphology are seen in cancer cells, with extensive fragmentation observed in cells 
from a number of cancer types [154]–[156]. This fragmentation is important for the 
proliferation and survival of cancer cells both in vitro and in vivo, as decreased 
proliferation and increased apoptosis is seen when fission is inhibited [155][156]. 
Fragmentation is linked to augmented metastatic potential, while decreased 
mitofusin 2 levels seen in some cancers promotes proliferation [156]. Recent work 
has shown that fragmentation in RAS driven transformed cells is dependent on post-
translational modification of Dnm1 by the MAPK pathway and inhibition of Dnm1 
function has a negative effect on tumour growth [157][158]. It is clear from these 
investigations that altered mitochondrial phenotype is an important feature of 
cancers, the importance of which is only just beginning to be understood. 
 
1.7 Cancer Associated Inflammation 
The links between cancer and inflammation have been recognised for many 
years. The association was first described in the mid 19th century when Virchow 
described the presence of leukocytes in tumours [159][160]. Since this initial finding, 
extensive investigations have uncovered a vital role in carcinogenesis for 
inflammatory cells, particularly in solid tumours.  
Cancer and inflammation are linked by a number of mechanisms. Firstly, sites 
of chronic inflammation are highly predisposed to cancer development and the 
presence of persistent inflammation has been shown to increase the risk of cancer 
development in numerous organs including the lung and GI tract [161]–[163]. 
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Secondly, analogous cellular signalling mechanisms are seen in both processes. For 
instance, RAS, NF-κB and STAT3 all show enhanced activity in both inflammatory and 
oncogenic environments [163]–[166]. Both intermediates and products of these 
inflammatory signalling pathways can act as growth factors and induce oncogenic 
transcription factor activation leading to down-stream effects that ultimately 
advance growth and survival of transformed cells [167]–[170]. Inflammatory 
mediators also propagate oncogenic signalling by activating additional pathways that 
control pro-tumourigenic processes including proliferation, angiogenesis and evasion 
of anti-tumourigenic inflammatory responses, as well as invasion and metastasis 
[160][163], with high concentrations of inflammatory cytokines found at the leading 
edge of invasive tumours [171][172].  
The central role of the tumour microenvironment in disease development and 
progression has recently been at the forefront of research. As a result, mechanisms 
which promote inflammatory cell infiltrates are more clearly understood and the 
function of recruited leukocytes are beginning to be elucidated. It is now recognised 
that numerous inflammatory cell types; including neutrophils, macrophages, 
dendritic cells, NK cells and T and B lymphocytes [160], [173]–[177]; are present in 
the tumourigenic niche. Signalling factors in the tumour microenvironment can 
polarise these recruited inflammatory cells towards both pro- and anti-tumourigenic 
functions, the balance of which determines the ultimate progression or rejection of 
the tumour. While anti-tumourigenic inflammatory responses have the capacity to 
completely eradicate transformed cells before they go on to develop a tumour, these 
responses are often dysfunctional as a result of manipulation of the CD8+ T cells and 
NK cells responsible for these functions by transformed cells [178]. Instead, 
oncogenic signalling primes the microenvironment for tumour promoting 
inflammatory responses, often establishing a chronic inflammatory environment 
[178]. For this reason, cancers are often referred to as “wounds that do not heal” 
[179]. 
Metabolic alterations in the tumour microenvironment can interact with 
inflammatory responses to influence tumour development and progression. As 
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mentioned above, oncogenic and inflammatory processes share numerous signalling 
processes, alterations to which can influence inflammatory responses. Metabolic end 
products are also known to interact with leukocytes. For instance, lactate, which is 
commonly found at high concentrations in tumours as a result of the Warburg Effect 
(See Section 1.5), can have inhibitory effects on cytotoxic T lymphocytes and dendritic 
cells, while localised acidosis as a result of lactate production can inhibit leukocyte 
migration [180]–[182]. Also, in a wounding scenario, Irg1l-dependent 𝛽-oxidation of 
fatty acids drives mitochondrial ROS production and leads to MMP-9 dependant 
macrophage recruitment [183]; a mechanism that could be similarly active in cancers. 
As our understanding of tumour metabolism continues to grow, the interactions 
between metabolic and inflammatory signalling processes and their effect on 
oncogenic processes will be further defined.   
One of the most frequent inflammatory infiltrates in tumours are tumour 
associated macrophages (TAMs), which are recognised to have disease-altering 
effects in the tumour microenvironment [174]. TAMs are highly plastic and can be 
polarised towards classical pro-inflammatory M1 or alternative anti-inflammatory 
M2 phenotypes, although such basic classification is disputed by macrophage 
biologists. TAMs are generally considered M2 in nature, as they are typically polarised 
to produce immunosuppressive mediators such as IL-10 and TGF-𝛽	[184]. In this way, 
TAMs manipulate the response of other inflammatory cells and contribute to 
suppression of anti-cancer responses. However, TAMs also contribute to tumour 
progression by generating pro-inflammatory cytokines including TNF-𝛼 and IL-6 and 
via non-cell-autonomous mechanisms such as production of VEGF to promote 
angiogenesis [185]–[187].  
Although less well characterised than TAMs, tumour associated neutrophils 
(TANs) are now appreciated to have important functions in the tumour 
microenvironment. Similar to other inflammatory cells in the vicinity of developing 
cancers, polarising factors in the tumourigenic niche, including those produced by 
TAMS, determine neutrophil phenotype [188]. For example, IFN-𝛽 signalling prompts 
an anti-tumourigenic neutrophil phenotype [189], while TGF-𝛽 promotes a pro-
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tumourigenic neutrophil response [188]. The mechanisms by which TANs contribute 
to tumour progression are complex and multiple pro-tumourigenic mechanisms are 
thought to be simultaneously active. Inflammatory mediators produced by 
neutrophils contribute to various tumourigenic processes, including proliferation and 
survival [190]. Also, the granular nature of neutrophils provides ROS and nitric oxide 
species (NOS) [191] which drive DNA instability and activate proteolytic enzymes 
leading to DNA damage and breakdown of the ECM, thereby assisting tumour 
development and invasion.  
These inflammatory infiltrates are known to have important functions in the 
tumour microenvironment but mechanisms of recruitment at very early stage of 
cellular transformation and the consequential effect on pre-neoplastic cells are as yet 
undetermined. Research has shown that HRASG12V-transformed cells recruit 
leukocytes at very early stages of development in vivo and interactions with recruited 
neutrophils are important for pre-neoplastic cell growth [192][193]. However, the 
mechanisms that regulate these processes remain elusive. Greater understanding of 
these mechanisms could provide targets for therapeutic intervention for cancer 
prevention and/or treatment.    
 
1.8 The Zebrafish as a Model Organism for Cancer Biology 
Zebrafish (Danio rerio) are small, freshwater teleosts that are indigenous to 
the rivers of India, although now found all over the world. Zebrafish were first 
developed as a model organism for scientific investigations by Streisinger, et al, who 
developed a method to produce homozygous diploid clones [194]. For many years, 
the model was used almost exclusively in the field of developmental biology. In 
recent times, use of the zebrafish as a model organism has grown considerably and 
is now generally accepted as a valid and influential vertebrate model organism. 
Zebrafish models are utilised in a wide variety of research areas including cancer, 
neuroregeneration and inflammation, with numerous human diseases having been 
recapitulated for in vivo investigations using zebrafish models.  
 26 
As a model organism, the zebrafish has a number of advantages. Importantly, 
there are high levels of genetic conservation between human and zebrafish genomes. 
This permits investigation of genetic components of developmental and disease 
mechanisms and increases translational propensity. Zebrafish are also highly 
amenable to genetic alterations, which has led to the development of a number of 
well-characterised transgenic zebrafish lines and genetic disease models. Another 
key advantage is the optical translucency of embryonic and larval developmental 
stages [195][196]. This allows unprecedented access for manipulation and 
visualisation of cellular processes in vivo and in real time. Zebrafish females produce 
large numbers of externally fertilised eggs that develop ex utero [197]. This not only 
allows for ease of sample collection at required developmental stage, but also 
enables generation of larger data sets in a relatively short time period. Various 
additional advantages specific to the research question at hand also exist. For 
example, of interest to this project is the sequential development of the immune 
system. During development, innate inflammatory cells begin to appear at 
approximately 15 hours post fertilization (hpf). However, functional adaptive 
immune cells do not arise until after two weeks post fertilization [198][199]. 
Therefore, early larval studies provide a model to investigate innate inflammatory 
reactions without complications from adaptive immune signalling mechanisms.  
These advantageous features give rise to three major approaches to zebrafish 
research. The first of these is genetic manipulation for identification and 
characterisation of genes and the processes they govern. Early zebrafish work 
involved large-scale mutagenesis screens which induced random mutations with the 
chemical mutagen ethylnitrosourea (ENU) [200][201]. These large-scale forward 
genetic screens are simply assessed in zebrafish by phenotypic screening using 
optical microscopy. Genetic alterations can also be generated using reverse-genetics 
approaches including permanent gene inactivation via TILLING [202] and transient 
knockdown using morpholinos [203]. Finally, transgenic approaches using 
transposon-mediated transgenics [204] facilitates generation of a continually 
expanding catalogue of transgenic zebrafish lines. Implementation of these genetic 
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approaches, both individually and in combination, have been used to identify a great 
number of genes, characterise the processes they control and monitor alterations in 
disease states [196]. These approaches have also been used to develop genetic 
disease models for broader studies. These disease models are now commonly utilised 
for the second major pillar of zebrafish research; drug discovery. Efficient embryo 
production, rapid development and optical transparency place zebrafish in an ideal 
position as an in vivo vertebrate model for large-scale pharmacological drug screens 
for identification of lead compounds and preliminary pharmacodynamic 
investigations [205]. Recent technological advances in robotics have further 
enhanced productivity and small-molecule screens in zebrafish have led to the 
discovery of various classes of small molecules for further study in numerous disease 
settings [206]–[209]. The final major approach to zebrafish studies is in vivo imaging. 
Optical transparency of embryonic and larval developmental stages allows 
monitoring of cellular interactions in real time. Incorporation of in vivo imaging with 
genetic approaches discussed above allows monitoring and manipulation of disease 
processes and gives unprecedented access to cellular interactions in vivo.  
The use of the zebrafish as cancer model was proposed as early as the 1980’s, 
when exposure to carcinogens was found to cause tumour formation [210]. Since 
then, a great many cancer models have been developed using various approaches 
and targeting numerous different tissues, reviewed in [211]. These models have 
contributed to enhancing our understanding of cancer mechanisms in vivo. One of 
the first transgenic zebrafish cancer models to be developed expressed the Myc 
oncogene under the control of the rag2 promoter to model leukaemia and found that 
fluorescently labelled transformed cells could be monitored and tracked in vivo [212]. 
A number of melanoma models have been developed using the BRAF [213] and RAS 
oncogenes [70][214]. These models were subsequently used to identify cancer-
associated genes using the miniCoopR approach [215] and to monitor melanocyte 
differentiation and cell fate [216] and leukocyte recruitment to transformed cells 
[192]. Comparative genomic studies in a zebrafish T cell acute lymphoblastic 
leukaemia has been used to identify functionally important cancer genes [217]. 
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Recently, a new model which allows conditional induction of epithelial cell 
transformation in larval zebrafish was developed for the study of very early 
oncogenic processes in vivo [74][218]. This KalTA4-ERT2/UAS based system permits 
temporal and spatial control of oncogene expression so oncogenic processes can be 
assessed from the very earliest stages of inception. These models, and others [211], 
highlight the significant contribution of zebrafish research to the cancer field, and 
demonstrates the versatility and range to the model system.      
 
1.9 Approaches to assess cancer metabolism in vitro and in vivo 
As discussed above, complex metabolic alterations occur in cancers (See 
Section 1.5 and 1.6). This complexity necessitates a variety of technical approaches 
to thoroughly elucidate these intricate metabolic mechanisms and evaluate their 
contribution to cancer development and progression. Both in vitro and in vivo 
approaches have been developed to assess metabolic processes, all of which help 
further our understanding of cancer metabolism, but also present challenges which 
must be addressed.   
In vitro metabolic studies can generally be divided into three main categories; 
nutrient utilisation, metabolomics and functional assays, with each of these broken-
down into further sub-categories. Nutrient up-take by cancer cells can be monitored 
directly using nutrient analogues which cannot be fully metabolised. For instance, 
accumulation of the fluorescently-labelled glucose analogue 2-(N-(7-nitrobenz-2-
oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) in cells can be measured using 
a simple spectrophotometer to assess glucose uptake [219]. Similar approaches are 
used using radio-labelled nutrient analogues. Substrate utilisation can also be 
assessed indirectly by measuring depletion from the cell medium using enzymatic 
assays which couple metabolic substrates and intermediates to probes which can be 
detected by fluorescence read-out [220]. Commercial kits are widely available to 
assess a variety of metabolic substrates using these approaches, providing useful 
insights into the substrates utilised by cancer cells and helping guide the focus of 
experimental projects towards more sophisticated mechanistic approaches. 
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However, considering the limited amount of information that can be gained about a 
single nutrient from these simple experiments, they often prove relatively expensive.  
Metabolomics, on the other hand, provides a much more detailed assessment 
of the metabolic profile of a sample, with a number of approaches available. Nuclear 
magnetic resonance spectroscopy (NMR), gas chromatography-mass spectrometry 
(GC-MS) and liquid chromatography-mass spectrometry (LC-MS) can all be employed, 
the choice of which is dependent on metabolites of interest and level of detail 
required. NMR is highly reproducible and produces robust results but offers low 
sensitivity and metabolite coverage. GC-MS and LC-MC, often used in combination, 
are much more specific and offer a broader metabolite range but are often difficult 
to reproduce [220]. These approaches can be utilised to gain detailed insights into 
metabolic parameters, including substrate utilization and flux through the various 
metabolic pathways. However, the specialist nature of these techniques makes them 
expensive and necessitates equipment and resources not readily available to all 
researchers.  
While these nutrient utilisation and metabolomic approaches provide 
detailed information on metabolite levels, functional assays allow for detailed 
assessment of energetic processes. So-called Seahorse assays have been developed 
to test glycolytic and respiratory function in real-time in response to system 
manipulation [221]. These assays measure oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR) as read-outs for mitochondrial functions and 
glycolysis, respectively, and are widely used with cellular systems to determine 
metabolic phenotype [222][223]. While these assays are highly sensitive and provide 
real-time information, they require specialist analysers and costly consumables.  
Overall, these in vitro approaches provide a detailed insight into the metabolic 
profile of cellular systems and how they change in response to manipulation. 
However, it is well established that the tumour microenvironment plays a vital role 
in cancer development. The complex cellular inter-play between cancer cells and 
other cells in the surrounding microenvironment simply cannot be replicated in vitro 
and, therefore, to fully understand the role of metabolic processes in cancer, in vivo 
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approaches must be considered. The metabolomics approaches described above can 
also be utilised in vivo and have successfully been used to determine metabolic 
profiles in various murine [224]–[226]and zebrafish models. [227]–[229] Despite this, 
an additional major caveat to this approach must be considered; the amount of 
substrate required is often limiting, be that technically, financially or ethically. As 
technology advances and these techniques are fine-tuned to be able to 
accommodate smaller and smaller samples this limitation may be overcome to allow 
the metabolomics approach to become the gold standard for metabolism research, 
but this constraint is presently a barrier for many in vivo applications.    
In vivo imaging techniques have been developed and utilised to monitor 
metabolic processes both in research and in the clinic. As mentioned previously, PET 
imaging uses an FdG glucose analogue tracer to quantifiably monitor glucose uptake 
in patients for both diagnosis and disease monitoring [94]–[99]. Amino acid and lipid 
metabolism can also be assessed by PET imaging using appropriate probes, 
including 18F-fluoro- ethyl-tyrosine (FET) [230], 11C-methionine [230], 18F-
flurothymidine (FLT) [231], 18F-choline [232] and 11C-acetate [233], all of which have 
been successfully utilised in the clinic.  
Due to the sensitive, quantifiable and longitudinal in situ details gained from 
in vivo imaging, this approach is highly desirable for mechanistic metabolic 
investigations in addition to clinical monitoring. As discussed above, the zebrafish 
presents itself as an ideal model organism for such investigations, with the optical 
transparency of larval stages and genetic tractability providing clear advantages over 
their rodent counterparts. To date, a variety of fluorescently-labelled metabolic 
tracers have been used in zebrafish models to investigate glycolytic and 
mitochondrial processes, as well as lipid metabolism [234]. Transgenic zebrafish lines 
have been developed to monitor gluconeogenesis, hypoxia and ROS production 
[229], [235], [236]. Despite these advances, the potential of the zebrafish for in vivo 
monitoring of metabolic processes has yet to be fully realised. The number of both 
probes and transgenic lines available remains limited and this lack of tools hinders 
progress in the field. Development of new transgenic zebrafish lines for specific 
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metabolic processes would allow unprecedented insights into metabolic mechanisms 
in vivo and in real-time. Combining these new tools with the metabolomic 
approaches described above would provide a powerful and more complete picture 
of metabolic landscapes in numerous disease settings, including cancers, and 
increase our disease understanding, potentially leading to diagnostic or therapeutic 
targets.  
 
1.10 Hypothesis and Aims of the Project 
While it has been established that metabolic and mitochondrial alterations 
are important features of cancers, their role during tumour initiation and 
development are less well defined. The hypothesis for this project is that metabolic 
and mitochondrial alterations occur at the very early, pre-neoplastic cell (PNC) stage 
of tumour initiation in vivo and are important for development and survival of pre-
neoplastic cells. Specifically, it is hypothesised that upregulation of the oncogene 
HRASG12V leads to disruption of the mitochondrial network, causing a metabolic shift 
towards glycolysis and subsequent lactate production. This lactate may then alter 
inflammatory cell recruitment and behaviour and polarise the tumour 
microenvironment towards pro-tumourigenic functions (Figure 1.9).  
The overall aim for the project is to begin to define a mitochondrial and 
metabolic phenotype for PNCs at very early stages of tumour development and 
determine the effect of phenotype manipulation on PNC growth and survival. 
Specifically, the aims of the project are to: 
• characterise a recently developed model for conditional epithelial cell 
transformation in superficial skin cells of the larval zebrafish, 
• investigate mitochondrial morphology in PNCs at very early stage of 
development, 
• investigate functional characteristics of the mitochondrial phenotype in 
developing PNCs, 
• investigate glycolytic metabolism in PNCs at very early stages of development, 
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• identify potential therapeutic targets for further study of cancer prevention 
mechanisms.  
Characterisation of metabolic and mitochondrial alterations at very early stages of 
tumour initiation and development will not only enhance our understanding of 
mechanisms of both tumour initiation and cancer persistence but may lead to 
identification of potential target for cancer prevention and/or therapeutic 
intervention.  
This thesis first addresses characterisation of a newly developed zebrafish 
model for cancer initiation. Following this, mitochondrial phenotype and glycolytic 
alterations and the consequential effects in PNCs are described. The thesis then 
explains new tools under development for metabolic investigations in a zebrafish 
model. Finally, the findings of the thesis are discussed in the context of current 
knowledge in the field and future directions for the project are proposed. 
 
 
  Figure 1.9 Schematic representation of the project hypothesis. The hypothesis for 
this project is that HRASG12V upregulation causes mitochondrial disruption leading to 
a metabolic shift towards glycolysis and a subsequent increase in lactate levels. This 
lactate alters inflammatory cell recruitment and creates a pro-tumourigenic 
environment.  
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2. Materials and Methods 
2.1 Solutions 
 Unless specified, all reagents were sourced from Sigma-Aldrich. 
 
30x Danieau’s Solution (Diluted to appropriate concentration in H20) 
NaCl 1.7 M 
KCl 21 mM 
MgSO4.7H20 12 mM 
Ca(NO3)2 18 mM 




Zebrafish System Water 
0.1% Methylene Blue 
 
Induction Solution 
0.3x Danieau’s Solution  
DMSO 5 µl/ml 
4-Hydroxy Tamoxifen 5 µM 
 
LB Broth 
Tryptone 10 g 
Yeast Extract 5 g 
NaCl 5 g 









0.1% Triton X-100 
 
Calcium-free Ringers Solution 
HEPES 5 mM 
KCl 2.9 mM 
NaCl 116 mM 
 
2.2 Construct Generation 
2.2.1 Bacterial Transformation and DNA Purification 
25 µl of One Shot™ TOP10 chemically competent E. coli (Invitrogen) were 
thawed on ice. 1 µl of reaction mix was added and gently mixed. Cells were incubated 
on ice for 30 minutes then heat-shocked at 42 °C for 30 seconds. Cells were incubated 
on ice for 2 minutes followed by addition of 250 µl of SOC medium (Invitrogen). Cells 
were incubated at 37 °C, 200 rpm for 1 hour. Cells were then plated onto appropriate 
antibiotic selection LB agar plates and grown at 37 °C for 18 hours.  
Bacterial colonies were selected and grown in appropriate antibiotic selection 
LB broth at 37 °C, 200 rpm. DNA plasmids were purified using the QIAgen Spin 
Miniprep kit (Ref 27106), according to manufacturer’s instructions and purified using 
Zymo Research DNA clean & concentrator kit (Cat. No. D4033) according to 
manufacturer’s instructions. 
 
2.2.2 Genetic Cloning 
All cloning procedures were carried out using Multisite Gateway® Cloning 
Technology (Invitrogen). Unless otherwise stated, all reagents and plasmids were 
sourced from Invitrogen.  
DNA of interest was PCR amplified using attB site containing primers (Table 
1). PCR reactions were set up according to Table 2 and run according to Table 3.  The 
resulting PCR product was purified using Zymo Research DNA clean & concentrator 
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kit (Cat. No. D4033), according to manufacturer’s instructions. 15 femtomoles of 
purified PCR product was combined with 100 ng of pDONR221 donor vector in TE 
buffer in a total volume of 8 µl, followed by addition of 2 µl of BP Clonase II enzyme 
mix. The reaction mix was incubated at 25 °C for a minimum of 16 hours. To isolate 
pME vectors, reaction mix was transformed into TOP10 competed cells, cultured 
(Kanamycin 50 µg/ml, Sigma-Aldrich) and purified as described above. pME entry 
clone generation was confirmed by sequencing with M13 Forward and T7 Reverse 
primers.    
5 femtomoles of each required entry clone was combined with 10 
femtomoles of pDest destination vector (Table 4) in TE buffer in a total volume of 8 
µl, followed by addition of 2 µl of LR Clonase II enzyme mix. The reaction mix was 
incubated at 25 °C for a minimum of 16 hours. To isolate DNA plasmids, reaction mix 
was transformed into TOP10 competed cells, cultured (Ampicillin 50 µg/ml, Sigma-
Aldrich) and purified as described above. DNA plasmid generation was confirmed by 
sequencing with M13 Forward and T7 Reverse primers using the Mix2Seq sequencing 
kit (Eurofins Genomics).      
 
Table 1: attB site containing primer sequences for PCR amplification of DNA for 
Multisite Gateway cloning 
Construct Primers 
Matrix-roGFP (Addgene 



































Table 2: PCR reaction mix for amplification of DNA fragments for Multisite Gateway 
cloning 
Template DNA 100 ng 
Pfu Polymerase (NEB) 1 µl 
10 Pfu Buffer (NEB) 5 µl 
dNTP Mix (NEB) 0.5 µl 
Fw Primer (10 µM stock) 1 µl 
Rev Primer (10 µM stock) 1 µl 
Nuclease Free H2O  
 
 
Table 3: PCR Cycling Conditions for amplification of DNA fragments for Multisite 
Gateway cloning 
Initial Denature 95 °C 2 minutes  
Denature 95 °C 30 seconds 32 Cycles 
Anneal Primer Optimised 30 seconds 
Extension 72 °C 3 minutes 






Table 4: Vectors used for construct generation with Multisite Gateway cloning. 
Final 
Construct 








CAAX (A kind gift 

























































2.3 Tol2 Synthesis 
Tol2 RNA was generated using pT3TS/Tol2 [243], which was linearized by 
restriction digest using BamHI (NEB) overnight at 37 °C, then transcribed using an 
mMessage mMachine T3 Kit (Invitrogen AM1348), according to manufacturer’s 
instructions.  
5 µl restriction digest product was mixed with 2 µl 10x buffer, 10 µl NTP mix, 
2 µl enzyme mix and 1 µl nuclease-free H2O. The synthesis mix was incubated at 37 
°C for 2 hours. Template DNA was degraded by incubating the reaction product in 
DNase mix for 15 min at 37 °C. RNA was extracted by standard phenol/chloroform 
extraction and resuspended in nuclease-free water.  
 
2.4 Zebrafish Husbandry 
Adult zebrafish (Danio rerio) were maintained according to standard practice 
[197]. Transgenic lines used during the project are shown in Table 5 and maintained 
under Home Office license, held by Dr. Yi Feng. Wild-type TUE, maintained by the CBS 
Aquatics Facility at The University of Edinburgh, were also used during the project.  
Zebrafish embryos were maintained at 28.5 °C for up to five days. For 
experimental purposes, embryos were anaesthetised by treatment with 0.02% 













Table 5: Transgenic lines used throughout the project 
Transgenic Line Phenotype Reference 
Krt4:KalTA4-ERT2 Superficial skin specific inducible 
expression of genes under control of 
UAS, green heart selection marker 
[74] 
UAS:eGFP-HRASG12V Expression of eGFP-HRASG12V when 
combined with GAL4 transcriptional 
activator, green heart selection 
marker 
[74] 
LysC:DsRed Red fluorescent neutrophils [244] 
Ubi:Matrix-roGFP Mitochondrial Matrix redox sensor, 










2.5 Microinjection of zebrafish eggs 
Adult zebrafish were set-up in segregated pairs overnight. The subsequent 
morning pairs were mixed, and fertilized eggs were promptly collected following 
mating. Eggs were aligned on a microinjection plate and injected into the blastodisc 
of the one-cell stage, no more than 20 minutes post fertilisation using a borosilicate 
glass capillary needle (World Precision Instruments 1B100F-4) and pneumatic pico 
pump (Warner Instruments PLI-90A) with the aid of a micro-manipulator. Injection 
solution was composed of DNA construct (15 ng/µl), Tol2 RNA (20 ng/ µl, see section 
2.3), 5x Danieau’s Solution, Nuclease-free H2O. DNA constructs used during the 
project are shown in Table 6.  
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Table 6: Constructs used for microinjection throughout the project. 
DNA Construct Phenotype Origin 
UAS:eGFP-HRASG12V Expression of eGFP-HRASG12V 
when combined with GAL4 
transcriptional activator, 
green heart selection marker 
Dr. T. Ramezani (Dr. Yi 
Feng Group) [74] 
UAS:eGFP-CAAX Expression of eGFP-CAAX 
when combined with GAL4 
transcriptional activator, 
green heart selection marker 





HRASG12V when combined with 
GAL4 transcriptional activator, 
green heart selection marker 
I. Riberio Bravo (Dr. Yi 
Feng Group), 
Unpublished 
UAS:mCherry-CAAX Expression of mCherry-CAAX 
when combined with GAL4 
transcriptional activator, 
green heart selection marker 
I. Riberio Bravo (Dr. Yi 
Feng Group), 
Unpublished 
Ubi: Matrix-roGFP Mitochondrial Matrix redox 
sensor, green heart selection 
marker 
L. Kelly, Generated during 
this project, original 
construct  
Ubi:Laconic Intracellular Lactate Sensor L. Kelly, Generated during 
this project, original 
construct  
UAS:Laconic Intracellular Lactate Sensor L. Kelly, Generated during 





Post injection, eggs were maintained in embryo medium at 50 eggs per plate 
until 6 hpf, at which point non-viable embryos were removed. Embryos were 
maintained at 28.5 °C until experimental time-points or grown to adulthood, as 
previously described.  
 
2.6 Generation of Transgenic Zebrafish Lines 
Wild-type TUE fish were mated, and eggs injected with DNA constructs, as previously 
described. 3 dpf embryos were screened for selection marker and reporter 
expression. Positive embryos were grown to adulthood, according to standard 
practice [197]. Adult fish were crossed to TUE fish and embryos were screened for 
selection marker and reporter expression to identify founder fish. A minimum of two 
founder fish were identified for each transgenic line, and the embryos grown to 
adulthood. Transgenic lines were established and characterised based on screening 
of F2 generation. 
 
2.7 Induction of UAS/KalTA4-ERT2 mediated gene expression 
Krt4:KalTA4-ERT2 fish were mated and eggs were injected with UAS:eGFP-
HRASG12V, as previously described. At 2 dpf eggs were screened to remove non-viable 
embryos and placed in induction solution (Section 2.1). As 4-hydroxy tamoxifen is 
light sensitive, embryos were maintained in the dark until specific experimental time-
points. Embryos were monitored for fluorescent HRASG12V expression and screened 
for PNC clone coverage using a Leica M205 stereoscope fitted with GFP, DsRed, or 
CFP filters, as appropriate. Unless otherwise stated, this mating and injection 
protocol was used for all experiments.  
 
2.8 Chemical treatment 
Embryos were screened at appropriate time points and treated with 1 µM 
mDIVI (Sigma-Aldrich) or 100 mM 2DG (Sigma-Aldrich) by immersion at 28.5 °C for 
specified time-frames, determined by experimental requirements. For glucose 
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supplementation, 100 mM D-Glucose solution (Sigma-Aldrich) was injected into the 
yolk sac at specified time points. 
 
2.9 Electron Microscopy 
Embryos were anesthetised and imaged (without embedding) using a Leica 
M205 stereoscope fitted with a GFP filter. Embryos were fixed in primary electron 
microscopy fixing solution (4% glutaraldehyde, 1% paraformaldehyde, 0.05 M sodium 
cacodylate, 1 mM MgSO4, 1% sucrose, H20, solution sourced from the COIL facility at 
the Wellcome Trust Centre for Cell Biology, The University of Edinburgh) for 30 
minutes at 4 °C with light shaking, before embryo decapitation and return to primary 
electron microscopy fixing solution overnight at 4 °C with light shaking. 
 Samples were then sent to the COIL facility at the Wellcome Trust Centre for 
Cell Biology, The University of Edinburgh for further processing. Briefly, samples were 
washed with 0.1 M cacodylate buffer then incubated in secondary electron 
microscopy fixing solution (2% OsO4, 0.1 M cacodylate buffer, H2O) for 2 hours at 
room temperature. Embryos were washed with 0.1 M cacodylate buffer then serial 
dehydrated with ethanol. Samples were then infiltrated with epoxy resin and 
hardened to produce sample blocks for sectioning. These steps, as well as sectioning 
and preparation for imaging were completed by Dr. Steven Mitchell at the COIL 
facility at the Wellcome Trust Centre for Cell Biology, The University of Edinburgh. 
Samples were imaged using a Jeol JEM1400 Plus Transmission Electron 
Microscope at the COIL facility at the Wellcome Trust Centre for Cell Biology, The 
University of Edinburgh, with assistance from Dr. Steven Mitchell. Images were 
viewed using FIJI (Version 2.0.0-rc-65/1.52b). 
 
2.10 Confocal Microscopy 
Embryos were anesthetised, screened and transferred to a glass bottomed 35 
mm imaging dish. 1% low-melting point agarose (Thermo Fisher Scientific) was 
heated to 80 °C (or until melted) then allowed to cool before addition to embryos. 
Embryos were appropriately aligned on the imaging dish using a pointed manipulator 
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prior to agarose setting. Once agarose was completely set, an appropriate volume of 
solution was added to the dish, determined by specific experimental requirements. 
Images and time-lapse videos were captured using a Leica TCS SP5 confocal 
microscope with installed Leica LAS AF software, Leica TCS SP8 confocal microscope 
with installed Leica LAS X software or Andor XDi Spinning disk confocal microscope 
with installed Andor iQ3 software, using the appropriate optical lens, as indicated.  
 
2.10.1 Observation of PNC phenotype by long-term in vivo imaging 
Embryos were screened at appropriate time points and embedded, as 
described above. Embryos were imaged using an Andor XDi Spinning disk confocal 
microscope fitted with a Super Apochromat 20x objective lens at 10-minute intervals 
for a duration of 24 hours. Videos were viewed using Imaris 8 (Version 8.3.1). Tile-
scan images of whole embryos were obtained using a Leica TSM SP8 confocal 
microscope fitted with an HC PL APO 10x CS2 objective lens at a pixel density of 
512x512. Images were viewed using FIJI (Version 2.0.0-rc-65/1.52b). 
 
2.10.2 In vivo live imaging of Annexin V localisation 
Ubi:SecA-YFP fish were crossed to Krt4:KalTA4-ERT2 fish and eggs were 
injected with UAS:mCherry-HRASG12V followed by induction at 2 dpf, as previously 
described. Embryos were screened for YFP (Annexin V) and mCherry (PNC) expression 
at appropriate time points and embedded as described above. Embryos were imaged 
using a Leica TSM SP5 confocal microscope fitted with an HCX PL APO W 40x water 
immersion objective lens at a pixel density of 512x512 with bidirectional scanning 








2.10.3 Analysis of neutrophil recruitment by in vivo imaging 
LysC:DsRed fish were crossed to Krt4:KalTA4-ERT2 fish and eggs were injected 
with UAS:eGFP-HRASG12V followed by induction at 2 dpf, as described previously. 
Embryos were screened for DsRed (neutrophils) and GFP (PNCs) expression at 
appropriate time points and embedded as described above. Embryos were imaged 
using an Andor XDi Spinning disk confocal microscope fitted with a Super Apochromat 
20x objective lens at 10-minute intervals for a duration of 24 hours using the 488 nm 
and 561 nm lasers. Videos were viewed and analysed using Imaris 8 (Version 8.3.1). 
Neutrophil recruitment was assessed by using the Spots module to monitor the 
number of neutrophils at each time-frame of the movie. The number of PNCs in the 
first frame of the movie was manually counted for normalisation.  
For drug treatment experiments, drugs were added approx.30 minutes prior 
to the start of time-lapse imaging. Time-lapses were imaged using a Leica TSM SP5 
confocal microscope fitted with an HC PLAN APO 20x objective lens at a pixel density 
of 512x512 at intervals of 2 minutes for a duration of approximately 16 hours using 
the 488nm and 543 nm lasers. Movies were viewed and analysed using Imaris 8 
(Version 8.3.1). Neutrophil recruitment was assessed by using the Spots module to 
monitor the number of neutrophils at each time-frame of the movie. The number of 
PNCs in the first frame of the movie was manually counted for normalisation. 
 
2.10.4 In vivo live Imaging of Laconic 
UAS:Laconic was co-injected with UAS:mCherry-HRASG12V into Krt4:KalTA4-
ERT2 fertilised eggs and induced at 2 dpf, as described previously. Embryos were 
screened for reporter (and PNC, as necessary) expression at appropriate time points 
and embedded as described above. Embryos were imaged using a Leica TSM SP8 
confocal microscope fitted with an HC PL APO 40x CS2 objective lens at a pixel density 
of 512x512 with bidirectional scanning using the 514 nm and 561 nm lasers.  
TFP and YFP emission collection ranges were determined by lambda scanning 
using the 514 nm laser. Emission peaks were detected at 495 nm and 530 nm, as 
expected. Emission collection bands were set to a 20 nm range centred on each of 
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these peaks to isolate YFP and TFP fluorescent channels. Images were acquired 
sequentially to reduce bleed-through. An additional mCherry channel was added for 
PNC imaging, excited using the 561 nm laser and acquired during the same scan 
sequence as the TFP channel.   
Images were viewed and analysed using FIJI (Version 2.0.0-rc-65/1.52b) and 
FIJI ratio profiler was used to generate a YFP/TFP channel. 
 
2.11 Immunohistochemistry 
Unless otherwise stated, all washes and incubation steps were carried out at 
room temperature with light shaking (60-65 rpm). For mDIVI and 2DG treatment 
experiments, embryos were treated 16 hours prior to fixation. 
Embryos were screened  for PNC expression at appropriate time points and 
fixed in 4% PFA for 2 hours at room temperature (static). Embryos were washed 3 
times with PBT for 5 minutes, before incubation with blocking solution (PBT + 5% 
Goat serum (Sigma-Aldrich)) for 2 hours. Embryos were incubated in primary 
antibody according to Table 7. Embryos were washed 10 times in PBT for 15 minutes, 
followed by incubation in secondary antibody (1:200 Alexa Fluor 488 goat anti-rabbit 
IgG (H+L) Invitrogen A11008 or Alexa Fluor 633 goat anti-rabbit IgG (H+L) Invitrogen 
A21071) for 2 hours. Embryos were washed 3 times in PBT. Where appropriate, 
embryos were incubated with Hoechst 33342 for 30 minutes, followed by 3 washes 
with PBT. Embryos were embedded and imaged, as described previously. 
PCNA samples were imaged using a Leica TSM SP5 confocal microscope fitted 
with an HCX PL APO W 40x water immersion objective lens at a pixel density of 
512x512 with bidirectional scanning using the 488 nm and 633 nm. Images were 







Table 7: Antibodies used for immunohistochemistry 
Antibody Concentration Staining Conditions 
GFP (D5.1)XP® Rabbit 
mAB (Cell Signalling 
Technology 2956) 
1:200 4 °C, overnight 
Purified Rabbit Anti-
active Caspase 3 (BD 
559565) 




1:200 4 °C, overnight 
 
Caspase 3 samples were imaged using a Leica TSM SP8 confocal microscope 
fitted with an HC PL APO 40x CS2 objective lens at a pixel density of 1024x1024 with 
bidirectional scanning using the 488 nm and 633 nm lasers. Samples were quantified 
by manual cell count of PNCs and caspase 3 positive cells using FIJI (Version 2.0.0-rc-
65/1.52b).  
 
2.12 EdU staining 
EdU staining was completed using the Click-iT™ Plus Edu Alexa Fluor™ 647 
Imaging Kit (Thermo Fisher Scientific, C10640). Unless otherwise stated, all washes 
and incubation steps were carried out at room temperature with light shaking (60-65 
rpm). For mDIVI and 2DG treatment experiments, embryos were treated 16 hours 
prior to fixation. For glucose supplementation experiments, D-Glucose was injected 
into the yolk sac 2 hours prior to fixation. 
Embryos were screened at appropriate time points. 500 mM EdU was injected 
into the yolk sac of embryos 2 hours prior to fixing in 4% PFA for 30 minutes at room 
temperature. Embryos were incubated with 3% bovine serum albumin (Sigma-
Aldrich) in PBT for 5 minutes, PBT for 20 minutes, then 3% bovine serum albumin in 
PBT for 5 minutes. Embryos were incubated in reaction mix (1x Click-iT reaction 
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buffer, copper protectant, Alexa Fluor™ picolyl azide, reaction buffer additive, 
according to manufacturer’s instructions) for 30 minutes. Embryos were washed 3 
times in PBT for 5 minutes and once in 3% bovine serum albumin in PBT for 5 minutes 
before immunohistochemistry staining for GFP, as described in section 2.11.  
Embryos were imaged using a Leica TSM SP5 confocal microscope fitted with 
an HCX PL APO W 40x water immersion objective lens at a pixel density of 1024x1024 
with bidirectional scanning. Images were viewed using Imaris 8 (Version 8.3.1) or FIJI 
(Version 2.0.0-rc-65/1.52b).  
For quantification of PNC proliferation, PNCs were isolated using the Surfaces 
module based on absolute GFP intensity in individual images. The EdU channel was 
subsequently masked outside PNC surfaces and the Spots module was used to count 
EdU positive cells within the PNC surface. However, due to inaccuracies of PNC 
surface generation in fixed and antibody stained samples, it became clear that some 
EdU signal from PNC neighbouring cells was included in the masked channel. 
Therefore, Edu signal in the masked channel was manually assessed to verify PNC 
specificity. Percentage of proliferating PNCs was then calculated following manual 
counting of PNCs. Due to inconsistencies associated with this method of analysis, 
automated co-localisation of EdU signal with Hoechst staining was also attempted 
using Imaris and a newly developed nuclear segmentation software package called 
PickCells (Dr. Sally Lowell Group, The University of Edinburgh), but again 3D 
segregation of PNCs caused inaccuracies. 
To assess Edu signal in the PNC niche, the Edu channel was masked to include 
all EdU signal inside the PNC surface and within 15 µm (approximately one cell 
diameter) of the surface. The number of EdU positive cells within this area was then 
counted using the Spots module. Proliferative capacity was assessed by normalising 






2.13 TUNEL staining 
TUNEL staining was completed using the Click-iT™ TUNEL Alexa Fluor™ 647 
Imaging Assay (Thermo Fisher Scientific, C10247). Unless otherwise, all washes and 
incubation steps were carried out at room temperature with light shaking (60-65 
rpm). 
Embryos were screened at appropriate time points and fixed in 4% PFA for 2 
hours at room temperature (static). Embryos were washed 4 times with PBT for 5 
minutes. Embryos were incubated with proteinase K (10 µg/ml) for 30 seconds 
followed by 2 rinses with PBT and re-fixation with 4% PFA for 20 minutes at room 
temperature. Embryos were washed 4 times for 5 minutes with PBT prior to 
incubation with TdT reaction buffer for 10 minutes at 37 °C with shaking, followed by 
incubation for 1 hour with TdT reaction mix (TdT buffer, EdUTP, TdT enzyme, 
according to manufacturer’s instructions) at 37 °C. Embryos were washed once for 5 
minutes with PBT, then 3% bovine serum albumin in PBT for 30 minutes and again 
twice for 5 minutes with PBT. Embryos were incubated with Click-iT TUNEL reaction 
cocktail (1x Click-iT TUNEL reaction buffer, copper protectant, Alexa Fluor™ picolyl 
azide, 10x Click-iT TUNEL reaction buffer additive, according to manufacturer’s 
instructions) for 30 minutes at 37 °C. Embryos were washed 3 times in PBT for 5 
minutes and once in 3% bovine serum albumin in PBT for 5 minutes before 
immunohistochemistry staining for GFP, as described in section 2.12. 
Embryos were imaged using a Leica TSM SP5 confocal microscope fitted with 
an HCX PL APO W 40x water immersion objective lens at a pixel density of 512x512 
with bidirectional scanning. Images were viewed using Imaris 8 (Version 8.3.1). 
 
2.14 MitoTracker Staining 
Embryos were screened at appropriate time points then incubated with 500 
nM MitoTracker Red CMXRos (Thermo Fisher Scientific M7512) or 500 nM 
MitoTracker Deep Red FM (Thermos Fisher Scientific M22426) for 30 minutes at 28.5 
°C in the dark followed by washing 3 times with 0.3x Danieau’s solution for 30 
seconds. Embryos were embedded and imaged, as described previously. During 
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imaging, embryos were maintained in freshly prepared induction solution and kept 
in the dark. For all mDIVI treatment experiments, embryos were treated two hours 
prior to staining.  
Embryos were imaged using a Leica TSM SP5 confocal microscope fitted with 
an HCX PL APO 63x glycerol immersion objective lens at a pixel density of 2048x2048. 
Resulting images were analysed using Imaris 8 (Version 8.3.1). PNCs were isolated 
using the Surfaces module based on absolute GFP intensity in individual images. Each 
MitoTracker channel was subsequently masked outside PNC surfaces to allow for 
analysis of mitochondrial staining specifically within PNCs. Mitochondrial fragments 
were then isolated using the Surfaces module based on absolute intensity of the 
respective channels in individual images to generate feature statistics as reported.    
Colocalization of dual MitoTracker staining was assessed using the Coloc 
module of Imaris (Version 8.3.1). Masked MitoTracker channels (above) were plotted 
on a 2D histogram, followed by automatic calculation of colocalization thresholds. 
This results in generation of a Coloc channel with a number of associated statistical 
parameters, including the Pearson’s coefficient of colocalization which is 
independent of fluorescence intensity, as reported. 
 
2.15 Staining for reactive oxygen species 
Embryos were screened at appropriate time points then incubated with 5 µM 
CM-H2DCFDA (Invitrogen C6827) or 10 µM DHE (Invitrogen D11347) for 15 minutes 
at 28.5 °C in the dark followed by washing 3 times with 0.3x Danieau’s solution for 30 
seconds. Embryos were embedded and imaged, as described previously. During 
imaging, embryos were maintained in freshly prepared induction solution and kept 
in the dark. 
Embryos were imaged using a Leica SP5 confocal microscope fitted with a HC 
PLAN APO 20x objective lens at a pixel density of 512x512 with bidirectional scanning. 




2.16 Characterisation of Ubi:Matrix-roGFP 
F2 generation Ubi:Matrix-roGFP embryos were screened for reporter 
expression at 3 dpf. Positive embryos were embedded for imaging, as described 
previously. Embryos were imaged using the Andor XDi Spinning disk confocal 
microscope fitted with a Super Apochromat 20x objective lens. 
Still images were taken prior to wounding. Embryos were wounded using the 
337 nm nitrogen laser as part of the MicroPoint module, immediately followed by 
time-lapse capture at 140 millisecond intervals for a duration of 45 minutes post 
wounding. Movies were viewed using Imaris 8 (Version 8.3.1). 
 
2.17 Analysis of glucose uptake 
Embryos were screened at appropriate time points. 5 mg/ml 2-NBDG 
(Invitrogen) or 100 mM Se-NBD-glucose (Vendrell group, The University of 
Edinburgh) was injected into the vasculature immediately followed by embryo 
embedding, as previously described. Embryos were embedded and imaged 1-hour 
post injection using a Leica TSM SP8 confocal microscope fitted with an HC PL APO 
40x CS2 objective lens at a pixel density of 1024x1024 with bidirectional scanning. 
Images were viewed using Leica LASX software (Version 1.1.0.12420).  
 
2.17.1 Characterisation of Se-NBD-glucose in vivo 
Wild-type TUE eggs were collected from natural matings and injected (as 
previously described) with 4.2 ng/embryo Anti-sense glut2 morpholino (5ʹ-
ATGACCTGCAGAC AACAAGGACACC-3’) [245]. At 28 hours post fertilisation, control 
and glut2 morphants were injected into the yolk sac with 100 mM SE-NBD-glucose 
followed by embryo embedding as described above. Embryos were imaged using a 
Leica TSM SP8 confocal microscope fitted with an HC PL APO 10x CS2 objective lens 
at a pixel density of 512x512. Images were viewed using Leica LASX software (Version 




2.18 Analysis of neutrophil recruitment to a tailfin wound 
LysC:DsRed eggs were collected from natural matings and maintained 
according to standard protocol. At 3 dpf, embryos were screened for fluorescent 
neutrophils. Tailfin transection was performed just below the tip of the notochord 
using a scalpel. Embryos were treated with 100 mM 2DG. At 6 hpw, embryos were 
fixed with 4% PFA for 2 hours at room temperature. Embryos were embedded as 
described above and imaged using a Leica SP5 confocal microscope fitted with a HC 
PLAN APO 20x objective lens at a pixel density of 512x512 with bidirectional scanning. 
Images were viewed and analysed using FIJI (Version 2.0.0-rc-65/1.52b). For analysis 
of neutrophil recruitment, all neutrophils within 200 µm of the wound site were 
manually counted.  
 
2.19 Respiratory and Glycolytic Measurements 
Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) 
were collected using the Seahorse XFe24 Extracellular Flux Analyser (Agilent 
Technologies). All experiments were carried out in collaboration with Dr. Roderic 
Carter, Morton Group, The University of Edinburgh. 
Sensor cartridges were hydrated overnight in Seahorse XF Calibrant Solution 
(Agilent Technologies). Approximately 45 min prior to the start of the experiment, 75 
μl of appropriate treatments (see Table 8 and Table 9) were loaded into injection 
ports on the sensor cartridge plate and inserted into the XFe24 analyser for 
calibration. 
Embryos were anaesthetised by treatment with 55 mg/L eugenol (Sigma), 
screened, dechorionated, and loaded into an islet capture plate (Agilent 
Technologies) (1 embryo/well) in a randomised order according to Figure 2.1. Islet 
capture screens were added to keep embryos in position. A final volume of 525 μl 
0.3x Danieau’s Solution was added to each well. Islet capture plate was incubated at 
27 °C until sensor calibration was complete. 
Following sensor calibration, the islet capture plate was loaded into the XFe24 
analyser. The experimental protocol assigned to the plate is outlined in Table  
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8 or Table 9, as appropriate. Experiments were carried out at approximately 27 °C 
(+/- 1 °C). All treatments used were from Seahorse XF Cell Mito Stress Test Kit (Agilent 
technologies 103015-100) or Seahorse XF Glycolytic Rate Assay Kit (Agilent 
Technologies 103344-100) diluted in 0.3x Danieau’s Solution. Controls were treated 
with 0.3x Danieau’s Solution. Post run analysis was completed using Agilent Seahorse 







Figure 2.1: Plate layout for respiratory and glycolytic measurements. Islet 
capture plate was loaded (1 embryo/well) in a randomised order. Four well were 
left empty (marked X) to normalise for temperature fluctuations across the plate. 
Four well held embryos that were treated with only Danieau’s solution to 
normalise for technical fluctuations resulting from drug injection.  
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Table 8: Experimental Protocol for respiratory analysis using the Seahorse XFe24 
Extracellular Flux Analyser 
 No. Cycles Mix Wait Measure 
Basal 4 2 min 1 min 2.5 min 
FCCP (5 µM) 4 2 min 1 min 2.5 min 
Antimycin/Rotenone (2 µM / 2 
µM) 
9 2 min 1 min 2.5 min 
 
Table 9: Experimental Protocol for glycolytic analysis using the Seahorse XFe24 
Extracellular Flux Analyser 
 No. Cycles Mix Wait Measure 
Basal 6 2 min 1 min 2.5 min 
2DG (100 mM) 2 2 min 1 min 2.5 min 
FCCP (5 µM) 4 2 min 1 min 2.5 min 
 
2.20 Embryo dissociation and analysis by flow cytometry or FACS 
Embryos were screened at appropriate time points (50 embryos per group) 
then incubated on ice in calcium free Ringer’s solution for 15 minutes. Embryos were 
rinsed twice in calcium free Ringers’ solution before addition of dissociation solution 
(Calcium free Ringer’s solution, 2 mM CaCl2, 0.25% Collagenase D (Gibco)) and 
incubation at 28.5 °C with vigorous shaking (200 rpm). Embryos were additionally 
mechanically dissociated by vigorous pipetting at 5-minute intervals. When embryos 
were sufficiently dissociated (approx. 20 minutes), cells were pelleted by 
centrifugation at 3,000 rpm for 3 minutes. Cells were washed twice with PBS by 
centrifugation at 3,000 rpm for 3 minutes, then resuspended in 500 µl PBS and 
filtered using a 40 µm cell strainer (Corning). 
For analysis of cell cycle by flow cytometry, cells were incubated with 1 µg/ml 
Hoechst 33342 at 37 °C for 45 minutes. Cells were then analysed using a BD 
LSRFortessa cell analyser, with assistance from staff at the Queen’s Medical Research 
Flow Cytometry and Cell Sorting Facility. 
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For FACS analysis, cells were processed by staff at the Queen’s Medical 
Research Flow Cytometry and Cell Sorting Facility using a BD FACS Aria II cell sorter. 
 
2.21 Analysis of gene expression by RT-PCR and qRT-PCR 
Embryos were screened at appropriate time points (50 embryos per group). 
All solution was removed and TRIzol reagent (Invitrogen) was added to maintain RNA 
integrity. Embryos were frozen at -80 °C for a minimum of overnight. Samples were 
thawed and manually homogenised using a pestle, by passing through a 27.7G needle 
(BD Microlance) and vigorous vortexing. RNA was isolated from the resulting cellular 
suspension using the Direct-zol RNA MiniPrep Kit (Zymo Research Cat. Number 
R2050), according to manufacturer’s instructions. RNA was eluted into a final volume 
of 15 µl. For cDNA synthesis, the BioRad iScript™ Advanced cDNA synthesis Kit for RT-
qPCR (Cat. Number 1725037) was used. 15 µl of isolated RNA was mixed with 4 µl 5x 
iScript Advanced Reaction Mix and 1 µl iScript Advanced Reverse Transcriptase and 
incubated at 46 °C for 20 minutes then 95 °C for 1 minute. cDNA was stored at -20 °C 
for further analysis. 
For RT-PCR, cDNA was added to PCR reaction mix, as shown in Table 10 and 
run according to Table 11. PCR product was mixed with gel loading dye (NEB) and run 
on a 2.5 % agarose gel at 100 V for 1.5 hour then images using the GelDoc-Ite Imaging 
System. 
 
Table 10: RT-PCR reaction mix for analysis for gene expression 
cDNA 10 µl  
dNTP Mix (Promega) 1 µl 
Fw Primer (10 mM) 1 µl 
Rev Primer (10 mM) 1 µl 
Q5 Reaction Buffer (NEB) 1 µl 
Q5 DNA Polymerase (NEB) 0.5 µl 
H2O 39.5 µl 
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Table 11: RT-PCR cycling conditions for gene expression analysis 
Initial Denature 95 °C 2 minutes  
Denature 95 °C 30 seconds 35 Cycles 
Anneal Primer Optimised 30 seconds 
Extension 72 °C 2 minutes 
Final Extension 72 °C 7 minutes  
 
For qRT-PCR, cDNA was added to PowerUp™ SYBR™ Green Master Mix 
(Thermo Fisher Scientific A25742) and loaded into a 96-well PCR plate (MicroAmp® 
EnduraPlate™ Optical 96-well Fast Clear Reaction Plate, Applied Biosciences, 
4483485) with appropriate primers at 1 mM (Table 13) to a final volume of 10 µl per 
well. qRT-PCR was performed using the StepOne™ Real-time PCR system according 
to the protocol shown in Table 12 and analysed using Microsoft Excel (Version 
16.16.1). 
 
Table 12: qRT-PCR cycling conditions for analysis of gene expression 
 Temperature Duration Cycles 
UDG Activation 50 °C 2 minutes Hold 
Dual-lock DNA 
polymerase 
95 °C 2 minutes Hold 
Denature 95 °C 15 seconds 40 cycles 










Table 13: Primer Sequences for RT-PCR and qRT-PCR 
Gene Primer Sequence 
rps11 Fw: ACAGAAATGCCCCTTCACTG 
Rev: GCCTCTTCTCAAAACGGTTG 
Dnm1l Fw: AGCCAGTCAGGTGATCGCCGA 
Rev: CGCAGGGTTCGCGTGAAGGG 
Opa1 Fw: GCCGGAAGTGTAGTTACCTG 
Rev: AGGTGGTCTCTGTGGGTTGT 
Mitofusin 1 Fw: TCGGGTCCCGTCAACGCCAA 
Rev: ACTGAACCACCGCTGGGGCT 
Mitofusin 2 Fw: GCTGGGACGCATCGGCCAAT 
Rev: GAGCGATCCACCACCCGCAG 
GLUT2 Fw: GGCTATTGTCATTGGCATCCTT 
Rev: GACACACCAGCAGTAGCAGACTCT 
MCT4 Fw: GACACGGCTTGGATCTCCTCTA 
Rev: TGCCAAGACCATACCCAATGA 
SOD2 Fw: CTGGGGCTGGCTGGGCTTTG 
Rev: GCAGCTTGGAAACGCTCGCT 
LDHa Fw: TCCTTCTCAAGGATCTGACCGA 
Rev: TGTGCGTCTTGAGAAACAGGC 
Hexokinase 1 Fw: GGTGAATTGGACGAAGGGCTTTAA  
Rev: CCTCTTGATCCCCTCTCTCAGAAG 









2.22 Lactate Assay 
Lactate concentrations were assessed using a commercially available lactate 
assay kit (Sigma-Aldrich MAK064), according to manufacturer’s instructions.  
Embryos were screened at appropriate time points (20 embryos/group) and 
mechanically homogenised in as small a volume as possible using a pestle. 200 µl 
assay buffer was added and samples were centrifuged for 10 minutes at 13,000 g. 
Samples were filtered using a 10 KDa molecular weight cut-off filter (Amicon® Ultra 
2 ml Centrifugal filters Ref: UFC201024). The filtrate was mixed with enzyme mix and 
substrate and incubated at room temperature for 30 minutes in the dark with gentle 
shaking (60 rpm). Absorbance was measured at 450 nm using a Biotek Synergy HT 
plate reader.  
 
2.23 Statistical analysis 
All graphs were generated were using GraphPad Prism 7 (Version 7.0c). 
Where appropriate, statistical analysis was completed using GraphPad Prism 7 
(Version 7.0c), as indicated with corresponding figures.  
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3. Characterisation of a zebrafish model of pre-neoplastic cell initiation in the 
superficial epithelial skin layer.  
Our knowledge of established cancers continues to expand, and yet our 
understanding of the earliest stages of tumour initiation and development remains 
relatively under-developed. This is largely due to difficulties detecting and visualising 
these processes in vivo. To overcome this barrier, an in vivo larval zebrafish model for 
conditional epithelial cell transformation was developed [74][218]. This model makes 
use of a modified GAL4/UAS expression system, whereby the human estrogen 
receptor 𝛼 (ERT2) is fused to the KalTA4 transcriptional activator [246]. The system 
allows for spatial control by using a specific promoter for tissue of interest to restrict 
expression of KalTA4-ERT2. Temporal control of oncogene expression under the 
control of the upstream activating sequence (UAS) can then be achieved by 
treatment with 4-hydroxytamoxifen (4-OHT) (Figure 3.1 A). For the purposes of this 
project the KalTA4-ERT2 element was expressed under the control of the keratin 4 
(Krt4) promoter, which is specific for the superficial epithelial skin layer of the 
zebrafish (Figure 3.1 B), while oncogene transformation was achieved exclusively 
using the fluorescently tagged human HRASG12V oncogene.     
It is well recognised that the interactions between transformed cells and their 
immediate microenvironment are important for cancer progression. Therefore, an 
ideal model for the study of the earliest stages for tumour initiation and development 
would permit detection and visualisation of such interactions. To achieve such, this 
model employs a combination of transgenic lines and transgenic construct 
microinjection to generate mosaic transformation of epithelial cells. This is 
accomplished by generating a stable transgenic zebrafish line of the Krt4:KalTA4-ERT2 
element (Supplemental Figure 1) which is then microinjected at the one cell stage 
(Figure 3.1 C) with the transgenic construct for the UAS:eGFP-HRASG12V element 
(Supplemental Figure 2). The addition of 4-OHT results in mosaic expression of 
superficial epithelial cells which express fluorescent HRASG12V, termed pre-neoplastic 




control of the earliest stages of tumour initiation and development in vivo, allowing 
monitoring and manipulation of developing PNCs and their dynamically forming 
niche.   
While this model was developed primarily by Dr. Thomas Ramezani prior to 
commencement of this project, a complete and sufficient characterisation had yet to 
be carried out. Early work for this project involved characterisation of this model of 
HRASG12V transformation of superficial epithelial skin cells in larval zebrafish.  
 
3.1 Morphological characterisation of the pre-neoplastic cell phenotype 
PNCs were observed over-time to monitor PNC phenotype development and 
establish an experimental time-line. Krt4:KalTA4-ERT2 eggs were injected with 
UAS:eGFP-HRASG12V at the one cell stage and raised according to standard protocols 
until 2 days post fertilisation (dpf), at which point 4-OHT was added to induce 
oncogene expression. This was used as the standard protocol for all future 
experiments. Embryos were monitored at 30 min intervals for signs of fluorescent 
HRASG12V expression. The first signs of PNC induction were observed at approximately 
6.5 hours post induction (hpi). Given realistic operating procedures, including 
screening large numbers of embryos and preparation for imaging, 8 hpi was 
determined as an appropriate time-point for experimental commencement (Figure 
3.2 A + B).  
Figure 3.1: A Gal4/UAS based larval zebrafish model for pre-neoplastic cell 
initiation in the superficial epithelial skin layer. A. Schematic details for 
transient induction of oncogene expression. KalTA4-ERT2 is held in the cytoplasm 
by heat-shock proteins, shown in red. Addition of 4-OHT allows for dissociation 
of heat shock proteins and translocation to the nucleus. Binding to the UAS 
allows for expression of the UAS controlled oncogene of interest. Adapted from 
[74] B. Schematic cross-section of larval zebrafish skin with transformation of 
superficial skin cells. Larval skin is formed of two epithelial layers, and outer 
superficial layer atop a basal layer that is bound to the underlying basement 
membrane. The Krt4 promoter drives expression exclusively in superficial cells, 
resulting in PNC initiation specifically in this layer. Adapted from [74] C. 
Schematic of a zebrafish zygote. The fertilised egg is encapsulated in a protective 
chorion. Transgenic constructs are injected directly into the egg at the one-cell 
stage, as shown by the schematic micro-injection needle.  
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Figure 3.2: PNCs 
develop dynamically 
over time.  
A. Schematic 
experimental time-
line from egg injection 
at the one-cell stage 
through induction at 2 
dpf and experimental 
time-points from 8 hpi 
B. Tile-scan image of a 
2dpf embryo at 8hpi 
showing mosaic 
expression of PNCs in 
the superficial skin 
layer (green). C. Still 
frames from in vivo 
time-lapse microscopy 
(Supplemental Movie 
1) monitoring PNC 
development over 
time. PNCs are seen to 
dynamically change 
morphology and 
become highly motile 
as the movie 




PNCs were monitored over time from 8 to 32 hpi at 10 min intervals (Figure 3.2 C, 
Supplemental Movie 1). It was observed that PNCs develop dynamically over time, 
becoming highly motile and heterogeneously expressing HRASG12V as PNC initiation 
progresses. The phenotype appears to be quite aggressive as cellular morphology 
alters dramatically over time (Figure 3.2 C) and occasional PNC death is observed (see 
Section 3.3). Drastic alterations to cell morphology were confirmed with electron 
microscopy (Figure 3.3 A), while flow cytometric analysis revealed an increase PNC 
size (Figure 3.3 B + C).  
 
3.2 Detection of proliferation in pre-neoplastic cells and the pre-neoplastic cell 
niche 
As cancer is a disease of excessive proliferation of transformed cells, one 
would postulate that proliferation of PNCs is a requirement for disease development 
and progression. In vivo time-lapse imaging (discussed above) suggests that PNC 
proliferation increases over time, as occasional cell division can be observed. A 
number of approaches were attempted to define PNC proliferative capacity. 
Proliferating cell nuclear antigen (PCNA) is an important component of 
cellular replicative machinery, acting as a cofactor for DNA polymerase 𝛿 [247][248]. 
Hence, expression is observed in proliferating cells. Protocol optimisation for 
immunofluorescence staining for PCNA commenced. Despite comprehensive 
attempts to optimise an immunofluorescence protocol to detect PCNA accumulation 
in PNCs, a baseline PCNA signal was detected in all cells, which 
Figure 3.3: PNCs show altered morphology and increased cell size at 24 hpi. A. 
Representative electron microscopy images of control superficial epithelial cells 
and PNCs showing alterations in morphology of PNCs at 24 hpi. Scale Bar 1.5 µm 
B. Representative dot plots from flow cytometry analysis of GFP expressing PNCs 
and control cells at 24 hpi. Flow cytometry reveals the percentage of GFP+/FSC-
AreaHigh cells is higher in HRASG12V cells than control cells, as seen in Q2, 
suggesting that the size of PNCs is larger than control cells. C. Quantification 
from B. The mean area of PNCs is increased relative to control cells at 24 hpi. 
Mean + SEM, n=10 experiments, Mann-Whitney Test, p < 0.0001 
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made identification of PCNA-positive proliferating cells difficult and highly subjective 
(Figure 3.4 A). Variations in fluorescence intensity within samples and slight 
alterations in imaging settings could skew data, therefore it was decided that PCNA 
detection was an unreliable method to observe PNC proliferation.  
Figure 3.4: PCNA staining and Hoechst 33342 cell cycle analysis were deemed 
unsuitable for determination of PNC proliferation. A. Representative images 
from PCNA immunostaining at 24 hpi. While PCNA signal was detected, strong 
baseline signal made identification of proliferating cells difficult and somewhat 
subjective. B + C. Cell cycle analysis by flow cytometry following Hoechst 33342 
loading of dissociated embryos at 24 hpi. Hoechst loading appears efficient, as 
smooth peaks are evident. However, low numbers of cells in S and G2/M phases 
lead to high standard deviation. No difference is seen between control and 
experimental groups. n = 2 experiments. 
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Hoechst 33342 is a widely used DNA stain that can be used to monitor cellular 
proliferation. As a cell transitions through the cell cycle, the quantity of DNA in the 
cell increases. This leads to an increase in fluorescence intensity of Hoechst staining 
as the cell moves into the S and G2/M proliferative stages of the cell cycle [249][250]. 
PNC carrying embryos were dissociated at 24 hpi, followed by Hoechst loading and 
analysis by flow cytometry. While Hoechst loading appeared efficient, as evidenced 
by smooth peaks of Hoechst intensity (Figure 3.4 B), the detection of proliferative cell 
cycle stages proved less efficient (Figure 3.4 B + C). Low cell numbers in S and G2/M 
phases coupled with high standard deviation made the data debatable. This 
ambiguity, in addition to large numbers of embryos required to assess sufficient 
numbers of PNCs for this approach and lack of in situ information, led to the decision 
not to pursue the technique further.  
EdU (5-ethynyl-2’-deoxyuridine) is a thymidine analogue that is incorporated 
into DNA during replication for the detection of cellular proliferation [251]. Following 
extensive protocol optimisation, successful Edu staining was achieved (Figure 3.5 A). 
However, despite indications of enhanced proliferative capacity in PNCs during initial 
experiments, detailed analysis revealed remarkably low levels of PNC proliferation, 
with little difference detected between PNCs and control cells. A statistically 
significant increase in EdU incorporation is detected in PNCs at 16 hpi and 32 hpi, but 
given the persistently low level of proliferation, the biological relevance of this 
increase is debatable. Quantification of these experiments was completed by manual 
count of PNCs and manual count of EdU positive signal within PNCs to indicate the 
percentage of proliferating cells. In an effort to strengthen confidence in this result, 
alternative methods of quantification of EdU incorporation were attempted, but all 
had high margins for error and proved inaccurate. Automated cell counts using Imaris 
software to identify PNC surfaces and count based on Hoechst staining was 
attempted but was highly inaccurate. Nuclear co-localisation of EdU with Hoechst 
staining using a newly developed PickCells software (developed by Dr. Sally Lowell, 
The University of Edinburgh) was useful, but had issues isolating PNCs in 3D.  Despite 





increases detected using EdU, combined with observations from the numerous other 
technical approaches (described above), lead to the conclusion that superficial PNCs 
do not display significant proliferative capacity and show no increase relative to 
control superficial cells.  
 
3.3 Detection of apoptotic cell death of pre-neoplastic cells 
Based on observations of in vivo time-lapse imaging, discussed above, it was 
clear that some PNCs undergo cell death as induction continues post 24 hpi. The level 
of cell death was assessed to further understand mechanisms of PNC induction and 
as a parameter for monitoring PNC manipulation in later experiments.  
Annexin V is a cellular protein that binds to phosphatidylserine (PS). 
Externalisation of PS is a feature of apoptotic cell death, whereby PS is flipped across 
the cell membrane, allowing annexin V to bind [252]. Hence, annexin V is widely used 
as a marker for apoptotic cells. To investigate apoptotic cell death in this model, a 
transgenic line with annexin V fluorescently tagged with YFP under the control of the 
ubi promoter (Ubi:SecA-YFP) generated in the lab was used. Incorporating this with 
the PNC initiation model using mCherry tagged HRASG12V, as opposed to GFP, allowed 
for in vivo imaging of annexin V activity in PNCs. Live-imaging revealed increased 
annexin V activity in embryos carrying PNCs relative to control cells at later stages of 
PNC initiation (Figure 3.6). However, the annexin V transgenic line was highly 
granular in nature, making signal quantification difficult and, therefore, while the 
data were encouraging and consistent with previous  
Figure 3.5: Successful Edu staining was achieved at various time-points, but 
proliferation levels remain persistently low in both PNCs and control cells A. 
Representative images from EdU staining at 8, 16, 24 and 32 hpi in PNCs and 
control superficial epithelial cells. Scare bar 50 µm B. Quantification from A 
achieved by manual cell count of PNCs and EdU positive signal inside PNCs. 
Results show the percentage of proliferating PNCs over time is low and 
biologically relevant alterations are not observed. Mean + SEM, n ≥ 5 embryos 
from 3 independent experiments, Mann-Whitney Test between individual groups 
as shown.  
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observations from in vivo imaging, alternative methods for quantification of 
apoptosis were pursued.  
  Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) is an 
in situ apoptosis assay based on incorporation of modified dUTPs at the 3’ end of 
fragmented DNA which can then be fluorescently labelled to identify apoptotic cells    
[253]. Protocol optimisation for TUNEL staining in the PNC initiation model was 
undertaken, however various issues arose. Apoptotic PNCs were successfully 
detected, however off-target, extra-nuclear labelling was also observed 
(Supplemental Figure 3). During staining, PNC morphology had deteriorated, which 
was thought to be due to the use of proteinase K during the TUNEL protocol, which 
can damage barrier integrity and cause shedding of superficial skin cells when used 
to excess. Titration of proteinase K to optimise the protocol and reduce loss of cellular 
integrity was unsuccessful, as sufficient concentrations to achieve TUNEL staining and 
maintain PNC integrity could not be achieved.   
Instead, immunostaining for cleaved-caspase 3 activity was used as a marker 
for apoptotic cell death. Caspase 3 is a well-recognised member of the cellular 
apoptotic pathway. Proteolytic cleavage of caspase 3, primarily by caspase 8, 9 and  
Figure 3.6: Detection of annexin V activity in PNCs. Annexin V activity was 
monitored in PNCs by combining the Ubi:SecA-YFP transgenic line with mCherry 
tagged HRASG12V. Live-imaging reveals that there is increased annexin V activity in 
PNCs relative to control superficial epithelial cells at 32 hpi, as indicated by the 
white arrows, consistent with observed PNC cell death at later stages of PNC 
induction. However, the annexin V transgenic line shows some non-specific signal 
and is quite granular nature, making it difficult to quantify. Scale bar 50 µm. 
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10, results in protein activation and  leads to induction of apoptotic cell death via the 
so-called “execution pathway” [254]–[257]. Immunostaining reveals that caspase 3 
activity increases over time during PNC development (Figure 3.7 A). Quantification 
Figure 3.7: Cleaved caspase-3 activity increases over time in PNCs. A. Representative 
images of cleaved caspase-3 activity in PNC over time. PNC specific caspase-3 activity 
increases over time during PNC development, as indicated by the white arrows. Scale 
bar 50 µm B. Quantification from A. Apoptotic cell death in PNCs significantly 
increases over time, reaching 15% by 32 hpi. Mean + SEM, n = 12 embryos from 3 
independent experiments, Kruskal-Wallis test, p < 0.0001. 
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by manual cell counting shows that, by 24 hpi approx. 5% of PNC are positive for 
cleaved-caspase 3 activity. This increases to approx. 15% by 32 hpi (Figure 3.7 B). This 
finding is consistent with in vivo observations and provides a parameter for 
monitoring PNC status following manipulation in later experiments. Also, it reveals 
that dynamic signalling during PNC development results in a complex PNC 
microenvironment with divergent PNC fate. While interesting and highly relevant, 
this feature is outside the scope of this project but is being investigated by other 
members of the group. 
 
3.4 Observation of neutrophil recruitment to developing pre-neoplastic cells 
Previous work by the group , and others, has shown that alternative models of 
developing PNCs initiate an inflammatory response, whereby innate immune 
leukocytes are recruited, a response which was found to be important for the 
proliferation on PNCs [192]. It was therefore necessary to confirm that similar 
recruitment of leukocytes was seen in this new model of PNC initiation. To monitor 
neutrophil recruitment to PNCs the neutrophil reporter line LysC:DsRed [244] was 
incorporated into the model. Krt4:KalTA4-ERT2;LysC:DsRed eggs were injected with 
UAS:eGFP-HRASG12V, resulting in embryos carrying PNCs as previously described with 
the addition of red fluorescently labelled neutrophils [244]. Time-lapse in vivo 
imaging commenced at 8 hpi and recruitment of neutrophils to developing PNCs was 
monitored at 10 min intervals over the course of 24 hours (Supplemental Movie 2). 
This interval allows for analysis of the number of neutrophils recruited while 
maximising embryo survival due to phototoxicity. However, such an interval does not 
allow for more detailed analysis of individual neutrophil behaviour due to the speed 
at which neutrophils migrate. Analysis of in vivo imaging shows that the recruitment 
of neutrophils to PNCs persists from 8 hpi (Figure 3.8) and the number of neutrophils 
remains constant. As mentioned, this imaging interval does not allow for detailed 
behavioural analysis. Further study is required to investigate the mechanisms of 




alterations in the PNC niche. While important, this is outside the scope of this project. 
 
3.5 Discussion 
Development of a new model for human HRASG12V-transformed PNC initiation 
in superficial epithelial larval zebrafish skin has provided an opportunity to 
investigate previously undetectable stages of cancer initiation in an in vivo setting. 
While technical development of this model was complete prior to this project 
beginning, a detailed characterisation of phenotype development was an initial 
priority. Observational studies determine that PNCs are detected at approximately 
6.5 hpi and continue to develop dynamically over time. Cellular size and morphology 
are dramatically altered, and cells become highly motile, while apoptosis is observed 
at later stages of induction. Recruitment of neutrophils to developing PNCs is 
consistent with previously reported observations.  
Morphological alterations observed by in vivo imaging were verified using 
electron microscopy. These images suggest changes in cell shape and polarity, 
providing more detailed indications of phenotypical characteristics of PNCs. While 
changes in cell size were quantified by flow cytometry, alterations in morphological 
Figure 3.8: Neutrophil recruitment to PNCs increases over time. Quantification 
of recruited neutrophil numbers over time for in vivo time-lapse imaging. Number 
of neutrophils recruited to PNCs remains constant over time. Aligned replicates 
with linear regression analysis, n = 9 embryos from 3 independent experiments. 
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characteristics observed by electron microscopy were not quantified. Due to the 
mosaic nature of this model and loss of fluorescence during the fixation procedure, 
positional markers are used to determine the position of PNCs for electron 
microscopy. However, the fixation procedure causes sample shrinkage, which 
increases the scope for error and adding considerable time to sectioning and imaging. 
Completion of sufficient numbers of embryos for quantifiable analysis is highly time-
consuming and, while these morphological alterations are an important feature of 
the model, would not provide data that contributes to the metabolic phenotypes 
under investigation in this project. Should time and funding become available, a more 
detailed and quantifiable electron microscopy analysis of morphological 
characteristics of PNCs could be completed in the future.   
It is evident from these observations that superficial PNCs do not exhibit 
enhanced proliferative capacity. Quantification of EdU staining indicated low 
proliferation index in both PNCs and control cells and, while statistically significant 
differences are detected at some time-points, the biological significance of these 
changes are thought to be negligible. In contrast to cells of the more stem-like basal 
epithelial layer, superficial epithelial cells are fully differentiated. During the blastula 
period of zebrafish development, superficial epithelial cells become remarkably flat, 
become lineage-restricted and their cell cycle becomes longer and less synchronous 
[258]. Therefore, given the developmental stage of embryos in these experiments, it 
is not altogether surprising that control cells are not highly proliferative. However, 
the finding that oncogenic RAS transformed PNCs do not increase proliferative 
capacity was somewhat unexpected. Murine models have shown that transformed 
keratinocytes have the ability to escape differentiation-associated growth controls 
[259], yet overexpression of HRASG12V in superficial epithelial cells in this model does 
not appear sufficient to induce proliferation. Perhaps additional cellular insults are 
required to overcome the differentiation state and induce a proliferative phenotype 
in superficial PNCs, similar to the BRAF/p53 cooperation required for melanoma 
formation in some zebrafish models [213]. This theory that the proliferative capacity 
of epithelial PNCs is linked to their differentiation state is strengthened by the 
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knowledge that similar experiments using this model in the basal epithelial layer 
found significantly increased proliferation in basal PNCs (Feng Lab, Unpublished 
data). With this in mind, it can be concluded that the basal epithelial model would be 
more appropriate to assess proliferative parameters moving forward, as HRASG12V 
transformation does not appear sufficient to induce proliferation in superficial 
epithelial cells.  
Observations also reveal that, at later stages of induction, some PNCs undergo 
cell death. To assess this an annexin V transgenic line, developed by fellow group 
member Ziyuan (Elva) Chang was used. This line revealed increased annexin V activity 
in PNCs at later stages of induction, consistent with previous observations. However, 
quantification of this line was difficult due to the granular nature of the signal. 
Therefore, alternative approaches were considered. Issues arose with TUNEL 
protocol optimisation, thought to be due to proteinase K treatment, although further 
consideration of optimisation approaches highlights that method of fixation may also 
have been an issue [260]. Instead, cleaved caspase-3 was ultimately used as a marker 
for apoptotic cell death, as caspase 3 cleavage initiates programmed cell death 
pathways. Immunostaining revealed increased caspase-3 activity at later stages of 
induction, reaching up to 15% by 32 hpi. This apoptotic cell death could be a response 
to hyper-active HRASG12V expression due to differential concentrations of UAS in each 
cell following micro-injection or could be an inherent phenotype arising from PNC 
communication and required for tumour initiation. This is an interesting finding as it 
reveals divergent phenotypes of PNCs during tumour initiation and development. It 
highlights that this model represents a heterogenous population of PNCs, a 
phenotype also observed by morphological and behavioural divergences during in 
vivo microscopy. While the signalling and cellular interactions at these later stages of 
induction may be vital for ultimate tumour initiation and progression, they remain 
outside the scope for this project, but are under investigation by fellow group 
members.  
Inflammatory cell recruitment has been shown to be vital for PNC progression 
in previously established PNC initiation models [192]. This new model allows for 
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temporal resolution of cellular interactions from the very earliest stages of PNC 
initiation. Therefore, determination of a time-line of neutrophil recruitment to 
developing PNCs was made possible. Neutrophil numbers are seen to increase from 
eight hpi and appear to remain constant over time. Inflammatory mechanisms in the 
PNC niche remain to be elucidated, though the contribution of secondary 
characteristics of the phenotype, such as cell death, cannot be overlooked. These 
detailed inflammatory mechanisms are an active area of research within the group, 
with various inflammatory pathways under investigation by fellow group members.   
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4. Mitochondrial and Metabolic Alterations Occur Very Early During Pre-Neoplastic 
Cell Development and are Potential Targets for Cancer Prevention. 
Having gained sufficient understanding of the newly developed model system 
for inducible HRASG12V transformation of superficial epithelial skin cells in larval 
zebrafish, the project set about investigating metabolic alterations in the developing 
PNC niche. There are a great many metabolic processes that have been shown to be 
altered in established cancer and may play a role during PNC initiation, ranging from 
processes involved in glycolysis and oxidative phosphorylation to lipid and amino acid 
metabolism. Each could be investigated in their own right, but such a body of work is 
vastly beyond the capacity of a single research project. It was therefore decided to 
take a broad approach to potential metabolic alterations by considering the location 
where a number of metabolic processes occur, the mitochondria, and investigating 
glycolytic processes that are known to be altered in established cancers to determine 
the role of these processes during tumour initiation and development.  
 
4.1 Mitochondrial morphology is altered at very early stages of PNC initiation. 
Mitochondrial hyper-fragmentation is  a feature of established cancer cells and is 
required for tumour growth and survival [154]–[156]. Mitochondrial morphology in 
PNCs was investigated to determine if this was also a feature of early PNC initiation. 
Using an in vivo confocal microscopy approach, fragmentation of mitochondria was 
observed at very early stages of initiation (Figure 4.1). Control epithelial cells display 
an elongated, tubular morphology (Figure 4.1 A CAAX, white arrow). Meanwhile, 
PNCs have a highly fragmented morphology at 24 hpi (Figure 4.1 A HRASG12V white 
arrows), consistent with observations in more established cancer cells. Quantification 
of staining reveals there is a significant increase in the number of mitochondrial 
fragments in PNCs relative to control cells (Figure 4.1 B) and a significant decrease in 
the size of those fragments (Figure 4.1 C), indicating that mitochondrial 
fragmentation has occurred. Due to the resolution limits of confocal microscopy, 
individual mitochondria could not be observed using this 
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technique. To verify the fragmentation phenotype and visualise individual 
mitochondrial fragments in PNCs electron microscopy was performed. Resulting 
images confirm that mitochondria in PNCs appear smaller and more numerous 
relative to control epithelial cells (Figure 4.1 D). While the double membrane 
structure appears potentially compromised in these smaller fragments, cristae 
structure appears intact, suggesting these mitochondrial fragments are still 
functional. This phenotype has been observed at the earliest measured time-point of 
8 hpi and persists over time. In fact, while no change in the number of mitochondrial 
fragments is seen, the fragments appear to become significantly smaller over time 
(Figure 4.2). This suggests that despite the fragmentation events occurring early, 
Figure 4.1: Mitochondrial Fragmentation is observed in PNCs. A. Representative 
images from in vivo MitoTracker Deep Red FM staining at 24 hpi. Control 
epithelial cells have an elongated, tubular structure, as indicated by the white 
arrow. PNCs show highly fragmented morphology, as indicated by the white 
arrows. Scale bar 5 µm. B + C. Quantification from A. Automated analysis using 
Imaris software to generate surfaces for mitochondrial staining specifically in 
PNCs to analyse numerous parameters. Analysis reveals a significant increase in 
the number of mitochondrial fragments (B) and a significant decrease in the size 
of mitochondrial fragments (C) in PNCs relative to control epithelial cells. Mean + 
SEM, Mann-Whitney Test, n ≥ 6 embryos from ≥ 3 experiments D. Representative 
images from electron microscopy at 24 hpi. Control epithelial cells show a 
stereotypical mitochondrial morphology, indicated by the red arrow. PNCs show 
smaller and more numerous mitochondria, indicated by the blue arrows. Scale bar 
1.5 µm  
 77 
functional consequences may become more pronounced over time, although further 
experimental replicates are necessary to confirm this. Together, these data suggest 
that mitochondrial fragmentation is a very early alteration following HRASG12V 
oncogene activation and this phenotype may have a dynamic effect on PNC 





Figure 4.2: Mitochondrial fragmentation is observed at very early stages of PNC 
development and persists over time. A. Representative images from in vivo 
MitoTracker Deep Red staining at 8 hpi. Control epithelial cells have an 
elongated, tubular structure, while PNCs show highly fragmented morphology. 
Scale bar 5 µm. B + C. Quantification from A. Automated analysis using Imaris 
software to generate surfaces for mitochondrial staining specifically in PNCs to 
analyse numerous parameters. Analysis reveals a significant increase in the 
number of mitochondrial fragments (B) and a significant decrease in the size of 
mitochondrial fragments (C) in PNCs relative to control epithelial cells. Mean + 
SEM, Mann-Whitney Test, n ≥ 3 embryos from ≥ 2 experiments. D + E. 
Comparison of number and size of mitochondrial fragments at 8 hpi and 24 hpi. 
There appears to be no change in the number of mitochondrial fragments overs 
time, indicating that the phenotype persists over time. There is a significant 
decrease in the size of fragments over time, suggesting that condensation of 
fragments may occur over time. Mean + SEM, Mann-Whitney Test, n ≥ 3 embryos 
from ≥ 2 experiments. 
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4.2 Mitochondrial fragmentation is dependent on the mitochondrial fission 
regulator Dnm1l.  
Following determination of a mitochondrial fragmentation phenotype in 
PNCs, possible mechanisms for the phenotype were investigated. The cycle of 
mitochondrial fragmentation that naturally occurs in cells is governed by a number 
of regulatory proteins, including Dnm1, Opa1, Mitofusin 1 and Mitofusin 2 (See 
Section 1.5). Initially, RT-PCR was performed to visualise changes in gene expression 
of these regulatory proteins by gel electrophoresis. Data revealed an apparent 
increase in expression of the fission protein Dnm1l in embryos carrying PNCs relative 
to wild-type embryos, while expression of the mitochondrial fusion protein Opa1 
appeared to be reduced (Figure 4.3 A). This was encouraging but bands on the gel 
electrophoresis were quite weak and sometimes difficult to visualise. Following much 
protocol optimisation, data from qRT-PCR showed no significant difference in the 
expression of the fission regulatory protein Dnm1 or the fusion regulatory proteins 
Opa1, Mitofusin 1 or Mitofusin 2 (Figure 4.3 B). While expression alterations were 
not detected, this is not altogether surprising. cDNA 
 
Figure 4.3: Upregulation of Dnm1l expression in PNCs was not quantifiably 
detected. A. Representative image of gel electrophoresis following RT-PCR. 
Stronger expression of the mitochondrial fission protein Dnm1l is detected in PNC 
carrying embryos relative to wild-type embryos. Meanwhile, reduced expression 
of the mitochondrial fusion protein Opa1 is detected in PNCs carrying embryos. 
B. Fold change of gene expression detected by qRT-PCR. Analysis reveals no 
change in the expression of Dnm1l, Opa1, Mitofusin 1 or Mitofusin 2 in the 
presence of PNCs. Mean + SEM, n = 7 independent experiments, Multiple t tests 
between groups 
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used for these experiments was isolated from whole embryos with mosaic expression 
of PNCs in superficial epithelial skin (n = 50 embryos per group). The ratio of 
transformed cells relative to the total number of cells in a zebrafish embryo is quite 
small and changes of gene expression in PNCs will be masked by that of non-
transformed cells. Therefore, detected changes are expected to be subtle and one 
must remain conscious of potential false negatives. Isolation of cDNA from FACS 
isolated PNCs was attempted but achieving sufficient numbers of PNCs for RNA 
isolation and cDNA synthesis without the need for costly amplification was not 
achieved.  
Previous studies indicate that mitochondrial fragmentation in oncogene 
transformed cells is a direct result of upregulation of the mitochondrial fission protein 
Dnm1 (often referred to as Drp1), which is phosphorylated by members of the MAPK 
signalling pathway [158][157]. The zebrafish orthologue of Dnm1, Dnm1l, a 1:1 
orthologue, shares close to 90% homology with the human protein, with all 
functional elements conserved (Supplemental Figure 4). Although inconclusive, the 
trend towards Dnm1l upregulation in embryos carrying PNCs detected by RT-PCR, 
combined with reports that Dnm1l is also controlled at the post-translational level 
[261]–[263], was sufficient to hypothesise that mitochondrial fragmentation in PNCs 
is dependent on Dnm1l upregulation. To test this theory, embryos were treated with 
the Dnm1 specific small molecule GTPase inhibitor mDIVI-1 [264]. Treatment resulted 
in rapid recovery of mitochondrial phenotype to wild-type morphology (Figure 4.4 A, 
white arrows). Reduced number (Figure 4.4 B) and increased size of mitochondrial 
fragments (Figure 4.4 C) is observed at two hours post treatment (hpt), suggesting 
that fragmentation is dependent upon Dnm1l activity.   
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4.3 Dnm1l-dependent mitochondrial fragmentation has consequences for 
mitochondrial function. 
Although mitochondrial fragmentation appears quite extreme in PNCs, 
fragmentation is a normal process at certain stages of the cell cycle. It was therefore 
investigated if functional alterations are associated with the fragmentation 
phenotype. 
Mitochondrial staining using dyes with differential dependence on 
mitochondrial membrane potential was undertaken to determine if membrane 
potential was altered. Co-staining with MitoTracker Red CMXRos and MitoTracker 
Figure 4.4: Mitochondrial fragmentation in PNCs is dependent on Dnm1l 
activity. A. Representative images from in vivo MitoTracker Deep Red staining 
at 24 hpi following 2 hr treatment with the Drp1 specific GTPase inhibitor 
mDIVI-1. Treatment restores mitochondrial morphology to wild-type (White 
arrows). Scale bar 5 µm B + C. Quantification from A. Automated analysis using 
Imaris software to generate surfaces for mitochondrial staining specifically in 
PNCs to analyse numerous parameters. Analysis reveals a significant decrease 
in the number of mitochondrial fragments (B) and a significant increase in the 
size of mitochondrial fragments (C) in PNCs following mDIVI-1 treatment. Mean 
+ SEM, Mann-Whitney Test, n ≥ 6 embryos from ≥ 3 experiments. 
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   Deep 
Figure 4.5: Dnm1l dependent reduced mitochondrial membrane potential is 
detected in PNCs. A. Representative images from co-staining with MitoTracker Red 
CMXRos and MitoTracker Deep Red FM at 24 hpi. There are clear differences in dye 
accumulation between PNCs and control epithelial cells, with PNCs showing less 
MitoTracker CMXRos staining and, thus reduced mitochondrial membrane potential. 
Scale bar 5 µm B. Quantification from A. Imaris software was used for automatic and 
unbiased quantification of dye colocalization (See Section 2.14). Colocalization 
threshold plots reveal vastly reduced accumulation of MitoTracker CMXRos in PNCs, 
suggesting reduced membrane potential.  C + D. Quantification from A + B. 
Colocalization analysis reveals reduced Pearson’s Coefficient of Colocalization in 
PNCs at 24 hpi (C), which is recovered following treatment with mDIVI-1 (D), 
indicating that loss of mitochondrial membrane potential is reversible. Mean + SEM, 
Mann-Whitney Test, n ≥ 6 embryos from ≥ 3 experiments 
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Red FM indicates membrane potential changes as MitoTracker Red CMXRos is more 
highly dependent on membrane potential, hence, perturbation of membrane 
potential leads to differential staining. Imaging revealed reduced mitochondrial 
membrane potential in PNCs relative to control epithelial cells (Figure 4.5 A). 
Colocalization analysis using Imaris software (See Section 2.14) shows drastic 
alteration in colocalization of dyes (Figure 4.5 B) and significantly reduced Pearson’s 
coefficient of colocalization (Figure 4.5 C), indicating significantly reduced 
mitochondrial membrane potential in PNCs. Interestingly, this phenotype is rapidly 
recovered following treatment with mDIVI-1 (Figure 4.5 D). This shows that reduced 
mitochondrial membrane is dependent on Dnm1l activity.  
Reduced mitochondrial membrane potential is indicative of reduced 
functional capacity but does not give indications of the type and degree of 
disturbance. To assess this, a protocol using the Seahorse Extracellular Flux       
Analyser [221] was established in collaboration with Dr. R. Carter, The University of 
Edinburgh. This instrument can be used to measure oxygen consumption rate (OCR) 
to assess respiratory function and extracellular acidification rate (ECAR) to monitor 
glycolytic capacity (see Section 4.5). The assay was established such that a single 
embryo was added to each well of a specialised 24-well islet capture plate and held 
in place by an overlaid securing small screen (Figure 4.6 A). To investigate OCR and 
respiratory capacity, a drug manipulation protocol was established. Following 
measurement of baseline OCR, treatment with the oxidative phosphorylation 
uncoupler FCCP permitted assessment of maximum OCR capacity. Finally, co-
treatment with the complex III inhibitor antimycin and the complex I inhibitor 
rotenone allowed the respiratory contribution to OCR to be analysed (Figure 4.6 B). 
Implementation of this protocol in the PNC initiation model revealed no difference in 
baseline OCR (Figure 4.6 C + D), or in baseline respiratory capacity (Figure 4.6 E + F). 
However, a subtle yet significant decrease in the maximum respiratory capacity is 
detected in PNC carrying embryos relative to wild-type controls (Figure 4.6 G). This 
indicates that respiratory function is compromised, and cells are unable to respire to 
full capacity. Further experimental replicates are necessary to determine 
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Figure 4.6: A protocol for analysis of respiratory function in zebrafish larvae 
reveals impaired respiratory capacity in PNC bearing embryos. A. 
Representative image of plate set up for extracellular flux analysis. A single 
embryo was added to each well of a specialised islet capture plate and secured in 
place by a screen. B. Representative schematic of drug manipulation protocol for 
assessment of respiratory function in larval zebrafish. The OCR readout (blue) is  
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if this effect Is dependent on the Dnm1L-dependent phenotype as statistically 
significant recovery was not detected following mDIVI treatment in a small number 
of experiments (Figure 4.6 H). The small effect size is fully expected within the 
context of the whole-embryo approach, where the proportion of transformed cells 
makes up a small fraction of the total volume of the embryo. This assay, however, 
provides a method for in vivo analysis of respiratory parameters in zebrafish larvae 
and gives indications of the adverse functional consequences of the mitochondrial 
phenotype in PNCs.   
 
 
Figure 4.6 (Continued) monitored over time. Following assessment of baseline 
OCR (black arrow) the respiration uncoupler FCCP was added (black line) to 
assess reserve OCR (red arrow) and maximum OCR (green arrow). Finally, co-
treatment with the complex III inhibitor antimycin and the complex I inhibitor 
rotenone (black line) allowed the non-respiratory contribution to OCR (orange 
arrow) to be determined, and hence the baseline respiration (magenta arrow) 
and the maximum respiratory capacity (purple arrow) to be assessed. C. OCR 
readout over time according to protocol described in B. Mean + SEM, n ≥ 20 
embryos from 5 experiments, Two-way ANOVA followed by Sidak’s multiple 
comparisons test. D. Quantification from C. Baseline OCR, determined at cycle 4 
of protocol measurement, shows no significant difference between wild-type 
embryos and PNC carrying embryos. Mean + SEM, n = 40 embryos from 5 
experiments, Mann-Whitney test, p = 0.1623. E. Respiratory OCR over time, 
determined using data from C as described in B. Mean + SEM, n ≥ 20 embryos 
from 5 experiments, Two-way ANOVA followed by Sidak’s multiple comparisons 
test. F. Quantification from E. Baseline respiration determined at cycle 4 of 
protocol measurement, shows no significant difference between wild-type 
embryos and PNC carrying embryos. Mean + SEM, n = 20 embryos from 5 
experiments, Mann-Whitney test, p = 0.1563. G. Quantification from E. Maximum 
respiratory capacity, determined at cycle 7 of protocol measurement, shows a 
subtle yet significant decrease in PNC carrying embryos relative to wild-type 
controls. Mean + SEM, n = 20 embryos from 5 experiments, Mann-Whitney test, p 
= 0.0444. H. Maximum respiratory capacity following treatment with mDIVI. 
Although significance is not achieved, recovery of respiratory is seen following 
treatment with mDIVI-1 suggesting this phenotype is at least partly due to 
mitochondrial fragmentation. Mean + SEM, p ≥ 8 embryos from 2 experiments, 
Kruskal-Wallis test, p = 0.2198.    
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4.4 Despite mitochondrial alterations, increased reactive oxygen species are not 
detected in the PNC niche. 
Given the degree of mitochondrial change observed in PNCs, one would 
expect an increase in reactive oxygen species (ROS) in the PNC niche. Alternative 
zebrafish models of PNC initiation have also shown that hydrogen peroxide is 
produced in the PNC niche [192]. It was hypothesized that there may be a link 
between the increased H2O2 production and the mitochondrial fragmentation 
phenotype. To test this, the general oxidative stress indicator CM-H2DCFDA was used 
to monitor ROS production in the PNC niche. Surprisingly, remarkably little ROS signal 
was detected by time-lapse microscopy from 16 – 20 hpi (Supplemental Movie 3, 
Figure 4.7 A). The dye appeared to be working as signal was detected in leukocytes 
in the PNC niche (Figure 4.7 A, turquoise arrows). Very faint signal is detected in PNCs 
with very strong HRASG12V expression (Figure 4.7 A, yellow arrows), but given the 
intensity of mCherry-HRASG12V expression and the weakness of dye it is difficult to 
determine if this is artefactual. In attempt to overcome this an alternative oxidative 
stress indicator was tested. Dihydroethidium (DHE) is a superoxide indicator that 
translocates to the nucleus following oxidation, resulting in red nuclear staining in 
cells in which superoxide has been generated. Again, remarkably little superoxide 
signal was detected in the PNC niche (Supplemental Movie 4, Figure 4.7 B). Positive 
DHE signal was detected in just three PNCs (Figure 4.7 B, magenta arrows) and three 
neighbouring cells at 24 hpi. Taken together, these data suggest that ROS generation 
is not a feature of PNC development, despite significant mitochondrial alterations.    
Like all extrinsically applied compounds, these ROS indicators have technical 
obstacles, with a fine balance between embryo tolerance and signal detection often 
required. To circumvent this issue, and to robustly test that ROS generation is not a 
feature of PNC development, transgenic reporter zebrafish lines for localized redox 
stress were generated. Three individual transgenic lines were generated, with the 
roGFP redox stress reporter [265] localized to the cytoplasm, the mitochondrial 
matrix and the mitochondrial inner membrane [237] under the control of the  
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Figure 4.7: Reactive oxygen species are not detected in the PNC niche. A. 
Representative still images from Supplemental Movie 3 showing CM-H2DCFDA 
staining in PNCs at 20 hpi. CM-H2DCFDA signal is detected in leukocytes 
(turquoise arrows). However only very faint signal is detected in PNCs with very 
high HRASG12V expression (Yellow arrows), indicating general ROS are not 
significantly increases in PNCS. Scale Bar 50 µm B. Representative still images 
from Supplemental Movie 4 showing DHE staining in PNCs at 24 hpi. DHE signal 
is detected in only three PNCs (magenta arrows), suggesting superoxide 
generation is not a significant feature of PNC development.  Scale bar 50 µm. 
Figure 4.8: A newly generated redox sensor localised to the mitochondrial matrix 
shows increased oxidation following wounding. Representative images from 
Supplemental Movie 5 showing response to sterile laser injury (yellow circle) in 
Ubi:Matrix-roGFP at 3 dpf. Increased oxidative stress is seen immediately post 
wounding, indicating the reporter behaves as expected.  
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ubiquitous Ubi promoter. Owing to the time taken for generation and 
characterisation of transgenic zebrafish lines, only the mitochondrial matrix-localized 
line (Supplemental Figure 5) was grown to the required generation and characterised 
within the time-frame of this project. To verify that this reporter was behaving as 
expected, the response to wounding was tested. It is known that rapid ROS 
generation occurs post wounding in zebrafish larvae [266], therefore Ubi:Matrix-
roGFP larvae were subjected to sterile laser injury at 3 dpf. Immediately post 
wounding an increase in oxidation was detected (Supplemental Movie 5, Figure 4.8), 
suggesting that the reporter was behaving as expected. Following this, the 
mitochondrial matrix redox reporter was incorporated into the PNC initiation model. 
Again however, little oxidative signal was detected at 24 hpi (Supplementary Movie 
6, Figure 4.9). As further confirmation that the reporter behaves as expected, 
increased oxidative stress is detected in a PNC that undergoes cell death (Figure 4.9, 
white arrow). Enhanced signal is not detected in other PNCs, suggesting the ROS 
generation in the mitochondrial matrix is not a feature of PNC development. 
However, completion of the cytoplasmic redox sensor will give indications of more 
general oxidative stress during PNC development.  
The finding that PNCs do not generate ROS during development was highly 
surprising. Given the drastic mitochondrial phenotype and previous published        
work, ROS generation was unquestionably expected, and its absence was puzzling. 
One possible explanation for undetectable ROS in the PNC niche is rapid 
detoxification to prevent cell death. To test this, expression of the mitochondrial 
detoxification enzyme superoxide dismutase 2 (SOD2) was assessed by qRT-PCR at 
24 hpi. Increased SOD2 expression was not detected (Figure 4.10). As mentioned, the 
whole embryo approach to qRT-PCR used in this project is open to false negatives, so 
increased SOD2 activity cannot be ruled out using this technique, but an increase of 
sufficient magnitude to completely detoxify mitochondrial ROS in the PNC niche 









Figure 4.9: Increased oxidative stress is only detected in PNCs undergoing cell 
death. Representative still images from Supplemental Movie 6 showing oxidative 
stress in the PNC niche using Ubi:Matrix-roGFP. Oxidative stress in not detected 
in PNCs during development. However, when a PNC undergoes apoptosis (white 
arrow) oxidative stress is detected. This both verifies that the reporter behaves as 
expected and indicates that mitochondrial matrix ROS are not generated in the 
PNC niche. Scale bar 100 µm. 
Figure 4.10: Increased SOD2 
expression is not detected in 
embryos carrying PNCs. qRT-
PCR expression analysis of the 
mitochondrial detoxification 
enzyme SOD2 in embryos 
carrying PNCs relative to wild-
type controls. There is no 
detectable difference in SOD2 
expression in PNC bearing 
embryos, suggesting 
enhanced detoxification of 
ROS by SOD2 is not occurring 
in the PNC niche. Mean + 
SEM, n=7 experiments, t test. 
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4.5 Glycolytic flux is increased following HRASG12V induction.  
In addition to mitochondrial fragmentation, it is well established that mature 
cancer cells exhibit a metabolic switch from oxidative phosphorylation to glycolytic 
metabolism, termed the Warburg effect. Following the success in developing an 
assay of respiratory analysis using the Seahorse extracellular flux analyser, a similar 
assay development strategy was undertaken to assess glycolytic function in this PNC 
initiation model in collaboration with Dr. R. Carter, The University of Edinburgh. 
Again, the assay was established such that a single embryo was added to each well 
of a 24-well islet capture plate and secured using a screen (Figure 4.11 A). Baseline 
extracellular acidification rate (ECAR) was measured over time. Then, to assess 
glycolytic flux, which represents the flow of molecules through the glycolytic 
pathway, the competitive glucose inhibitor 2-deoxyglucose (2-DG) was added, 
followed by addition of the respiration uncoupler FCCP to assess the contribution of 
glycolysis to respiratory function (Figure 4.11 B). The addition of 2-DG inhibits 
glycolysis as glucose cannot enter the pathway, therefore the drop in ECAR is 
indicative of the contribution of glycolytic flux to the ECAR. Significantly increased 
glycolytic flux was detected in embryos bearing PNCs relative to wild-type controls at 
20 hpi (Figure 4.11 C + D). Using the complimentary oxygen consumption rate (OCR 
data not shown), the contribution of glycolysis to respiratory function can be 
assessed by following 2-DG treatment with FCCP treatment using a similar strategy 
to that described in Figure 4.6. It was found that maximum OCR was only marginally 
decreased following 2-DG and FCCP treatment (Figure 4.11 E). This suggests that 
embryos can cope with respiration when glucose cannot be utilised, so clearly other 
inputs to the oxidative phosphorylation pathway can maintain sufficient respiratory 
function, indicating that, while glycolytic flux is enhanced, it is not utilised for energy 





4.6 Glucose uptake is not increased in PNCs.  
As glycolytic flux is enhanced following PNC induction, it was expected that glucose 
uptake would be increased in PNCs, in accordance with The Warburg Effect [92]. To 
test this, the fluorescent 2-NBDG compound was used to monitor glucose uptake. 
Surprisingly, enhanced 2-NBDG signal was not detected in PNCs relative to non-
transformed cells (Figure 4.12 A), suggesting that glucose uptake was not enhanced 
in PNCs during development.  
This was further verified using a red fluorescent glucose compound recently 
developed by Sam Benson and Dr. Marc Vendrell, The University of Edinburgh. To 
verify this compound, SeNBD-Glucose (Unpublished), behaved as expected in 
zebrafish larvae, accumulation was monitored following morpholino knock-down of 
the GLUT2 glucose transporter. Decreased accumulation of SeNBD-glucose was 
detected in the head region of GLUT2-morpholino embryos (Figure 4.13), consistent 
Figure 4.11: Glycolytic flux is enhanced in the presence of PNCs. A. Representative 
image of plate set up for extracellular flux analysis. A single embryo was added to 
each well of a 24-well islet capture plate and held in place using a screen. B. 
Representative schematic of drug manipulation protocol for analysis of glycolytic 
function in zebrafish larvae. The ECAR readout (blue) monitored over time. 
Following assessment of baseline ECAR (Black arrow), the glycolytic flux (magenta 
arrow) can be assessed by the addition of the glycolysis inhibitor 2-DG (black line). 
The respiration uncoupler FCCP was then added (black line) to assess the 
contribution of glycolysis to respiratory function using the complimentary OCR data 
(not shown). C. ECAR readout over time according to the protocol described in B. 
Mean + SEM, n = 16 embryos from 3 experiments. D. Quantification from C. 
Glycolytic flux, determined at cycle 7 of measurement, shows enhanced glycolytic 
flux in the presence of PNCs relative to wild-type controls. Mean + SEM, n = 16 
embryos from 3 experiments, Mann-Whitney test, p = 0.0060. E. Maximum oxygen 
consumption rate determined from OCR date complimentary to that shown in C. 
Maximum OCR is marginally reduced in the presence of PNCs relative to wild-type 
controls, suggesting that enhanced respiratory function is not utilised for 
respiratory function. Mean + SEM, n = 16 embryos from 3 experiments, Mann-
Whitney test, p = 0.0426 
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Figure 4.12: Glucose uptake is not increased in PNCs. A. Representative images 
from glucose tracing using 2-NBDG in PNCs at 24 hpi. Glucose uptake is not 
enhanced in PNCs relative to non-transformed cells. Scale bar 50 µm. B. 
Representative images from glucose tracing using the newly developed SeNBD-
Glucose in PNCs at 24 hpi. Again, glucose uptake in PNCs is not increased. Scale bar 
50 µm. C. Fold change of gene expression detected by qRT-PCR at 24 hpi. No 
change in GLUT2 expression is detected in the presence on PNCs relative to wild-




with previous findings as the GLUT2 transporter is primarily neuronally expressed in 
zebrafish larvae [245]. Use of SeNBD-glucose similarly did not show enhanced 
accumulation in PNCs at 24 hpi (Figure 4.12 B). Given the increase in glycolytic flux 
detected, this was highly unexpected considering glucose is required to fuel 
glycolysis.    
 Further to this, expression of the glucose transporter GLUT2 was assessed by 
qRT-PCR. Despite the issues associated with the qRT-PCR approach in this project, 
expression of GLUT2 was assessed in the presence of PNCs relative to wild-type 
embryos, with no significant difference detected between the groups (Figure 4.12 C). 
However, as GLUT2 is primarily a neuronal glucose transporter in larval zebrafish 
[245], the contribution of this to PNC development is questionable and assessment 
of other glucose transporters, such as GLUT1 and GLUT5 may be more appropriate 
moving forward.   
 
4.7 Alterations in lactate levels were not detected in PNCs. 
At the culmination of the glycolytic pathway pyruvate has one of two fates; 
conversion to acetyl-coA by PDH or conversion to lactate by lactate dehydrogenase 
(LDH) [76]. Increased lactate levels following enhanced glycolysis are characteristic of 
The Warburg Effect and are associated with poor prognosis in cancer patients [267]. 
Figure 4.13: In vivo 
characterisation of Se-NBD-
glucose. Representative images 
following yolk injection of 100 
mM Se-NBD-glucose at 28 hpf. 
Morpholino knock-down of the 
GLUT2 glucose transporter 
results in decreased 
accumulation of Se-NBD-glucose 
in the head region of embryos 
(white arrows), consistent with 
published work using the 2-
NBDG glucose analogue [245].  
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It was therefore of interest to determine if lactate levels are increased in PNCs at 
early stages of development.   
To assess if lactate levels were altered in the presence of PNCs a commercially 
available lactate assay, similar to those described in Section 1.9, was used. This assay 
revealed no change in lactate concentration in PNC bearing embryos relative to wild-
type controls (Figure 4.14 A), although subtle alterations could be masked using this 
whole embryo approach. Despite attempts, sufficient numbers of PNCs could not be 
isolated to attempt the assay in a PNC-specific manner, as the small sample size was 
not within the detection range of the assay.  qRT-PCR analysis of LDH-A and the 
lactate transporter MCT4, which is commonly altered in established cancer, revealed 
unchanged expression in the presence of PNCs (Figure 4.14 B). These findings suggest 
that lactate concentrations in the PNC niche are not increased, although it is difficult 
to conclude with certainty due to the errors associated with these techniques. 




Figure 4.14: Increased lactate concentration is not detected in the presence of 
PNCs. A. Lactate concentration determined using commercially available lactate 
assay kit. A marginal decrease in lactate concentration is detected in the presence 
of PNCs relative to wild-type controls. Mean + SEM, n = 5 experiments, Mann-
Whitney test, p = 0.1984. C. Fold change of gene expression determined by qRT-
PCR at 24 hpi. Expression of LDH-a and the lactate transporter MCT4 remains 
unchanged in the presence of PNCs relative to wild-type controls. Mean + SEM, n 
= 5, Mann-Whitney test. 
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are required to assess lactate levels in vivo. Generation of a transgenic reporter 
zebrafish lines is underway to facilitate this, as further discussed in section 5.1. 
 
4.8 PNC survival is linked to glycolytic metabolism, but not to mitochondrial 
fragmentation. 
Having earlier demonstrated the effect of mitochondrial fragmentation on 
mitochondrial function, the effect of this phenotype on PNC development was 
investigated. To assess if Dnm1l-dependent mitochondrial fragmentation is required 
for PNCs survival, cleaved caspase-3 activity in PNCs was assessed as a marker of 
apoptosis. At 24 hpi, no change in caspase-3 activity in PNCs was  
detected following treatment with mDIVI-1 (Figure 4.15), suggesting that 
mitochondrial fragmentation is not responsible for induction of apoptosis and is not 
a requirement for PNC persistence. To assess if glycolytic signalling is important for 
PNC survival cleaved caspase-3 levels were assessed as a measure of apoptotic cell 
death. Following 2-DG inhibition, increased caspase-3 activation was detected 
Figure 4.15: mDIVI-1 treatment does not induce apoptosis in PNCs. A. 
Representative images of cleaved caspase-3 activity in PNCs at 24 hpi, untreated 
or 16 hpt mDIVI-1. Scale Bar 50 µm B. Quantification from A. No difference in 
PNC apoptosis is detected following treatment with mDIVI-1, indicating that 
mitochondrial fragmentation does not induce apoptosis and is not a requirement 
for PNC survival. Mean + SEM, n ≥ 12 embryos from 3 experiments, Mann-
Whitney test, p = 0.6114 
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specifically in PNCs relative to untreated controls (Figure 4.16). This suggests that 
glycolysis is important for PNC survival and elevated glycolytic flux could be vital for 
PNC persistence.  
 
4.9 Neutrophil recruitment to developing PNCs is altered by glycolytic signalling, 
but not by mitochondrial fragmentation.  
As shown in Section 3.4 (Figure 3.8), this model of PNC initiation is consistent 
with others, in that recruitment of neutrophils to developing PNCs is observed. This 
is a major research interest for the group and one of the hypotheses of this project is 
that metabolic alterations are involved in the signalling that induces this response.  
To determine if Dnm1l-dependent mitochondrial fragmentation is involved in 
neutrophil recruitment to developing PNCs, time-lapse microscopy following mDIVI-
treatment was undertaken. Analysis reveals that neutrophil recruitment is not 
altered by mDIVI-1 treatment (Figure 4.17), suggesting that mitochondrial 
Figure 4.16: PNC apoptosis is increased following glycolysis inhibition. A. 
Representative images of cleaved caspase-3 activity in PNCs at 24 hpi, untreated 
or 16 hpt 2-DG. Scale bar 50 µm. B. Quantification from A. Increased apoptotic 
cell death is detected in PNCs following inhibition of glycolysis by 2-DG 
treatment, indicating glycolysis is important for PNC survival. Mean + SEM, n ≥ 10 
embryos from 3 experiments, Mann-Whitney test, p = 0.03 
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fragmentation does not induce the inflammatory response observed in the PNC 
niche.  
To investigate the role of glycolytic signalling in establishing a pro-inflammatory 
niche, embryos were treated with 2-DG and recruitment of neutrophils to the PNC 
niche was monitored by time-lapse microscopy. Analysis reveals that recruitment of 
neutrophils is significantly reduced following treatment with 2-DG (Figure 4.18). 
However, as neutrophils are inherently highly glycolytic cells it is possible that 2-DG 
could be acting directly on neutrophils. To test this, recruitment of neutrophils to a 
wound following 2-DG treatment was assessed. Surprisingly, no change in number of 
neutrophils recruited to the wound at 6 hpw was detected following treatment with 
2-DG (Figure 4.19). This suggests that glycolytic signalling in the PNC niche plays an 
important role in the recruitment of neutrophils at early stages of PNC initiation. 
 
































Figure 4.17: Neutrophil recruitment to developing PNCs is not altered by mDIVI-
1 treatment. Quantification of recruited neutrophil numbers to PNCs following 
mDIVI-1 treatment. Treatment with mDIVI-1 does not alter the number of 
neutrophils recruited to developing PNCs, suggesting that mitochondrial 
fragmentation is not involved in establishing an inflammatory response in the 
PNC niche. Aligned replicates with linear regression analysis, n = 7 embryos from 
3 independent experiments. 
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Figure 4.18: Recruitment of neutrophils to the PNC nice is impaired following 2-DG 
treatment. Quantification of recruited neutrophil numbers to PNCs following 2-DG 
treatment. Glycolysis inhibition with 2-DG appears to impair neutrophil 
recruitment, suggesting that glycolytic signalling is important for establishing an 
inflammatory response in the PNC niche. Aligned replicates with linear regression 
analysis, n = 6 embryos from 3 independent experiments. 
Figure 4.19: Neutrophil recruitment to a wound is not impaired following 2-DG 
treatment. A. Representative images from LysC:DSRed embryos at 6 hpw, 
untreated or 6 hpt 2-DG. Scale bar 80 µm. B. Quantification from A. Number of 
neutrophils recruited to wound at 6 hpw following treatment with 2-DG. Inhibition 
of glycolysis does not appear to alter recruitment of neutrophils to a wound. Mean 
+ SEM, n = 16 embryos from 2 experiments, Mann-Whitney test, p = 0.3748 
 99 
4.10 Metformin treatment induces PNC specific apoptotic cell death. 
From the findings presented above, it is clear that mitochondrial 
fragmentation is an early alteration in PNCs and this phenotype has functional 
consequences, most notably impaired respiratory capacity. As this is a distinguishing 
feature of PNCs, it was of interest to determine if this phenotype could be targeted 
for therapeutic or preventative interventions.  
Metformin is a mitochondrial complex I inhibitor commonly used for the treatment 
of type 2 diabetes. Many studies and trials are currently underway to investigate 
metformin in a cancer paradigm, both as a cancer treatment and for its potential in 
cancer prevention (reviewed in [268]). Metformin has two mechanisms of action; it 
acts on complex I of the electron transport chain and can activate the MAPK-
dependent AMPK signalling pathway, with both processes altering a cells capacity to 
generate energy [268][269]. Hence, metformin alters cellular function and fate by 
manipulating cellular energy consumption. As PNCs in this model have altered MAPK 
activity as a result of HRASG12V-transformation and appear to have a respiratory 
impairment, it was of interest to probe their response to metformin. Detection of 
cleaved caspase-3 activity as a measure of apoptotic cell death was used to consider 
the effect of metformin treatment on PNCs. It was found that treatment with 
metformin induced rapid and PNC-specific apoptotic cell death (Figure 4.20). Despite 
a wide spread in the data, at 4 hpt caspase-3 activity in PNCs had significantly 
increased from 5% in untreated controls to an average of 26% in metformin treated 
embryos, reaching a high of 50% in some samples (Figure 4.20 B). In fact, by 16 hpt 
there appeared to be fewer PNCs for analysis in metformin treated embryos 
(observational detail, data not shown), suggesting that a considerable number of 
PNCs had died by apoptosis by this time-point. This increase in apoptotic cell death 
is PNC specific as caspase-3 activity was not seen in other cells in the PNC niche 
(Figure 4.20 A). This indicates that altered MAPK activity and the mitochondrial 
fragmentation-induced respiratory impairment seen in PNCs makes them susceptible 
to apoptotic cell death following metformin 
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treatment and places metformin as an ideal candidate for further investigations of 
cancer prevention.  
 
4.11 Discussion  
The role of mitochondrial phenotype, and downstream processes dependent 
upon such, during PNC initiation and development have not previously been 
determined. While it is known that these features play important roles in the 
progression of established cancers, the timing of these alterations and their role in 
initiation remains elusive. Using a newly established in vivo larval zebrafish model for 
tumour initiation, the mitochondrial phenotype and the possible effect of 
mitochondrial alterations during PNC initiation and development was investigated. 
 Mitochondria undergo significant Dnm1l-dependent fragmentation at very 
early stages of PNC development. This has functional consequences as reduced 
mitochondrial membrane potential and impaired respiratory capacity are observed. 
The phenotype does not appear to induce mitochondrial ROS and does not appear to 
be important for PNC survival. Treatment with the complex I inhibitor metformin 
Figure 4.20: Metformin treatment induces apoptotic cell death in PNCs. A. 
Representative images of cleaved caspase-3 activity at 24 hpi, untreated or 4 hpt 
metformin. Increased caspase-3 activity is seen following metformin treatment. 
Scale bar 50 µm B. Quantification from A. Percentage of PNCs undergoing 
apoptosis is significantly increased following metformin treatment. Mean + SEM, n 
≥ 12 embryos from 3 experiments, Mann-Whitney test, p = 0.0001. 
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induces PNC specific apoptosis, placing mitochondrial and respiratory alterations as 
potential targets for preventative and therapeutic interventions.  
It was determined that mitochondrial fragmentation, similar to that seen in 
established cancers [154]–[156], occurs at very early stage of PNC development. In 
fact, fragmentation is apparent from the earliest stages of PNC detection and persists 
over time as significant fragmentation is still detectable at 24 hpi. This would indicate 
that the phenotype has important roles during the initiation stages of cancer, as well 
as later stages of progression. 
To understand how mitochondrial fragmentation might affect tumour 
initiation, it is important to determine mechanistic insights of how this phenotype 
arises. Previous work suggests that upregulation of the mitochondrial fission protein 
Dnm1 in vitro is responsible for mitochondrial fragmentation following 
phosphorylation by members of the MAPK pathway [157][158]. Isolation of PNCs by 
FACS for analysis of expression levels of mitochondrial fusion and fission proteins was 
attempted. PNCs were successfully isolated, but extraction of a sufficient quantity of 
RNA for cDNA synthesis was not achieved without the need for amplification. As 
amplification adds significant cost, it was instead decided, for the purposes of this 
project, to analysis cDNA synthesised from RNA extracted from whole embryos 
carrying PNCs. This approach means that expression levels in all cells in the embryo, 
not just PNCs, will be analysed and any changes occurring in PNCs could be masked 
by the basal expression level in other cells. Only highly significant alterations will be 
detected, and the likelihood of false negatives is high. To overcome this, recent 
funding has been secured to carry out RNA sequencing analysis in this model, which 
will test this result specifically in PNCs. In the interim, attempts were made to 
visualise this Dnm1l upregulation by immunostaining. Antibodies for mammalian 
orthologues of Drp1 with predicted reactivity for the zebrafish orthologue were 
trialled but proved unsuccessful.  
Despite these results, previously published work [157][158], suggested that 
upregulation of Dnm1l was responsible for the extensive mitochondrial 
fragmentation seen in PNCs. A pharmacological approach to test this using the Drp1-
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specific GTPase inhibitor mDIVI-1 [264] resulted in rapid recovery of conventional 
mitochondrial phenotype, indicating that the fragmentation phenotype is a result of 
Dnm1l activity. This also reveals that fragmentation is reversible, so mitochondria are 
not damaged beyond recovery. Excessive fragmentation induces apoptosis and 
therefore a delicate balance must exist in PNCs so as not to cause cell death while 
still enabling the downstream alterations to occur. Mitochondrial fragmentation as a 
result of Drp1 upregulation in cancer is not novel, but the occurrence of the 
phenotype so early in development suggests vital importance for oncogenic 
processes. Fragmentation and its downstream effects must clearly be involved in 
tumour establishment and progression. Given the clear importance of Dnm1l 
expression, this conclusion would be better supported with a non-pharmacological 
approach as mDIVI-1 is administered via immersion and acts globally on the embryos. 
Also, issues of tissue penetration and toxicity are always to be considered with 
pharmacological approaches. Therefore, a genetic approach to knock-down Dnm1l 
expression specifically in PNCs is currently under development. Using a dominant 
negative form of the protein [147], Dnm1l expression will be reduced specifically in 
PNCs to assess the effect on PNC development and reinforce these findings.  
    As mitochondrial fragmentation occurs naturally as part of the cell cycle, 
mitochondrial membrane potential was assessed to determine if the fragmentation 
observed in PNCs was destructive. A number of different MitoTracker stains are 
available to analyse mitochondria, with distinct properties and colours associated 
with each. When used in combination a variety of mitochondrial parameters can be 
assessed. To investigate membrane potential MitoTracker Red CMX-Ros combined 
with MitoTracker Green FM is the ideal combination. Accumulation of MitoTracker 
Red CMX-ROS is highly dependent on membrane potential, while MitoTracker Green 
FM accumulates in mitochondrial independent of membrane potential [270]. In this 
approach, colocalization of the two stains should occur in intact mitochondria, while 
loss of membrane potential can be assessed based on loss of red signal. However, 
due to the colour profile of this combination it could not be used in the PNC model. 
Instead, the far red MitoTracker Deep Red FM was used in combination with 
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MitoTracker Red CMXRos. MitoTracker Deep red FM is not independent of 
membrane potential. Accumulation occurs in mitochondria with lost membrane 
potential but staining intensity is altered [271]. Therefore, this approach can be used 
to assess reduced membrane potential, but not complete loss, provided fluorescence 
intensity is closely monitored. To overcome this intensity dependence on membrane 
potential, automated Imaris software analysis was used to calculate the 
colocalization independent of fluorescence intensity. This approach revealed 
reduced mitochondrial membrane potential in PNCs and indicated that 
fragmentation has functional consequences for mitochondria. As membrane 
potential was rapidly recovered following treatment with mDIVI-1, this further shows 
that the mitochondrial fragmentation phenotype is dependent on Dnm1l activity.  
To further probe the consequential effect of mitochondrial fragmentation a 
protocol for assessment of respiratory function was developed. The Seahorse 
extracellular flux analyser can be used to measure oxygen consumption rate (OCR) to 
assess respiratory function. Originally developed for used with cell culture, there are 
few publications using the instrument for in vivo analysis. At the time of assay 
development just two papers had been published using the instrument for in vivo 
zebrafish analysis [272][273] and crucial details were missing from both. While 
Stackley, et al, [272] gave in-depth protocol details, information on run temperature 
was missing, which preliminary work revealed to be highly relevant, as data varied 
greatly with just minor changes in temperature. Meanwhile, Gilbert, et al, [273] 
missed vital run protocol information, temperature information and embryo staging 
data. Using these publications as a basis, a protocol for in vivo detection of respiratory 
function in embryos up to 60 hpf was developed. During the course of protocol 
optimisation treatment with the ATP-synthase inhibitor oligomycin was included to 
assess ATP production, as is standard with in vitro respiratory assays using this 
instrument [222]. However, tissue penetration issues arose at later developmental 
stages, and the compound was dropped from the final protocol. As previously 
mentioned, it became apparent during optimisation that temperature fluctuations 
can skew the data considerably. Therefore, temperature was carefully monitored 
 104 
over the course of each run and only technical repeats with the same temperature 
range were included for final analysis. The final protocol allows assessment of 
baseline respiration, maximum OCR, reserve OCR, baseline respiration, maximum 
respiratory capacity, reserve respiratory capacity and non-respiratory OCR based on 
treatment with the respiration uncoupler FCCP and co-treatment with the complex 
III inhibitor antimycin and the complex I inhibitor rotenone (Figure 4.6 B). This 
protocol allows for in vivo assessment of these respiratory parameters, providing 
detailed information on metabolic alterations in larval zebrafish up to 60 hpf. In this 
PNC initiation model, impaired respiratory capacity was detected in PNC bearing 
embryos, which was rescued following mDIVI-1 treatment suggesting that 
mitochondrial fragmentation alters respiratory function in PNCs. Detecting this using 
a whole embryo approach, where the basal metabolism of the vastly out-numbering 
non-transformed cells of the embryo masks PNC alterations, suggests considerable 
impairment; much greater than that suggested by the data. Overall these findings 
indicate that respiratory impairment in induced during PNC development as a result 
of Dnm1l-dependent mitochondrial fragmentation.    
The finding that ROS are not elevated in the PNC niche was initially surprising. 
Previous work in other PNC initiation models suggest important roles for hydrogen 
peroxide in the PNC niche [192] and there is a large and continually growing body of 
work to suggest that mitochondrial fragmentation is associated with elevated ROS 
generation in cancer (reviewed in [143] ). However, further literature investigations 
lead to the finding that ROS generation is linked to mitochondrial membrane 
potential. It was previously found that a threshold mitochondrial membrane 
potential is required for generation of hydrogen peroxide [274]. Considering reduced 
membrane potential was found in PNCs, it is plausible that mitochondrial 
fragmentation-induced reduction of mitochondrial membrane potential is a 
protective mechanism against excessive ROS production in PNCs. Excessive ROS is 
known to lead to apoptosis. Therefore, it is possible that while sufficient levels of ROS 
are maintained in PNCs to allow for intracellular signalling processes, these are below 
detectable levels for in vivo imaging. Reduced mitochondrial membrane potential 
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prevents excessive ROS production, thereby preventing cell death by apoptosis. 
Considering the large body of evidence linking mitochondrial fragmentation with ROS 
production and the detection of excessive ROS production in a variety of cancers, this 
would be an unexpected mechanism. However, studies to date have involved in vitro 
work or work in established cancers. There is, therefore, potential for this mechanism 
to act during PNC development, before a cell is fully transformed and protected from 
apoptosis by resistance to oxidative stress but no longer be active in fully transformed 
cells. Also, previous work has shown a NOX-mediated mechanism of ROS production, 
as opposed to mitochondrial ROS. Based on the findings presented here, 
mitochondria in PNCs are not damaged, merely altered. Therefore, while 
mitochondrial ROS may be elevated within standard cellular range, this could be 
outside the detection range of the approaches used here. This would explain the lack 
of ROS detected using the mitochondrial matrix redox sensor, but not using the more 
general ROS dyes. Clearly further, more focused studies will be required to probe the 
link between ROS and mitochondrial fragmentation during these early stages of 
cancer development. The development of new transgenic lines during this project for 
localised redox stress will help with these investigations, aiding future work to 
determine the role of redox signalling in the PNC niche.  
Having confidently established that mitochondrial fragmentation occurs in 
PNCs and has consequential effects on mitochondrial function, determination of the 
effect of this phenotype on PNC development followed. Inhibition of mitochondrial 
fragmentation does not appear necessary for PNC survival, as no increase in cleaved-
caspase 3 activity is detected following mDIVI-1 treatment. This is not altogether 
surprising, as mDIVI-1 returns mitochondria to a more fused phenotype, generally 
not associated with programmed cell death. However, given the necessity of cancer 
cells to proliferate to establish a tumour, the identification of such a phenotype so 
early during PNC development is encouraging as it proves mitochondrial 
fragmentation is important for oncogenic processes and places the phenotype as a 
potential target for cancer prevention.  
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One of the driving forces behind this program of work is the hypothesis that 
metabolic alterations in PNCs are involved in signalling that initiates trophic 
inflammatory responses in the developing PNC niche. To test this possibility, 
recruitment of neutrophils in the PNC niche was monitored following mDIVI-1 
treatment. Pharmacological approaches are less than ideal for this type of analysis as 
global compound action on both PNCs and neutrophils makes it difficult to accurately 
interpret the results. However, inhibition of Dnm1l expression specifically in 
neutrophils does not appear to alter their migration (Unpublished, correspondence 
with Dr. Qing Deng, Perdue University). Regardless, no change was observed in 
number of recruited neutrophils to the PNC niche following Dnm1l inhibition, 
indicating that mitochondrial fragmentation or its downstream consequences do not 
play a role in neutrophil recruitment. This will be verified using the dominant negative 
form of Dnm1l discussed above when generation and characterisation has been 
completed. 
Alterations to glycolytic metabolism are well characterised features of 
established cancers but their role during early cancer development is less well 
established. This project set out to investigate the glycolytic phenotype at early 
stages of PNC development and how alterations to glycolytic signalling may be 
involved in PNC development. Enhanced glycolytic flux was detected and this appears 
to be important for PNC survival. However, how this flux is fuelled and the effect of 
increased glycolysis on lactate levels remains ambiguous.   
Initial experiments involved optimisation of a new protocol for in vivo 
glycolytic analysis using the Seahorse Extracellular Flux analyser. To date, the limited 
number of publications using this instrument for in vivo zebrafish analysis have 
primarily investigated oxygen consumption rate (OCR) for respiratory manipulations 
[272][273][275]. While mentions of ECAR have been made [272], little conclusive 
findings on glycolytic capacity have been published. Standard in vitro protocols for 
glycolytic functional analysis using the Seahorse extracellular flux analyser use 
oligomycin treatment to determine glycolytic capacity [223]. Oligomycin treatment 
was included in early experimental optimisations but, as has previously been 
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published [273], there appeared to be tissue penetration issues at later 
developmental stages. For this reason, oligomycin treatment was not included in the 
final protocol. This penetration issue could be partially responsible for the lack of 
published ECAR data using this instrument for zebrafish analysis to date, as it limits 
the information determinable from relatively costly experiments. However, while 
glycolytic capacity could not be determined using this technique, glycolytic flux was 
successfully determined by inhibiting glycolysis using the competitive inhibitor 2-DG. 
The glycolytic flux represents the rate at which molecules move through the glycolytic 
pathway and is used as a measure of glycolytic function. The rapid decrease in ECAR 
function following 2-DG addition allows the contribution of glycolytic function to the 
ECAR to be assessed (Figure 4.11) [223], giving indications of the intracellular flow 
through the glycolytic pathway. Finally, it was of interest to determine the effect of 
glycolytic inhibition on respiratory function. The Seahorse extracellular flux analyser 
measures ECAR and OCR simultaneously. By following glycolytic inhibition with 
addition of the mitochondrial uncoupler FCCP, the complimentary OCR read-out 
could be used to monitor the ability of embryos to respire when glycose cannot be 
utilised as a fuel source. The rise in OCR following FCCP treatment is indicative of 
respiratory function, therefore the contribution of glycolysis to oxidative 
phosphorylation could be analysed. This protocol allows previously unattainable in 
vivo analysis of glycolytic function and its effect on respiratory capacity. However, 
caution is required. As previously mentioned, temperature fluctuations appear to 
impact on consistency, as does developmental stage of embryos. Careful embryo 
staging and temperature monitoring is required to ensure reproducible results. Also, 
high variation of baseline ECAR was observed between technical repeats. The reason 
for this remains unknown but could be due to inherent differences associated with 
using an in vivo system. Care must be taken when comparing technical repeats to 
ensure experimental conditions and baseline ECAR levels are consistent.  
Implementation of this protocol in the PNC initiation model revealed 
significantly enhanced glycolytic flux in PNC bearing embryos. Similar to the 
respiratory alterations determined using this technique, detection of glycolytic 
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adaptations using a whole-embryo approach is indicative of substantial upregulation 
of glycolytic function. To identify such change at very early stages of PNC 
development suggest importance for oncogenic processes. However, impairment to 
respiratory function following glycolytic inhibition appears to be minimal as 
maximum OCR remains relatively unchanged following 2-DG treatment. This suggests 
that enhanced glycolytic function is not utilised for energy generation. Of course, the 
possibility remains that impairment of respiratory function following glycolytic 
inhibition is below detectable levels using this approach, but it seems likely that the 
enhanced glycolytic flux observed is at least not entirely used for energy production. 
Given the number of intermediates in the glycolytic pathway which can feed into 
other mechanistic avenues, it seems likely that enhanced flux is at least partly 
required for cellular functions beyond that of ATP generation. 
Given these findings, it was highly surprising that glucose uptake was not 
enhanced in PNCs or the PNC niche. Glucose is the primary input for glycolysis and 
increased activity of the pathway suggests a need for more substrate. 2-NBDG is the 
only commercially available fluorescently labelled glucose compound for glucose 
tracing. This compound has been used in vivo in zebrafish in the past and is well 
tolerated. However, delicate imaging protocols are required due to the colour profile 
of 2-NBDG in combination with mCherry PNCs. Therefore, verification of this result 
was sought.  
The Vendrell group based at the Centre of Inflammation Research at The 
University of Edinburgh is involved in generation of fluorescent compounds for 
dynamic imaging. Sam Benson, a PhD candidate in the Vendrell group, has recently 
generated a red fluorescent glucose compound, named Se-NBD-glucose. Before this 
compound was used for experimental purposes, characterisation of Se-NBD-glucose 
in vivo in zebrafish was undertaken, in collaboration with the Vendrell group. Se-NBD-
glucose showed similar distribution to that of 2-NBDG following vascular injection 
(data not shown). Also, knock-down of the glucose transporter GLUT2 using a GLUT2 
anti-sense morpholino revealed reduced accumulation of Se-NBD-glucose in the 
head of 28 hpf embryos (Figure 4.13), recapitulating published work using 2-NBDG 
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[245]. These data were sufficient for confirmation that Se-NBD-glucose behaves as a 
fluorescent glucose analogue in vivo. Following this, use of Se-NBD-glucose in the PNC 
initiation model replicated 2-NBDG findings, in that enhanced uptake was not 
observed in PNCs or the PNC niche. Unchanged expression of the glucose transporter 
GLUT2 further indicates that glucose uptake does not appear to be a phenotype of 
PNCs. However, upon reflection, it was noted that GLUT2 is primarily a neuronal 
transporter in larval zebrafish and expression of GLUT1 and GLUT5 may prove more 
informative. Nonetheless, unaltered glucose uptake in PNCs was a puzzling finding as 
it is at odds with the detection of enhanced glycolytic flux. It is possible that enhanced 
flux could be fuelled by glucose-6-phosphate generated from glycogen stores, or 
alternative sugar derivatives [76][276], although this seems unlikely given that the 
yolk composition is primarily lipids and amino acids [277][278] and independent 
feeding has not commenced at this developmental stage. As D-glucose inhibits 2-
NBDG uptake [279], it is theoretically possible that PNCs are saturated with 
endogenous glucose that is transported into the cell using a glucose transporter other 
than GLUT2, but this too seems unlikely. This leaves the outstanding question of how 
enhanced glycolytic function is sustained in PNCs. 
Indications that glycolytic products are not fully utilised for respiratory energy 
generation suggest alterations to intracellular lactate. Lactate metabolism is an active 
area of cancer research and has been shown to play important roles in oncogenic 
processes [267]. Therefore, it was of interest to investigate lactate metabolism during 
PNC development. A commercially available lactate assay carried out on dissociated 
whole embryos carrying PNCs suggests lactate concentration is not altered. This assay 
was attempted using FACS isolated cells, but sufficient cell numbers for lactate 
detection were not achieved. It is possible that PNC specific alterations in lactate 
levels could be masked using this method or that expression is altered below 
detectable levels for this kit. However unchanged expression of LDH-A also strongly 
suggests that intracellular lactate concentration is not increased in PNCs. Unaltered 
MCT4 expression indicates it is also unlikely that export of lactate from PNCs is 
enhanced, although this result required clarification in a PNC specific manner. While 
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these techniques have high margins for error, they consistently imply that lactate 
levels are not altered in PNCs during development. Like glucose uptake findings, this 
conclusion too leads to further outstanding questions. If glycolytic end-products are 
not necessary for respiratory function and do not lead to increased lactate, what 
processes are they necessary for and how does this impact PNC development? 
Despite not fully elucidating mechanistic alterations to glycolytic signalling in 
PNCs, the pathway appears to be important for PNC survival. Increased PNC-specific 
apoptosis was detected following glycolytic inhibition using 2-DG, indicating that 
intact glycolysis is a requirement for PNC endurance. This would suggest that 
alterations to glycolytic metabolism in PNCs is a potential target for cancer 
prevention, although mechanistic determinations are required before this avenue 
could be pursued.  
One of the ongoing interests of the Feng lab is how PNCs induce a trophic 
inflammatory response during initiation. While indications point towards a role for 
glycolytic signalling in this process, data must be interpreted with care. It seems 
important to address that the treated and untreated groups appear to show different 
neutrophil numbers from the very beginning of the time-lapse experiment. For these 
experiments 2-DG was added to treated embryos approximately 30 min prior to 
imaging commencement due to technical constraints. It is therefore plausible that 2-
DG action is already in effect when imaging starts, however further experimental 
analysis will determine this for certain. Neutrophils are highly glycolytic cells by 
nature, and this is increased upon activation. Therefore, global manipulation of the 
environment has a high likelihood of acting directly on neutrophils. While wounding 
experiments do not show an effect of 2-DG treatment on peak neutrophil 
recruitment at 6 hpw, pharmacological approaches remain inadequate for this type 
of analysis. In order to appropriately determine the role of glycolytic signalling in 
neutrophil recruitment to PNCs, first mechanisms of glycolytic adaptations must be 
identified. This will allow targets to be recognised for manipulation in a PNC specific 
manner and allow the consequential effect on neutrophil recruitment to be assessed.     
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The finding that metformin treatment induces PNC specific apoptosis is highly 
encouraging. It reinforces the idea that mitochondrial fragmentation and the 
resultant respiratory impairment in PNCs have potential as therapeutic targets for 
cancer prevention and agrees with the growing body of evidence that places 
metformin as a potential cancer preventative intervention. Despite this, further work 
is necessary before this compound can be suggested for use in such a capacity. For 
instance, one issue surrounding studies of metformin is concentration. Many in vitro 
studies use concentrations that are not physiologically relevant and therefore must 
be interpreted with caution. Typical human plasma concentrations are in the range 
of 4 µM to 15 µM following a single dose of metformin [269]. While 10 mM treatment 
was used in this project, the plasma concentration of compound is unknown. 
Metformin requires active transport into cells by a number of mammalian 
transporter families [268]. The ability of transporters to internalise metformin in 
zebrafish is not well defined, therefore compound concentrations at the site of action 
are not known. Determination of compound uptake and plasma concentrations will 
allow clarification of whether induction of PNC apoptosis can be achieved with 
physiologically relevant concentrations of metformin.  In order to fully elucidate the 
mechanisms of cancer prevention by metformin in this model detailed 
pharmacodynamic studies are necessary to first fully understand how metformin 
behaves in zebrafish. Then, further mechanistic studies can commence. As metformin 
can act through both complex I and MAPK-dependent AMPK activation [268][269], 
determination of mechanisms of action will be necessary. Treatment with alternative 
complex I inhibitors, such as rotenone, should give indications as to whether this 
mechanism is responsible for PNC susceptibility to metformin. Following this, studies 
of the effect of metformin on PNC development including analysis of the cell cycle, 
proliferation and inflammatory responses will further contribute to elucidation of 
suitability of metformin for cancer prevention in vivo. 
The findings presented here reveal that mitochondrial and metabolic 
alterations occur at vary early stages of tumour initiation and are important for 
tumourigenic processes. While these findings are encouraging, it is clear that the 
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whole-embryo approach taken with many methods for these analyses is not the best 
means, as likelihood for false negatives introduces hesitation in drawing conclusions. 
Moving forward, PNC-specific techniques are required for metabolic analysis to 
determine mechanisms of alteration and the importance for PNC development. This 
will be aided by the generation of new transgenic zebrafish lines for in vivo imaging 
of metabolic processes as further discussed in Section 5.
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5. Generation of new transgenic reporter zebrafish lines for in vivo imaging of 
metabolic processes. 
 Section 1.9 discussed the various in vitro and in vivo techniques available for 
metabolic investigations and highlighted the need for more sensitive and specific 
tools for assessment of metabolic processes in vivo. Throughout this project isolation 
of PNCs in the required numbers for the available techniques proved challenging and 
hindered confidence in findings. The whole-embryo approach proved insufficient for 
detection of metabolic alterations in such a small subset of cells and, currently, there 
are limited tools available to assess metabolic changes in defined cellular populations 
in vivo. As previously discussed, the zebrafish presents an exciting opportunity for 
development of new transgenic reporter lines. Such tools would allow sensitive and 
specific monitoring of metabolic changes in vivo and in real time, presenting a 
promising method for metabolic investigations moving forward.  
To this end, development of a number of transgenic zebrafish reporter lines 
commenced during this project with the ultimate aim to generate a library of new 
tools to allow in vivo monitoring of metabolic processes which can be utilised across 
the spectrum of zebrafish development and disease research. Owing to the time and 
resources necessary for such an ambitious aim, completion of these new transgenic 
lines was not achieved during the time frame of this project. The below sections give 
details of the reporter lines currently under development and summarize the 
progress made to date.  
 
5.1 Laconic: a reporter for intracellular lactate 
The overarching hypothesis for this project is that metabolic alterations bring 
about changes in lactate levels during PNC initiation and development, altering 
inflammatory responses and polarising the developing microenvironment towards 
pro-tumourigenic roles. Given the difficulties assessing lactate levels encountered 
during this project, the generation of a new transgenic zebrafish reporter line for in 
vivo imaging of intracellular lactate levels would allow unprecedented analysis of 
lactate metabolism. The Laconic lactate sensor is a FRET-based sensor that has 
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proven successful for monitoring intracellular lactate concentration in vitro [238] and 
appeared a good candidate for translation in vivo. These FRET sensors are fusion 
proteins flanked by a pair of fluorescent proteins with overlapping 
excitation/emission spectra attached. Binding of a ligand to the sensor protein causes 
a conformational change leading to a change in energy transfer between the two 
fluorescent proteins and consequential alteration of fluorescent signal, referred to as 
FRET efficiency. Laconic is based on the bacterial transcriptional regulator Lldr with a 
TFP/Venus FRET pair which shows a decrease in FRET-efficiency when lactate binds 
[238]. By monitoring FRET efficiency intracellular lactate concentrations can be 
determined.   
Initial cloning issues led to commercial synthesis of the Gateway middle entry 
vector construct (Figure 5.1 A) and, while this resulted in a time delay for transgenic 
line generation, it allowed the construct to be codon optimised for zebrafish, 
therefore expression of the final sensor should be enhanced. The reporter was then 
cloned under the expression of the Ubi promoter (Figure 5.1 B) and injected into the 
one cell stage of wild-type zebrafish eggs. However, initial screening of F0 generation 
proved problematic. Expression of a blue eye (cry:eCFP) transgenic marker included 
in the genetic construct was detected, but Laconic expression was remarkably weak 
in all F1 offspring. This could be due to poor quality tol2 RNA at the time of injection, 
although selection marker expression suggests otherwise. Random incorporation 
into the genome, as is the case with tol2 transgenics, is susceptible to variation based 
on the locus on integration, and therefore genomic integration at an undesirable 
locus can result in poor expression [280]. As this is likely the case, the Ubi:Laconic 
construct has been re-injected and these F0 fish will be screened to identify a founder 
fish upon reaching adulthood, although unfortunately this stage had not been 
reached at the culmination of this project. 
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Figure 5.1: Construct maps for Laconic. A. Synthesised Gateway middle entry 
vector for Laconic. B. Final Ubi construct used for generation of Laconic 
transgenic zebrafish line. 
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Figure 5.2: Transient 
expression of Laconic for 
visualisation of 
intracellular lactate. A. 
Excitation/Emission 
spectra for mTFP and YFP 
and Mean fluorescent 
intensity from lambda 
scan of K4:KalTA4-
ERT2;UAS:Laconic at 24 hpi 
shows two peaks of 
fluorescence intensity, 
consistent with the 
TFP/YFP FRET pair. B. 
Representative images of 
transiently injected 
UAS:Laconic at 24 hpi in 
superficial skin cells. 
Combined image 
represents ratio TFP/YFP. 
Scale bar 50 µm. 
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Provisionally, Laconic was expressed under the control of the UAS promoter 
and used in combination with the Krt4:KalTA4-ERT2 line, leading to expression 
specifically in superficial skin cells.  Although this transient approach is not ideal, it  
can be used to confirm reporter expression and give preliminary insights of lactate 
levels. Using this approach, embryos were imaged at 24 hpi to confirm reporter 
expression. A lambda scan shows two peaks of fluorescence, consistent with those 
expected for the TFP/YFP FRET pair (Figure 5.2 A), indicating the reporter is 
expressing as expected. This represents the native state of the sensor with full FRET 
efficiency. The low TFP peak shows energy is being quenched and released from the 
neighbouring YFP fluorophore. Ratiometric image analysis can then be used to 
monitor relative expression of TFP and YFP to assess lactate levels in superficial skin 
cells (Figure 5.2 B). Using the transient approach prohibits quantification of FRET 
efficiency changes, as GAL 4 overexpression leads to signal amplification and inherent 
differences in fluorescence intensity may be present as a result of transient injection.  
Despite this, these early indications of reporter signal are encouraging and affirm 
confidence in the final reporter line.   
 
5.2 Pyronic: a reporter for intracellular pyruvate 
Pyruvate sits at an important metabolic junction in the cell. As the product of 
the glycolytic reactions, pyruvate has the potential to be converted to acetyl-CoA to 
feed the citric acid cycle and oxidative phosphorylation or be converted to lactate 
under conditions of hypoxia or during aerobic glycolysis. Therefore, assessment of 
cellular pyruvate can be highly informative; giving information about glycolytic rate, 
pyruvate transport and metabolite consumption. Pyronic is an intracellular pyruvate 
FRET sensor, which works by a similar principle to the Laconic sensor described 
above. Pyronic is based on the bacterial transcriptional regulator PdhR, which is 
flanked by a TFP/Venus FRET pair and shows a decrease in FRET-efficiency when 
pyruvate binds [239]. By monitoring FRET efficiency, intracellular pyruvate levels can 




Figure 5.3: Construct maps for Pyronic. A. Synthesised Gateway middle entry 
vector for Pyronic. B. Final Ubi construct used for generation of Pyronic 
transgenic zebrafish line. 
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Similar to the circumstances with the Laconic reporter, issues encountered 
during initial cloning lead to the commercial synthesis of the Gateway middle entry 
vector (Figure 5.3 A), which again allowed for zebrafish codon optimisation. The 
reporter was then cloned under the expression of the Ubi promoter (Figure 5.3 B) 
and, following validation by sequencing, injected into the one cell stage of wild-type 
zebrafish eggs. F0 embryos were screened for cry:CFP (blue eye) selection marker 
and pyronic reporter expression at 3 dpf using a fluorescent stereomicroscope fitted 
with a CFP/DsRed dual filter. Strong fluorescence of both the selection marker and 
pyronic reporter were observed, with expression particularly strong in muscle 
tissues. Embryos with strong positive signal were selected and raised to adulthood. 
These F0 fish will be screened to identify founder fish to establish a transgenic line, 
but unfortunately, sexual maturity had not been reached by the end of this project.  
 
5.3 Perceval-HR: an ATP:ADP ratio reporter 
ATP is a highly important signalling molecule and energy source within cells, 
with regulatory functions associated with numerous metabolic functions. The 
ATP:ADP ratio can be used as an indicator for energy consumption and changes in 
cellular energy status. Traditionally, luciferase-based assays were utilised to assess 
ATP levels in cells, but were often hindered by low-signal levels [281]. Perceval-HR is 
a mammalian optimised circularly permuted fluorescent protein (cpFP) based sensor 
for ATP:ADP ratio [241]. cpFPs are fusion proteins generated by connecting the 
original fluorescent proteins N and C termini via a peptide linker which acts as a 
detector and creating new N and C termini in close proximity to the chromophore. 
Conformational changes to this new fusion protein, cause by binding of a ligand to 
the peptide linker, cause a change in fluorescence signal [240]. The Perceval-HR 
sensor has two distinct excitation peaks, corresponding to differential protein 
conformations when the different nucleotides are bound. ATP binding is associated 




Figure 5.4: Construct maps for Perceval-HR. A. Gateway middle entry vector for 
Perceval-HR. B. Final Ubi construct used for generation of Perceval-HR transgenic 
zebrafish line. 
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fluorescence at 420 nm. By monitoring fluorescence at two excitation points, the 
ratiometric readout allows monitoring of ATP:ADP ratio within the cell [241]. 
Using a commercially available GW1-Perceval-HR (Addgene plasmid number: 
49082) vector as a template, Perceval-HR was cloned into the Gateway middle entry 
vector pDONR221 (Figure 5.4 A), with successful construct generation verified by 
sequencing (completed in collaboration with Dr. Derek Laux, Feng Lab). The reporter 
was then cloned into the final destination vector for expression under the control of 
the ubiquitous Ubi promoter (Figure 5.4 B) and, following validation by sequencing, 
injected into the one cell stage of wild-type zebrafish eggs. F0 embryos were 
screened for cry:CFP (blue eye) selection marker and Perceval-HR reporter 
expression at 3 dpf using a fluorescent stereomicroscope fitted with an eGFP filter. 
Strong fluorescence of both the selection marker and Perceval-HR reporter were 
observed. Embryos with strong positive signal were selected and raised. Future 
screening of this F0 generation will allow identification of founder fish and 
establishment of a transgenic line.  
 
5.4 Peredox: an NADH-NAD+ redox sensor 
NADH is a vital electron transfer cofactor with roles in various metabolic 
processes. Imaging approaches which monitor inherent autofluorescence of NADH 
have been used for many years to monitor cellular NADH-NAD+ redox state. However, 
as related cofactors such as NADPH also fluoresce at the same emission, there is 
ambiguity as to the accuracy of this approach [242]. Peredox is a GFP based cpFP (see 
Section 5.3) which works through a competitive binding scheme to report the NADH-
NAD+ ratio in a cell. Binding of NADH to the sensor increases fluorescence signal, 
while NAD+ binding does not alter signal intensity. By monitoring the fluorescent 
readout, the cellular NADH-NAD+ ratio can be determined. As this approach is 
dependent on signal intensity, the sensor is tandemly linked to another fluorescent 
protein to normalise for protein expression [242], in this case the mCherry 




Figure 5.5: Construct maps for Peredox-mCherry. A. Gateway middle entry 
vector for Peredox-mCherry. B. Final Ubi construct used for generation of 
Peredox-mCherry transgenic zebrafish line. 
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Using a commercially available pcDNA3.1:Peredox-mCherry (Addgene 
Plasmid Number 32383) vector as a template, Peredox-mCherry was cloned into the 
Gateway middle entry vector pDONR221 (Figure 5.5 A), with successful construct 
generation verified by sequencing. The reporter was then cloned into the final 
destination vector for expression under the control of the ubiquitous Ubi promoter 
(Figure 5.5 B) and, following validation by sequencing, injected into the one cell stage 
of wild-type zebrafish eggs. F0 embryos were screened for cry:CFP (blue eye) 
selection marker and Peredox-mCherry reporter expression at 3 dpf using a 
fluorescent stereomicroscope fitted with an eGFP/DsRed dual filter. While signal 
could be detected, it was deemed that this injection was unsuitable for transgenic 
line generation due to very low fluorescence levels. This is believed to have resulted 
from poor quality tol2 RNA as both selection marker and reporter signal were 
consistently low in all embryos screened. Unfortunately, re-injection of the construct 
could not be completed within the time-frame of this project but is planned for the 
near future with the hope to successfully establish a transgenic line moving forward.    
 
5.5 Cellular localised reporters for redox stress 
As described in Section 4.4, a new transgenic line encoding a mitochondrial 
matrix-localised redox reporter was generated, verified and utilised during this 
project. roGFP is a reversible ratiometric reporter that exhibits alterations in 
fluorescence signal in response to redox stress [265] and can be used to assess the 
redox state of the cell. By tagging the reporter to specific parts of the cell, more 
detailed information can be gained regarding redox processes.  
In addition to the mitochondrial matrix-localised roGFP, constructs for 
expression of roGFP specifically in the cytosol and mitochondrial inner membrane 
[237] were generated. Using the commercially available Cyto-roGFP (Addgene 
Plasmid Number 49435) and GPD-roGFP (Addgene Plasmid Number 49436) plasmids 
as templates, the reporters were cloned into the Gateway middle entry vector 




Figure 5.6: Construct maps for roGFP reporters. A. Final Ubi construct used for 
generation of Cyto-roGFP transgenic zebrafish line. B. Final Ubi construct used for 
generation of GPD-roGFP transgenic zebrafish line. 
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reporters were then cloned into the final destination vector for expression under the 
control of the ubiquitous Ubi promoter (Figure 5.6) and, following validation by 
sequencing, injected into the one cell stage of wild-type zebrafish eggs. F0 embryos 
were screened for roGFP reporter expression at 3 dpf using a fluorescent 
stereomicroscope fitted with an eGFP filter. Strong signal was detected for both 
reporter lines and positive embryos were raised to adulthood. F0 fish were screened 
and founders were successfully identified for both the cyto-roGFP and GPD-roGFP 
lines. Verification and characterisation of these lines could not be completed within 
the time-frame of this project, hence they were not utilised for experimental 
purposes. With F1 fish now growing, a full characterisation of these lines using a 
similar wounding approach to that used in Section 4.4 for Matrix-roGFP verification 
will contribute two new tools to the field and allow detailed analysis of cellular redox 
state to be completed.  
 
5.6 Conclusions 
The work discussed here represents the preliminary stages of a large body of 
longitudinal work which aims to develop a library of new tools and establish the 
zebrafish as an attractive model organism for in vivo metabolic studies. Whilst 
incomplete, the work done to date has made significant progress towards achieving 
this aim, with all the necessary construct components successfully assembled and 
progression to in vivo stages achieved for the majority of tools. Moving forward, this 
work will pave the way for successful generation of a number of transgenic zebrafish 





The aim of this project was to investigate alterations to cellular metabolism 
in PNCs and the effect these changes may have on cancer initiation in vivo. The 
project initially characterised a newly established zebrafish model for human 
HRASG12V mediated PNC initiation in the larval superficial skin layer. Following this, 
the metabolic phenotype in human HRASG12V driven PNCs was investigated. Assays of 
PNC mitochondrial phenotype, and respiratory and glycolytic functions revealed 
complex metabolic alterations at very early stages of PNC initiation. These were 
shown to be important for PNC proliferation and survival, placing these phenotypes 
as potential targets for cancer preventative interventions.  
 
6.1 A new zebrafish model for PNC initiation provides improved temporal 
resolution. 
The zebrafish has been used as a model organism for cancer research for 
many years now. A number of models have been developed based on xenograft and 
transgenic approaches using a variety of oncogenes and tumour suppressor genes in 
various tissues, reviewed in [211][282][283], among others. These models have been 
used to study different stages of cancer, from early developmental stages 
[192][193][284][70][72] through to later metastatic processes [285][213][286][212]. 
The most closely related model to that described here is the oncogenic HRAS 
melanoma model developed by Santoriello, et al, which uses the kita promoter to 
drive oncogene expression in melanocytes [70]. This model uses the GAL4/UAS 
system to express the HRASG12V oncogene and alterations in melanocytes can be 
observed from 2 dpf, allowing early oncogenic processes to be monitored. However 
the newly established modified GAL4/UAS [246] mediated, inducible model for PNC 
initiation in the larval superficial skin layer [218][74] described here is the first to 
allow both spatial and temporal control of oncogene expression, providing access to 
the very earliest stages of cellular transformation. The model permits monitoring and 
manipulation of PNC development and interactions with the microenvironment so 
that very early oncogenic processes can be determined.  
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While the model was developed prior to this project, a thorough 
characterisation had yet to be completed. Early work for the project involved detailed 
observational studies to define the phenotype of PNC development. These 
observational studies revealed dynamic development of PNCs over time, with cell 
shape, size and behaviour vastly altered, consistent with previous models. 
Heterogeneous populations of PNCs appear to be present, with some cells showing 
dramatic alteration while others display a less drastic observed phenotype. It is 
possible that the transient approach taken with this model is partly responsible for 
this heterogeneity, as varying oncogene expression levels and insertion sites are a 
consequence of this method. Future single-cell PNC analysis is planned to decipher 
the potential differential contributions of these differing phenotypes to oncogenic 
processes.  
While this model provides improved temporal resolution, there are a number 
of limitations. The transient nature of the model makes it experimentally expensive, 
as large numbers of fish are required and injecting large numbers of eggs is time-
consuming. Despite this input, the model is low throughput. Embryos with varying 
numbers of PNCs are generated following injection. Therefore, careful screening and 
selection of embryos with consistent PNC burden is important for experimental 
reproducibility and often few usable embryos are generated. While these issues may 
delay experimental progress, careful selection of embryos with consistent PNC 
phenotype allows the study of processes that are prohibited in other models.    
 
6.2 Model characteristics allow for expansive oncogenic studies in addition to those 
discussed here.  
RAS signalling typically induces pro-survival mechanisms to inhibit 
programmed cell death, and yet PNC apoptosis is observed in a subset of cells. While 
it is possible that a percentage of this cell death could be due to excessive HRASG12V 
oncogene expression following transient injection, this is unlikely to account for the 
phenotype as a whole. Persistent RAS signalling can induce replicative stress in a cell 
[32]. When DNA damage check-points remain intact, this stress leads to an oncogene-
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induced senescence (OIS) phenotype [287], features of which are also observed in 
this model. However, DNA damage check-point deficiency allows proliferation to 
continue with accumulation of additional genetic lesions [32]. Excessive DNA damage 
as a result would be sufficient to induce apoptotic cell death and could account for 
increases seen at later stages of PNC development. Fellow lab members are 
investigating PNC phenotype at these later stages, including induction of PNC 
senescence phenotype, to determine how these divergent PNC populations 
contribute to tumour development. For the purposes of this project, PNC apoptosis 
was uses as a parameter to monitor PNC survival following mechanistic intervention, 
as assessed by cleaved caspase-3 activity. 
Previous zebrafish models of cancer development have shown trophic innate 
inflammatory responses are vital for growth of transformed cells [192][193]. 
Although not discussed here, macrophage recruitment has also been monitored in 
this model and appears to show early and persistent responses to developing PNCs 
(data not shown). The observation that neutrophils and macrophages are similarly 
recruited at very early stages of development in this model reinforces previous 
studies and provides a platform for elucidation of temporal responses. Detailed 
inflammatory mechanisms are currently under investigation by the Feng group and 
others and future work will involve further analysis of how metabolic signalling in the 
PNC niche contributes to these processes.  
 
6.3 Mitochondria retain their functional capabilities following fragmentation and 
alterations can be targeted for therapeutic intervention. 
It is now well accepted that metabolic disruption is a feature of established 
cancers. A large number of metabolic changes have been well described and have 
been shown to play important roles in cancer progression and prognosis. Its role, 
however, at early stages of disease initiation and development is less well 
characterised, largely due to issues monitoring these early stages in vivo. Having 
established a new in vivo larval zebrafish model for tumour initiation which allows 
both spatial and temporal control of PNC induction, the metabolic changes at the 
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inception of PNC initiation could be monitored. In established cancers, while 
mitochondrial phenotype appears heterogenous among cancer types [154], 
fragmentation has been shown to be functionally important. The emergence of a 
fragmentation phenotype at such early stages of development verifies this functional 
importance and suggests vital contributions to oncogenic processes. In vitro work has 
shown that MAPK signalling is responsible for fragmentation downstream of RAS via 
a mechanism of ERK-mediated phosphorylation of Dnm1. It would appear that a 
similar mechanism is at play in vivo as pharmacological inhibition of Dnm1l recovered 
mitochondrial morphology in PNCs. Ongoing work for this project involves genetic 
manipulation of Dnm1l via expression of a dominant negative form of the protein 
[147] specifically in PNCs. Such an approach should verify pharmacological findings 
and instil further confidence in these mechanistic conclusions. While minimal 
alteration of expression of mitochondrial fusion and fission proteins was detected 
using a whole-embryo approach, planned RNA-Seq analysis in isolated PNCs will shed 
further light on true expression levels. It should also be pointed out that post-
translation modifications of these enzymes can greatly alter their activity, as shown 
in in vitro studies [261][262][263]. Therefore, it cannot be ruled out that upregulated 
activity in addition to expression contributes to the overall phenotype. While 
phosphorylation changes are difficult to assess in zebrafish due to lack of suitably 
reactive antibodies, this is an important consideration when postulating mechanisms 
of fragmentation.  
Observed Dnm1l-dependent decrease in mitochondrial membrane potential 
is consistent with expectations. Intact membrane potential is required for 
mitochondrial fusion and a decrease is associated with fragmentation [148]. While 
loss of membrane potential could not be measured due to the colour profiles 
involved, accumulation of the applied dyes is suggestive that complete loss of 
potential has not occurred. This indicates that, while functional alterations may arise, 
the mitochondria in PNCs remain active and functional, a theory that is further 
strengthened by the recovery of membrane potential following pharmacological 
inhibition of Dnm1l. Such recovery indicates that the mitochondria have retained 
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their functional capabilities and alterations are due to morphological changes as 
opposed to mitochondrial damage. Intact functional capabilities were further proven 
as alterations in baseline respiratory function were not detected in the presence of 
PNCs. Given the extensive fragmentation phenotype, maximum respiratory 
impairment is likely reactionary rather than an indication of mitochondrial damage, 
as reduced oxidative phosphorylation is a feature of mitochondrial fission.  
The finding that PNCs have a hyper-fragmented mitochondrial phenotype and 
consequential functional alterations that appear to be necessary for PNC 
proliferation was exciting. Although verification of proliferation dependence is 
necessary, as previously discussed, indications of reduced proliferative capacity in 
PNCs following inhibition of the mitochondrial fragmentation phenotype is consistent 
with previous reports and highlights the importance of mitochondrial alterations for 
oncogenic processes. This importance places mitochondrial characteristics as a 
targetable intervention for cancer prevention. There are a number of approaches 
that could be taken to determine possible interventions, including large-scale drug 
screens or the repurposing of pre-established drugs. The former approach takes 
considerable time and effort, but a small-molecule drug screen is currently underway 
by fellow group members to identify possible compounds for further investigation. 
The latter is a much more biased approach but can save time as pharmacokinetic 
studies are often already completed and drugs can be approved for trial more readily. 
This approach led us to metformin. Metformin is a complex I inhibitor that has been 
used for the treatment of type II diabetes for many years. A number of studies are 
currently underway to investigate use of metformin in a cancer setting, both as a 
treatment and for cancer prevention [269][268]. Given the mitochondrial phenotype 
observed in PNCs, particularly the reserve respiratory impairment, metformin 
presented as a potential compound to target this phenotype for prevention of PNC 
development. Induction of PNC-specific apoptosis following metformin treatment is 
highly encouraging. Future plans for this project involve further metformin studies to 
greater understand the mechanisms and effects of metformin on PNC development 
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and add in vivo data to the ever-growing movement for use of metformin for cancer 
prevention.  
 
6.4 Observed phenotypes do not suggest generation of mitochondrial ROS. 
Lack of detectable ROS generation in PNCs is surprising. It is widely reported 
that generation of ROS is increased in cancer cells and ROS have been shown to have 
important tumour promoting functions. Previous studies in zebrafish cancer 
development models report NOX-mediated hydrogen peroxide generation and its 
role in trophic inflammatory responses [192]. This mechanism of ROS generation 
would appear consistent with observed phenotypes in this model. While 
mitochondrial alterations are clear, mitochondrial damage is not evident, and, in fact, 
it is possible that reduced mitochondrial membrane potential is a protective 
mechanism against excessive ROS production [274]. At these early stages of PNC 
development mitochondrially-produced ROS could be locally elevated as a result of 
fragmentation, but not to levels above those which are tolerable. This mechanism 
would maintain sufficient ROS for signalling functions but not risk induction of 
apoptosis and/or cellular damage. As ROS levels are within normal cellular 
concentration ranges, this theory would explain lack of detectable mitochondrially-
produced ROS, as such concentrations are outside the detection range of most 
commercially available dyes. However, as the dyes used in this project are not 
mitochondria-specific, this theory does not explain why general ROS levels were not 
elevated in PNCs. It is possible that general cellular ROS are elevated in PNCs but not 
to concentrations within the detection range of the dyes used, but this seems unlikely 
as such issues have not been previously reported for these commonly used dyes. The 
generation of new transgenic reporter lines for redox stress should help with 
clarification of this issue. As mentioned above, the finding that ROS levels in the 
mitochondrial matrix are unchanged in PNCs is not surprising, as the mitochondrial 
phenotype does not suggest excessive ROS production within the organelle. 
However, future work involving characterisation and utilisation of the cytosolic roGFP 
redox reporter will further inform on more general cellular ROS alterations.     
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6.5 Development of a new assay for in vivo metabolic studies 
The development of a new assay for in vivo respiratory and glycolytic 
assessment using the Seahorse extracellular flux analyser is exciting. These new 
protocols permit unprecedented in vivo analysis of metabolic functions in real time 
in a whole organism. While issues of phenotype magnitude may be problematic for 
some applications, these assays have potential to be implemented in a wide variety 
of disease models to assess metabolic contributions to disease phenotypes. It is 
believed, however, that data collection from these protocols would be improved by 
utilisation of the 96-well analyser, instead of the 24-well instrument used in this 
project. This change would remove the need to secure embryos with screens, 
significantly improving experimental set-up time. Additionally, increased replicates in 
each experiment would improve standard deviation and increase the volume of data 
collected from relatively expensive experiments. Local instrument availability 
prevented testing of this idea but use of the 96-well instrument is advised for 
implementation of these protocols moving forward. 
 
6.6 More specific techniques are required to assess complex metabolic alterations 
in developing PNCs. 
Investigations of glycolytic alterations during PNC development in this model 
have led to somewhat ambiguous conclusions. It appears that glycolytic flux is 
enhanced in the presence of PNCs and this seems important for PNC survival, 
consistent with the Warburg effect. However, technical issues incite doubt in 
numerous experiments, making it difficult to reach confident conclusions. The whole-
embryo approach used in many of these experiments appears insufficient for these 
types of analysis and, moving forward, PNC-specific approaches will be necessary to 
confidently determine mechanisms and outcomes of metabolic alterations during 
PNC initiation.  
With this in mind, a number of new transgenic zebrafish reporter lines are 
currently under development, as discussed in Section 5. Future characterisation and 
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utilisation of these new lines will provide unparalleled in vivo observational access to 
metabolic alterations at the very earliest stages of cancer development. 
It is clear from the studies in this project that complex metabolic changes are 
taking place in PNCs during development, although precise mechanisms remain 
unclear. To address this complexity in an unbiased manner, future work for this 
project involves broad spectrum mass spectroscopy approaches to identify metabolic 
changes in PNCs. Targeted metabolomics and imaging mass spectroscopy (IMS) 
experiments are planned to identify PNC specific alterations across the entire 
metabolome, to establish molecules and pathways for further investigation. These 
experiments will be carried out with the help of a number of collaborators and 
optimisations of these techniques for use with this zebrafish model are already 
underway. These studies will be conducted alongside PNC specific RNA-Seq 
experiments, which will identify alterations in gene expression across the entire 
genome. This two-pronged approach will provide powerful data to help decipher the 
complex metabolic changes in PNCs at early stages of cancer development. Targets 
identified from these approaches will then be further investigated, with the hope to 
identify targets for cancer prevention interventions. 
 
6.7 Ongoing and Future Work. 
The finding that mitochondrial fragmentation occurs at early stages of PNC 
development via a Dnm1l-dependent mechanism is encouraging as it correlates with 
previous in vitro findings. Future analysis of the phenotype following MAPK inhibition 
and completion of a genetic model to express a dominant negative form of Dnm1l 
specifically in PNCs will allow confirmation of this mechanism and permit further, 
more detailed studies of the downstream effects of mitochondrial fragmentation in 
developing PNCs. Additionally, the suitability of metformin to target this phenotype 
will be investigated by further defining the effect of metformin on PNCs and 
determining metformin mechanism of action. 
The role of ROS signalling during PNC development was not the primary focus 
of this project. However, work completed suggests that generation of mitochondrial 
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matrix ROS is not a feature of this model. Characterisation and implementation of 
new transgenic lines for cytoplasmic and mitochondrial inner membrane redox stress 
generated during this project will provide detailed insights into ROS levels in PNCs 
and allow more detailed studies of ROS signalling and its potential contribution to 
PNC development to be completed.  
It is clear from these investigations that complex metabolic alterations are 
occurring in PNCs. Therefore, broad, unbiased approaches are necessary to fully 
comprehend these changes and identify pathways for further study. As discussed 
above, metabolomic and imaging mass spectroscopy studies are planned to give 
detailed insights into metabolic alterations during PNC development. These studies 
will give a complete and in-dept report of all metabolic changes and identify 
pathways and intermediates for further follow-up investigations beyond solely 
glycolytic parameters. It is known that lipid and amino acid metabolism are also 
altered in cancers. In fact, preliminary data using a BODIPY compound in this model 
suggests that PNCs show increased lipid uptake at early stages of induction (data not 
shown), further confirming the need for broader metabolic analysis. These detailed 
spectroscopy experiments represent a large and comprehensive body of work. 
Protocol optimisation has begun in conjunction with numerous collaborators and 
moving forward, it is hoped that this project will lead to identification of numerous 
metabolic parameters for further investigation. 
Analysis of gene expression levels in isolated PNCs was not completed during 
this project. While PNCs were successfully isolated, sufficient concentration of cDNA 
for analysis could not be synthesised without the need for costly amplification. 
Recent funding has been secured for RNASeq experiments to be carried out 
specifically in PNCs, allowing analysis of altered gene expression across the entire 
genome. These experiments will allow true expression levels of the genes looked at 
during this project to be determined and allow assessment of expression levels of 
additional metabolism associated genes. Combining these data with the 
metabolomics studies discussed above will provide a powerful and comprehensive 
report of metabolic alterations developing PNCs.  
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While these approaches can provide comprehensive details of metabolic 
alterations, the capacity of this model for in vivo studies cannot be overlooked. A 
number of new transgenic lines, discussed above, will provide detailed observational 
studies of numerous metabolic processes to be carried out and provide 
unprecedented access to these processes in vivo. Cloning of these reporters was 
completed during this project and, when adulthood has been reached, fish will be 
screened to identify founder fish and fully characterised before experiments 
commence.  
Although not discussed here, the important contribution of macrophages to 
cancer development is well accepted. Characterisation of macrophage recruitment, 
in addition to neutrophils, to developing PNCs is ongoing in the lab. Preliminary data 
shows macrophage recruitment at early stages of PNC development, similar in 
temporal response to neutrophil recruitment (data not shown). Moving forward, 
more comprehensive studies of both neutrophil and macrophage responses and their 
role in PNC initiation and development are planned, including the effect of metabolic 
alterations on leukocyte behaviour.    
 
6.8 Final Conclusions. 
The aim of this project was to investigate mitochondrial and metabolic 
alterations during cancer initiation. While the experiments described here are merely 
the tip of the iceberg in terms of fully understanding metabolic changes in PNCs, they 
clearly identify that alterations occur at very early stages of PNC initiation. The 
identification of a functionally-consequential hyper-fragmented mitochondrial 
phenotype in early PNCs and its importance for oncogenic processes places it as an 
ideal target for preventative interventions. While glycolytic studies are less 
conclusive, they prove that alterations are occurring in PNCs and provide justification 






Supplemental Figure 1: Construct map for Krt4:KalTA4-ERT2 Construct used for 
generation of transgenic zebrafish line. Designed and constructed by Thomas 
Ramezani (Yi Feng, The University of Edinburgh).  
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Supplemental Figure 2: Construct map for UAS:eGFP-HRASG12V Construct used 
for microinjection into the one-cell stage of Krt4:KalTA4-ERT2 zygotes. Designed 




Supplemental Figure 3: TUNEL staining for apoptotic cell death. Representative 
images from a TUNEL assay for detection of apoptotic cell death in PNCs. Positive 
staining is achieved; however, some non-specific extra-nuclear staining is also 
observed. Also, PNC morphology appears altered as a result of proteinase 












Supplemental Figure 4: Dnm1l is the zebrafish orthologue for human Dnm1. 
Clustal alignments for human Dnm1(Ensembl ENST00000452533.6) with two 
transcripts for zebrafish Dnm1l (Ensembl ENSDART00000006840.7 and Ensembl 
ENSDART00000173434.2, respectively). Ensembl reports 88.67 % homology 
between the human Dnm1 protein and zebrafish Dnm1l protein. The GTPase 
active region (aa 51-60, black box) shows 100 % conservation among all 





Supplemental Figure 5: Construct map for Ubi:Matrix-roGFP. Construct used for 
generation of transgenic zebrafish line. 
 141 
8. Bibliography 
[1] R. J. B. King and M. W. Robins, Cancer Biology, Third Edit. Pearson Education, 
2006. 
[2] American Cancer Society, “Cancer Facts and Figures 2018,” Am. Cancer Soc., 
pp. 1–71, 2018. 
[3] “Cancer Research UK: Cancer Incidence Statistics.” [Online]. Available: 
https://www.cancerresearchuk.org/health-professional/cancer-
statistics/incidence#heading-Two. [Accessed: 29-Aug-2018]. 
[4] V. Vedham and M. Verma, “Cancer-Associated Infectious Agents and 
Epigenetic Regulation,” in Methods in molecular biology, vol. 1238, 2015, pp. 
333–354. 
[5] “Cancer Research UK: Cancer Risk Statistics.” [Online]. Available: 
https://www.cancerresearchuk.org/health-professional/cancer-
statistics/risk#heading-One. [Accessed: 29-Aug-2018]. 
[6] J. M. P. Holly, L. Zeng, and C. M. Perks, “Epithelial cancers in the post-genomic 
era: should we reconsider our lifestyle?,” Cancer Metastasis Rev., vol. 32, no. 
3–4, pp. 673–705, Dec. 2013. 
[7] B. Alberts, A. Johnson, J. Lewis, M. Raff, K. Roberts, and P. Walter, Molecular 
Biology of the Cell, 5th Edition, 5th ed. Garland Science, 2007. 
[8] “Cancer Research UK: Cancer Survival Statistics.” [Online]. Available: 
https://www.cancerresearchuk.org/health-professional/cancer-
statistics/survival. [Accessed: 29-Aug-2018]. 
[9] “CRUK Catching Cancer Early: A new frontier for early detection research.” 
[Online]. Available: https://www.cancerresearchuk.org/funding-for-
researchers/research-features/2017-06-20-catching-cancer-earlier-a-new-
frontier-for-early-detection-research. [Accessed: 29-Aug-2018]. 
[10] “Cancer Research UK: Breast Cancer Screening.” [Online]. Available: 
https://www.cancerresearchuk.org/about-cancer/breast-
cancer/screening/breast-screening. [Accessed: 29-Aug-2018]. 
[11] “Cancer Research UK: Cervical Cancer Screening.” [Online]. Available: 
 142 
https://www.cancerresearchuk.org/about-cancer/cervical-cancer/getting-
diagnosed/screening/about. [Accessed: 29-Aug-2018]. 
[12] “Cancer Research UK: Bowel Cancer Screening.” [Online]. Available: 
https://www.cancerresearchuk.org/about-cancer/bowel-cancer/getting-
diagnosed/screening. [Accessed: 29-Aug-2018]. 
[13] “Cancer Research UK: HPV and Cancer.” [Online]. Available: 
https://www.cancerresearchuk.org/about-cancer/causes-of-
cancer/infections-hpv-and-cancer/hpv-and-cancer. [Accessed: 29-Aug-2018]. 
[14] D. Hanahan and R. A. Weinberg, “The Hallmarks of Cancer.,” Cell, vol. 100, no. 
1, pp. 57–70, Jan. 2000. 
[15] D. Hanahan and R. a Weinberg, “Hallmarks of cancer: The Next Generation.,” 
Cell, vol. 144, no. 5, pp. 646–74, Mar. 2011. 
[16] P. A. Futreal et al., “A census of human cancer genes.,” Nat. Rev. Cancer, vol. 
4, no. 3, pp. 177–83, Mar. 2004. 
[17] E. Porta-Pardo, L. Garcia-Alonso, T. Hrabe, J. Dopazo, and A. Godzik, “A Pan-
Cancer Catalogue of Cancer Driver Protein Interaction Interfaces.,” PLoS 
Comput. Biol., vol. 11, no. 10, p. e1004518, Oct. 2015. 
[18] F. Sanchez-Vega et al., “Oncogenic Signaling Pathways in The Cancer Genome 
Atlas.,” Cell, vol. 173, no. 2, p. 321–337.e10, Apr. 2018. 
[19] P. C. Nowell, “The clonal evolution of tumor cell populations.,” Science (80-. )., 
vol. 194, no. 4260, pp. 23–8, Oct. 1976. 
[20] D. J. Ashley, “The two ‘hit’ and multiple ‘hit’ theories of carcinogenesis.,” Br. J. 
Cancer, vol. 23, no. 2, pp. 313–28, Jun. 1969. 
[21] A. G. Knudson, “Mutation and Cancer: Statistical Study of Retinoblastoma,” 
1971. 
[22] C. Blanpain, “Tracing the cellular origin of cancer,” Nat. Cell Biol., vol. 15, no. 
2, pp. 126–134, Feb. 2013. 
[23] J. C. Y. Wang, “Good cells gone bad: the cellular origins of cancer,” Trends Mol. 
Med., vol. 16, no. 3, pp. 145–151, 2010. 
[24] J. S. Flier, L. H. Underhill, and H. F. Dvorak, “Tumors: Wounds That Do Not 
 143 
Heal,” N. Engl. J. Med., vol. 315, no. 26, pp. 1650–1659, Dec. 1986. 
[25] T. D. Tlsty and P. W. Hein, “Know thy neighbor: Stromal cells can contribute 
oncogenic signals,” Curr. Opin. Genet. Dev., vol. 11, no. 1, pp. 54–59, 2001. 
[26] T. D. Tlsty and L. M. Coussens, “Tumor Stroma and Regulation of Cancer 
Development,” Annu. Rev. Pathol. Mech. Dis, vol. 1, pp. 119–50, 2006. 
[27] A. van den Hooff, “Stromal Involvement In Malignant Growth,” Adv. Cancer 
Res., vol. 50, pp. 159–196, 1988. 
[28] A. F. Olumi, G. D. Grossfeld, S. W. Hayward, P. R. Carroll, T. D. Tlsty, and G. R. 
Cunha, “Carcinoma-associated fibroblasts direct tumor progression of initiated 
human prostatic epithelium.,” Cancer Res., vol. 59, no. 19, pp. 5002–11, Oct. 
1999. 
[29] J. L. Camps et al., “Fibroblast-mediated acceleration of human epithelial tumor 
growth in vivo.,” Proc. Natl. Acad. Sci. U. S. A., vol. 87, no. 1, pp. 75–9, Jan. 
1990. 
[30] M. Gleave, J. T. Hsieh, C. A. Gao, A. C. von Eschenbach, and L. W. Chung, 
“Acceleration of human prostate cancer growth in vivo by factors produced by 
prostate and bone fibroblasts.,” Cancer Res., vol. 51, no. 14, pp. 3753–61, Jul. 
1991. 
[31] P. Carmeliet and R. K. Jain, “Angiogenesis in cancer and other diseases,” 
Nature, vol. 407, no. 6801, pp. 249–257, Sep. 2000. 
[32] Y. Pylayeva-Gupta, E. Grabocka, and D. Bar-Sagi, “RAS oncogenes: weaving a 
tumorigenic web.,” Nat. Rev. Cancer, vol. 11, no. 11, pp. 761–74, Nov. 2011. 
[33] J. Cherfils and P. Chardin, “GEFs: Structural basis for their activation of small 
GTP-binding proteins,” Trends Biochem. Sci., vol. 24, no. 8, pp. 306–311, 1999. 
[34] S. Donovan, K. M. Shannon, and G. Bollag, “GTPase activating proteins: Critical 
regulators of intracellular signaling,” Biochim. Biophys. Acta - Rev. Cancer, vol. 
1602, no. 1, pp. 23–45, 2002. 
[35] M. F. Olson and R. Marais, “Ras protein signalling.,” Semin. Immunol., vol. 12, 
no. 1, pp. 63–73, Feb. 2000. 
[36] K. Koera et al., “K-ras is essential for the development of the mouse embryo.,” 
 144 
Oncogene, vol. 15, no. 10, pp. 1151–1159, 1997. 
[37] A. S. Dhillon, S. Hagan, O. Rath, and W. Kolch, “MAP kinase signalling pathways 
in cancer,” Oncogene, vol. 26, no. 22, pp. 3279–3290, May 2007. 
[38] M. P. Wymann and L. Pirola, “Structure and function of phosphoinositide 3-
kinases,” Biochim. Biophys. Acta - Mol. Cell Biol. Lipids, vol. 1436, no. 1–2, pp. 
127–150, 1998. 
[39] T. Kodaki, R. Woscholski, B. Hallberg, P. Rodriguez-Viciana Julian Downward, 
and P. J. Parker, “The activation of phosphatidylinositol 3-kinase by Ras,” Curr. 
Biol., vol. 4, no. 9, pp. 798–806, 1994. 
[40] P. Rodriguez-Viciana et al., “Phosphatidylinositol-3-OH kinase direct target of 
Ras,” Nature, vol. 370, p. 527, Aug. 1994. 
[41] G. G. Kelley, S. E. Reks, J. M. Ondrako, and A. V Smrcka, “Phospholipase Ce : a 
novel Ras effector,” EMBO J., vol. 20, no. 4, pp. 743–754, 2001. 
[42] R. M. F. Wolthuis, F. Zwartkruis, T. C. Moen, and J. L. Bos, “Ras-dependent 
activation of the small GTPase Ral,” Curr. Biol., vol. 8, no. 8, pp. 471–474, 1998. 
[43] K. Giehl, “Oncogenic Ras in tumour progression and metastasis.,” Biol. Chem., 
vol. 386, no. 3, pp. 193–205, Mar. 2005. 
[44] M. Malumbres and M. Barbacid, “RAS oncogenes: the first 30 years,” Nat. Rev. 
Cancer, vol. 3, no. 6, pp. 459–465, Jun. 2003. 
[45] I. A. Prior, P. D. Lewis, and C. Mattos, “A comprehensive survey of Ras 
mutations in cancer.,” Cancer Res., vol. 72, no. 10, pp. 2457–67, May 2012. 
[46] COSMIC Database, “KRAS Gene - Somatic Mutations in Cancer.” [Online]. 
Available: https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KRAS. 
[Accessed: 04-Sep-2018]. 
[47] COSMIC Database, “NRAS Gene - Somatic Mutations in Cancer.” [Online]. 
Available: https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NRAS. 
[Accessed: 04-Sep-2018]. 




[49] S. A. Mccarthy, C. A. Pritchard, and J. A. Abraham, “Rapid induction of heparin-
binding epidermal growth factor / diphtheria toxin receptor expression by Raf 
and Ras oncogenes,” Genes Dev., vol. 9, pp. 1953–1964, 1995. 
[50] L. M. Gangarosa, N. Sizemore, R. Graves-deal, S. M. Oldham, C. J. Der, and R. J. 
Coffey, “A Raf-independent Epidermal Growth Factor Receptor Autocrine Loop 
Is Necessary for Ras Transformation of Rat Intestinal Epithelial Cells,” J. Biol. 
Chem., vol. 272, no. 30, pp. 18926–18931, 1997. 
[51] A. Schulze, K. Lehmann, H. B. J. Jefferies, M. McMahon, and J. Downward, 
“Analysis of the transcriptional program induced by Raf in epithelial cells,” 
Genes Dev., vol. 15, no. 8, pp. 981–994, 2001. 
[52] K. Rosen, J. Rak, J. Jin, R. S. Kerbel, M. J. Newman, and J. Filmus, 
“Downregulation of the pro-apoptotic protein Bak is required for the ras-
induced transformation of intestinal epithelial cells.,” Curr. Biol., vol. 8, no. 24, 
pp. 1331–4, 1998. 
[53] S. R. Datta et al., “Akt phosphorylation of BAD couples survival signals to the 
cell- intrinsic death machinery,” Cell, vol. 91, no. 2, pp. 231–241, 1997. 
[54] X. Fang et al., “Regulation of BAD phosphorylation at serine 112 by the Ras-
mitogen-activated protein kinase pathway,” Oncogene, vol. 18, no. 48, pp. 
6635–6640, 1999. 
[55] T. Kinoshita, T. Yokota, K. Arai, and A. Miyajima, “Regulation of Bcl-2 
expression by oncogenic Ras protein in hematopoietic cells.,” Oncogene, vol. 
10, no. 11, pp. 2207–12, Jun. 1995. 
[56] L. Wu, Y. J. Nam, G. Kung, M. T. Crow, and R. N. Kitsis, “Induction of the 
apoptosis inhibitor ARC by Ras in human cancers,” J. Biol. Chem., vol. 285, no. 
25, pp. 19235–19245, 2010. 
[57] J. Rak et al., “Mutant ras Oncogenes Upregulate VEGF/VPF Expression : 
Implications for Induction and Inhibition of Tumor Angiogenesis,” Cancer Res., 
vol. 55, pp. 4575–4581, 1995. 
[58] C. Blancher, J. W. Moore, N. Robertson, and  a L. Harris, “Effects of ras and von 
Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, 
 146 
HIF-2alpha, and vascular endothelial growth factor expression and their 
regulation by the phosphatidylinositol 3’-kinase/Akt signaling pathway.,” 
Cancer Res., vol. 61, no. 19, pp. 7349–7355, 2001. 
[59] O. Kranenburg, M. F. B. G. Gebbink, and E. E. Voest, “Stimulation of 
angiogenesis by Ras proteins,” Biochim. Biophys. Acta - Rev. Cancer, vol. 1654, 
no. 1, pp. 23–37, 2004. 
[60] B. B. Ancrile, K. M. O. Hayer, and C. M. Counter, “Oncogenic Ras-Induced 
Expression of Cytokines: A New Target of Anti-Cancer Therapies,” Mol. Interv., 
vol. 8, no. 1, pp. 22–27, 2008. 
[61] A. Sparmann and D. Bar-Sagi, “Ras-induced interleukin-8 expression plays a 
critical role in tumor growth and angiogenesis,” Cancer Cell, vol. 6, no. 5, pp. 
447–458, 2004. 
[62] G. Yang et al., “The chemokine growth-regulated oncogene 1 (Gro-1) links RAS 
signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis,” 
Proc. Natl. Acad. Sci., vol. 103, no. 44, pp. 16472–16477, 2006. 
[63] B. Ancrile, K. H. Lim, and C. M. Counter, “Oncogenic Ras-induced secretion of 
IL6 is required for tumorigenesis,” Genes Dev., vol. 21, no. 14, pp. 1714–1719, 
2007. 
[64] M. S. Pepper, “Role of the Matrix Metalloproteinase and Plasminogen 
Activator – Plasmin Systems in Angiogenesis on have,” Arter. Thromb Vasc Biol, 
vol. 21, no. 7, pp. 1104–1117, 2001. 
[65] R. C. O’Hagan and J. Heyer, “KRAS Mouse Models: Modeling Cancer Harboring 
KRAS Mutations.,” Genes Cancer, vol. 2, no. 3, pp. 335–43, Mar. 2011. 
[66] C. Guerra et al., “Tumor induction by an endogenous K-ras oncogene is highly 
dependent on cellular context,” Cancer Cell, vol. 4, no. 2, pp. 111–120, Aug. 
2003. 
[67] S. R. Hingorani et al., “Preinvasive and invasive ductal pancreatic cancer and 
its early detection in the mouse.,” Cancer Cell, vol. 4, no. 6, pp. 437–50, Dec. 
2003. 
[68] X. Chen et al., “Endogenous expression of HrasG12V induces developmental 
 147 
defects and neoplasms with copy number imbalances of the oncogene,” Proc. 
Natl. Acad. Sci., vol. 106, no. 19, pp. 7979–7984, May 2009. 
[69] L. Chin et al., “Essential role for oncogenic Ras in tumour maintenance,” 
Nature, vol. 400, no. 6743, pp. 468–472, Jul. 1999. 
[70] C. Santoriello et al., “Kita driven expression of oncogenic HRAS leads to early 
onset and highly penetrant melanoma in zebrafish.,” PLoS One, vol. 5, no. 12, 
p. e15170, 2010. 
[71] D. M. Langenau et al., “Effects of RAS on the genesis of embryonal 
rhabdomyosarcoma.,” Genes Dev., vol. 21, no. 11, pp. 1382–95, Jun. 2007. 
[72] S. W. Park, J. M. Davison, J. Rhee, R. H. Hruban, A. Maitra, and S. D. Leach, 
“Oncogenic KRAS induces progenitor cell expansion and malignant 
transformation in zebrafish exocrine pancreas.,” Gastroenterology, vol. 134, 
no. 7, pp. 2080–90, Jun. 2008. 
[73] X. Le, D. M. Langenau, M. D. Keefe, J. L. Kutok, D. S. Neuberg, and L. I. Zon, 
“Heat shock-inducible Cre/Lox approaches to induce diverse types of tumors 
and hyperplasia in transgenic zebrafish,” Proc. Natl. Acad. Sci., vol. 104, no. 22, 
pp. 9410–9415, May 2007. 
[74] T. Ramezani, D. W. Laux, I. R. Bravo, M. Tada, and Y. Feng, “Live Imaging of 
Innate Immune and Preneoplastic Cell Interactions Using an Inducible 
Gal4/UAS Expression System in Larval Zebrafish Skin,” J. Vis. Exp., no. 96, pp. 
1–7, 2015. 
[75] A. Boiteux and B. Hess, “Design of Glycolysis,” Philos. Trans. R. Soc. Lond. B. 
Biol. Sci., vol. 293, no. 1063, pp. 5–22, 1981. 
[76] D. . Nelson and M. . Cox, Lehninger Principles of Biochemistry, Fifth. New York: 
Sarah Tenney, 2008. 
[77] N. Kresge, R. D. Simoni, and R. L. Hill, “Otto Fritz Meyerhof and the elucidation 
of the glycolytic pathway.,” J. Biol. Chem., vol. 280, no. 4, pp. 124–127, 2005. 
[78] J. E. Wilson, “Isozymes of mammalian hexokinase: structure, subcellular 
localization and metabolic function,” J. Exp. Biol., vol. 206, no. 12, pp. 2049–
2057, 2003. 
 148 
[79] J. V. Passonneau and O. H. Lowry, “The role of phosphofructokinase in 
metabolic regulation,” Adv. Enzyme Regul., vol. 2, no. C, pp. 265–274, 1964. 
[80] L. Hue and M. H. Rider, “Role of fructose 2, 6-bisphosphate in the control of 
glycolysis in mammalian tissues.,” Biochem. J., vol. 245, no. 2, p. 313, 1987. 
[81] W. J. Israelsen and M. G. Vander Heiden, “Pyruvate kinase: Function, 
regulation and role in cancer.,” Semin. Cell Dev. Biol., vol. 43, pp. 43–51, Jul. 
2015. 
[82] R. A. Harris, M. M. Bowker-Kinley, B. Huang, and P. Wu, “Regulation of the 
activity of the pyruvate dehydrogenase complex,” Adv. Enzyme Regul., vol. 42, 
pp. 249–259, 2002. 
[83] L. Shi and B. P. Tu, “Acetyl-CoA and the Regulation of Metabolism: Mechanisms 
and COnsequences,” Curr. Environ. Heal. Reports, vol. 33, pp. 125–131, 2015. 
[84] M. Adeva-Andany et al., “Comprehensive review on lactate metabolism in 
human health,” Mitochondrion, vol. 17, pp. 76–100, 2014. 
[85] M. Akram, “Citric Acid Cycle and Role of its Intermediates in Metabolism,” Cell 
Biochem. Biophys., vol. 68, no. 3, pp. 475–478, 2014. 
[86] J. P. Hosler, S. Ferguson-miller, and D. a Mills, “Energy Transduction: Proton 
Transfer Through the Respiratory Complexes,” Annu Rev Biochem, vol. 75, pp. 
165–187, 2006. 
[87] M. D. Brand and M. P. Murphy, “Control of electron flux through the 
respiratory chain in mitochondria and cells.,” Biol. Rev. Camb. Philos. Soc., vol. 
62, no. 2, pp. 141–93, 1987. 
[88] OpenStax College, “Biology,” 2013. 
[89] M. A. Bianchet, J. Hullihen, P. L. Pedersen, and L. M. Amzel, “The 2.8-A 
structure of rat liver F1-ATPase: configuration of a critical intermediate in ATP 
synthesis/hydrolysis.,” Proc. Natl. Acad. Sci. U. S. A., vol. 95, no. 19, pp. 11065–
70, Sep. 1998. 
[90] V. Adam-Vizi and C. Chinopoulos, “Bioenergetics and the formation of 
mitochondrial reactive oxygen species,” Trends Pharmacol. Sci., vol. 27, no. 12, 
pp. 639–645, 2006. 
 149 
[91] C. Quijano, M. Trujillo, L. Castro, and A. Trostchansky, “Interplay between 
oxidant species and energy metabolism,” Redox Biol., vol. 8, pp. 28–42, 2016. 
[92] O. Warburg, “On the origin of cancer cells.,” Science (80-. )., vol. 123, no. 3191, 
pp. 309–14, Feb. 1956. 
[93] P. S. Ward and C. B. Thompson, “Metabolic Reprogramming: A cancer hallmark 
even warburg did not anticipate.,” Cancer Cell, vol. 21, no. 3, pp. 297–308, Mar. 
2012. 
[94] S. S. Gambhir, “Molecular imaging of cancer with positron emission 
tomography,” Nat. Rev. Cancer, vol. 2, no. 9, pp. 683–693, Sep. 2002. 
[95] K. B. Nolop et al., “Glucose utilization in vivo by human pulmonary 
neoplasms.,” Cancer, vol. 60, no. 11, pp. 2682–9, Dec. 1987. 
[96] G. Di Chiro, “Positron emission tomography using [18F] fluorodeoxyglucose in 
brain tumors. A powerful diagnostic and prognostic tool.,” Invest. Radiol., vol. 
22, no. 5, pp. 360–71, May 1987. 
[97] K. Kubota et al., “Differential diagnosis of lung tumor with positron emission 
tomography: a prospective study.,” J. Nucl. Med., vol. 31, no. 12, pp. 1927–32, 
Dec. 1990. 
[98] N. C. Gupta et al., “Solitary pulmonary nodules: detection of malignancy with 
PET with 2-[F-18]-fluoro-2-deoxy-D-glucose.,” Radiology, vol. 184, no. 2, pp. 
441–444, Aug. 1992. 
[99] C. K. Hoh et al., “Cancer detection with whole-body PET using 2-[18F]fluoro-2-
deoxy-D-glucose.,” J. Comput. Assist. Tomogr., vol. 17, no. 4, pp. 582–9, 1993. 
[100] M. Kunkel et al., “Overexpression of Glut-1 and increased glucose metabolism 
in tumors are associated with a poor prognosis in patients with oral squamous 
cell carcinoma,” Cancer, vol. 97, no. 4, pp. 1015–1024, Feb. 2003. 
[101] J. Li, W. Xu, F. Kong, X. Sun, and X. Zuo, “Meta-analysis: Accuracy of 18FDG PET-
CT for distant metastasis staging in lung cancer patients,” Surg. Oncol., vol. 22, 
no. 3, pp. 151–155, Sep. 2013. 
[102] A. M. Evens and L. Kostakoglu, “The role of FDG-PET in defining prognosis of 
Hodgkin lymphoma for early-stage disease.,” Blood, vol. 124, no. 23, pp. 3356–
 150 
64, Nov. 2014. 
[103] L. Ceriani et al., “Utility of baseline 18FDG-PET/CT functional parameters in 
defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.,” 
Blood, vol. 126, no. 8, pp. 950–6, Aug. 2015. 
[104] A. Annibaldi and C. Widmann, “Glucose metabolism in cancer cells,” Curr. 
Opin. Clin. Nutr. Metab. Care, vol. 13, no. 4, pp. 466–470, 2010. 
[105] M. D. Hirschey et al., “Dysregulated metabolism contributes to oncogenesis,” 
Semin. Cancer Biol., vol. 35, 2015. 
[106] E. Bustamante and P. L. Pedersen, “High aerobic glycolysis of rat hepatoma 
cells in culture: role of mitochondrial hexokinase.,” Proc. Natl. Acad. Sci. U. S. 
A., vol. 74, no. 9, pp. 3735–9, Sep. 1977. 
[107] E. Bustamante, H. P. Morris, and P. L. Pedersen, “Energy metabolism of tumor 
cells. Requirement for a form of hexokinase with a propensity for 
mitochondrial binding.,” J. Biol. Chem., vol. 256, no. 16, pp. 8699–704, Aug. 
1981. 
[108] R. B. Robey and N. Hay, “Mitochondrial hexokinases, novel mediators of the 
antiapoptotic effects of growth factors and Akt,” Oncogene, vol. 25, no. 34, pp. 
4683–4696, Aug. 2006. 
[109] S. Mazurek, “Pyruvate kinase type M2: A key regulator of the metabolic budget 
system in tumor cells,” Int. J. Biochem. Cell Biol., vol. 43, no. 7, pp. 969–980, 
Jul. 2011. 
[110] J. Kim, I. Tchernyshyov, G. L. Semenza, and C. V. Dang, “HIF-1-mediated 
expression of pyruvate dehydrogenase kinase: A metabolic switch required for 
cellular adaptation to hypoxia,” Cell Metab., vol. 3, no. 3, pp. 177–185, Mar. 
2006. 
[111] V. R. Fantin, J. St-Pierre, and P. Leder, “Attenuation of LDH-A expression 
uncovers a link between glycolysis, mitochondrial physiology, and tumor 
maintenance,” Cancer Cell, vol. 9, no. 6, pp. 425–434, Jun. 2006. 
[112] A. Le et al., “Inhibition of lactate dehydrogenase A induces oxidative stress and 
inhibits tumor progression.,” Proc. Natl. Acad. Sci. U. S. A., vol. 107, no. 5, pp. 
 151 
2037–42, Feb. 2010. 
[113] I. P. M. Tomlinson et al., “Germline mutations in FH predispose to dominantly 
inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer,” 
Nat. Genet., vol. 30, no. 4, pp. 406–410, Apr. 2002. 
[114] B. E. Baysal et al., “Mutations in SDHD, a mitochondrial complex II gene, in 
hereditary paraganglioma.,” Science (80-. )., vol. 287, no. 5454, pp. 848–51, 
Feb. 2000. 
[115] D. W. Parsons et al., “An Integrated Genomic Analysis of Human Glioblastoma 
Multiforme,” Science (80-. )., vol. 321, no. 5897, pp. 1807–1812, Sep. 2008. 
[116] J. Balss, J. Meyer, W. Mueller, A. Korshunov, C. Hartmann, and A. von Deimling, 
“Analysis of the IDH1 codon 132 mutation in brain tumors,” Acta Neuropathol., 
vol. 116, no. 6, pp. 597–602, Dec. 2008. 
[117] C. Hartmann et al., “Type and frequency of IDH1 and IDH2 mutations are 
related to astrocytic and oligodendroglial differentiation and age: a study of 
1,010 diffuse gliomas,” Acta Neuropathol., vol. 118, no. 4, pp. 469–474, Oct. 
2009. 
[118] H. Yang, Y. Xiong, and K. Guan, “Metabolic alteration in tumorigenesis.,” Sci. 
China Life Sci., vol. 56, no. 12, pp. 1067–75, Dec. 2013. 
[119] E. K. Oermann, J. Wu, K.-L. Guan, and Y. Xiong, “Alterations of metabolic genes 
and metabolites in cancer.,” Semin. Cell Dev. Biol., vol. 23, no. 4, pp. 370–80, 
Jun. 2012. 
[120] C. R. Justus, E. J. Sanderlin, and L. V Yang, “Molecular Connections between 
Cancer Cell Metabolism and the Tumor Microenvironment.,” Int. J. Mol. Sci., 
vol. 16, no. 5, pp. 11055–86, Jan. 2015. 
[121] M. G. Vander Heiden, L. C. Cantley, and C. B. Thompson, “Understanding the 
Warburg Effect: The Metabolic Requirements of Cell Proliferation,” Science 
(80-. )., vol. 324, no. 5930, pp. 1029–1033, May 2009. 
[122] C. V Dang, “Links between metabolism and cancer.,” Genes Dev., vol. 26, no. 
9, pp. 877–90, May 2012. 
[123] J. S. Flier, M. M. Mueckler, P. Usher, and H. F. Lodish, “Elevated levels of 
 152 
glucose transport and transporter messenger RNA are induced by ras or src 
oncogenes.,” Science, vol. 235, no. 4795, pp. 1492–5, Mar. 1987. 
[124] C. Chen, N. Pore, A. Behrooz, F. Ismail-Beigi, and A. Maity, “Regulation of glut1 
mRNA by Hypoxia-inducible Factor-1,” J. Biol. Chem., vol. 276, no. 12, pp. 
9519–9525, Mar. 2001. 
[125] R. Blum, J. Jacob-Hirsch, N. Amariglio, G. Rechavi, and Y. Kloog, “Ras inhibition 
in glioblastoma down-regulates hypoxia-inducible factor-1α, causing glycolysis 
shutdown and cell death,” Cancer Res., vol. 65, no. 3, pp. 999–1006, 2005. 
[126] H. K. Kole, R. J. Resnick, M. Van Doren, and E. Racker, “Regulation of 6-
phosphofructo-1-kinase activity in ras-transformed rat-1 fibroblasts,” Arch. 
Biochem. Biophys., vol. 286, no. 2, pp. 586–590, 1991. 
[127] F. N. LOW, “Mitochondrial structure.,” J. Biophys. Biochem. Cytol., vol. 2, no. 4 
Suppl, pp. 337–40, Jul. 1956. 
[128] M. Brini, “Ca(2+) signalling in mitochondria: mechanism and role in physiology 
and pathology.,” Cell Calcium, vol. 34, no. 4–5, pp. 399–405, 2003. 
[129] S. Desagher and J. C. Martinou, “Mitochondria as the central control point of 
apoptosis.,” Trends Cell Biol., vol. 10, no. 9, pp. 369–77, Sep. 2000. 
[130] S. Grandemange, S. Herzig, and J. C. Martinou, “Mitochondrial dynamics and 
cancer,” Semin. Cancer Biol., vol. 19, no. 1, pp. 50–56, 2009. 
[131] H. A. L. Tuppen, E. L. Blakely, D. M. Turnbull, and R. W. Taylor, “Mitochondrial 
DNA mutations and human disease,” Biochim. Biophys. Acta - Bioenerg., vol. 
1797, no. 2, pp. 113–128, 2010. 
[132] S. A. Detmer and D. C. Chan, “Functions and dysfunctions of mitochondrial 
dynamics,” Nat. Rev. Mol. Cell Biol., vol. 8, no. 11, pp. 870–879, Nov. 2007. 
[133] A. Y. Seo, A.-M. Joseph, D. Dutta, J. C. Y. Hwang, J. P. Aris, and C. 
Leeuwenburgh, “New insights into the role of mitochondria in aging: 
mitochondrial dynamics and more,” J. Cell Sci., vol. 123, no. 15, 2010. 
[134] R. Rossignol, R. Gilkerson, R. Aggeler, K. Yamagata, S. J. Remington, and R. A. 
Capaldi, “Energy substrate modulates mitochondrial structure and oxidative 
capacity in cancer cells.,” Cancer Res., vol. 64, no. 3, pp. 985–93, Feb. 2004. 
 153 
[135] H. Chen, A. Chomyn, and D. C. Chan, “Disruption of Fusion Results in 
Mitochondrial Heterogeneity and Dysfunction,” J. Biol. Chem., vol. 280, no. 28, 
pp. 26185–26192, Jul. 2005. 
[136] P. A. Parone et al., “Preventing Mitochondrial Fission Impairs Mitochondrial 
Function and Leads to Loss of Mitochondrial DNA,” PLoS One, vol. 3, no. 9, p. 
e3257, Sep. 2008. 
[137] D. G. Breckenridge, B.-H. Kang, D. Kokel, S. Mitani, L. A. Staehelin, and D. Xue, 
“Caenorhabditis elegans drp-1 and fis-2 Regulate Distinct Cell-Death Execution 
Pathways Downstream of ced-3 and Independent of ced-9,” Mol. Cell, vol. 31, 
no. 4, pp. 586–597, Aug. 2008. 
[138] G. Twig et al., “Fission and selective fusion govern mitochondrial segregation 
and elimination by autophagy,” EMBO J., vol. 27, no. 2, pp. 433–446, Jan. 2008. 
[139] C. Van den Bogert, P. Muus, C. Haanen, A. Pennings, T. E. Melis, and A. M. 
Kroon, “Mitochondrial biogenesis and mitochondrial activity during the 
progression of the cell cycle of human leukemic cells,” Exp. Cell Res., vol. 178, 
no. 1, pp. 143–153, Sep. 1988. 
[140] D. H. Margineantu, W. Gregory Cox, L. Sundell, S. W. Sherwood, J. M. Beechem, 
and R. A. Capaldi, “Cell cycle dependent morphology changes and associated 
mitochondrial DNA redistribution in mitochondria of human cell lines.,” 
Mitochondrion, vol. 1, no. 5, pp. 425–35, May 2002. 
[141] M. Martínez-Diez, G. Santamaría, Á. D. Ortega, and J. M. Cuezva, “Biogenesis 
and Dynamics of Mitochondria during the Cell Cycle: Significance of 3ʹUTRs,” 
PLoS One, vol. 1, no. 1, p. e107, Dec. 2006. 
[142] T. T. Renault et al., “Mitochondrial shape governs BAX-induced membrane 
permeabilization and apoptosis,” Mol. Cell, vol. 57, no. 1, pp. 69–82, 2015. 
[143] J. Ježek, K. F. Cooper, and R. Strich, “Reactive Oxygen Species and 
Mitochondrial Dynamics: The Yin and Yang of Mitochondrial Dysfunction and 
Cancer Progression.,” Antioxidants (Basel, Switzerland), vol. 7, no. 1, Jan. 2018. 
[144] M. D. Buck et al., “Mitochondrial Dynamics Controls T Cell Fate through 
Metabolic Programming,” Cell, vol. 166, 2016. 
 154 
[145] M. Noguchi and A. Kasahara, “Mitochondrial dynamics coordinate cell 
differentiation,” Biochem. Biophys. Res. Commun., vol. 500, no. 1, pp. 59–64, 
2018. 
[146] T. Wai and T. Langer, “Mitochondrial Dynamics and Metabolic Regulation,” 
Trends Endocrinol. Metab., vol. 27, no. 2, pp. 105–117, Feb. 2016. 
[147] E. Smirnova, D. L. Shurland, S. N. Ryazantsev, and A. M. van der Bliek, “A human 
dynamin-related protein controls the distribution of mitochondria.,” J. Cell 
Biol., vol. 143, no. 2, pp. 351–8, Oct. 1998. 
[148] F. Legros, A. Lombès, P. Frachon, and M. Rojo, “Mitochondrial Fusion in Human 
Cells Is Efficient, Requires the Inner Membrane Potential, and Is Mediated by 
Mitofusins,” Mol. Biol. Cell, vol. 13, no. 12, pp. 4343–4354, Dec. 2002. 
[149] S. Hoppins, “The regulation of mitochondrial dynamics,” Curr. Opin. Cell Biol., 
vol. 29, pp. 46–52, 2014. 
[150] D. L. Longo and S. L. Archer, “Mitochondrial Dynamics — Mitochondrial Fission 
and Fusion in Human Diseases,” N. Engl. J. Med., vol. 369, no. 23, pp. 2236–
2251, Dec. 2013. 
[151] A. K. Lutz et al., “Loss of Parkin or PINK1 Function Increases Drp1-dependent 
Mitochondrial Fragmentation,” J. Biol. Chem., vol. 284, no. 34, pp. 22938–
22951, Aug. 2009. 
[152] S. Züchner et al., “Mutations in the mitochondrial GTPase mitofusin 2 cause 
Charcot-Marie-Tooth neuropathy type 2A,” Nat. Genet., vol. 36, no. 5, pp. 449–
451, May 2004. 
[153] A. Olichon et al., “Effects of OPA1 mutations on mitochondrial morphology and 
apoptosis: Relevance to ADOA pathogenesis,” J. Cell. Physiol., vol. 211, no. 2, 
pp. 423–430, May 2007. 
[154] G. Arismendi-Morillo, “Electron microscopy morphology of the mitochondrial 
network in human cancer,” Int. J. Biochem. Cell Biol., vol. 41, no. 10, pp. 2062–
2068, Oct. 2009. 
[155] A. Inoue-Yamauchi and H. Oda, “Depletion of mitochondrial fission factor 
DRP1 causes increased apoptosis in human colon cancer cells,” Biochem. 
 155 
Biophys. Res. Commun., vol. 421, no. 1, pp. 81–85, Apr. 2012. 
[156] J. Rehman et al., “Inhibition of mitochondrial fission prevents cell cycle 
progression in lung cancer.,” FASEB J., vol. 26, no. 5, pp. 2175–86, May 2012. 
[157] J. A. Kashatus et al., “Erk2 phosphorylation of Drp1 promotes mitochondrial 
fission and MAPK-driven tumor growth.,” Mol. Cell, vol. 57, no. 3, pp. 537–51, 
Mar. 2015. 
[158] M. N. Serasinghe et al., “Mitochondrial division is requisite to RAS-induced 
transformation and targeted by oncogenic MAPK pathway inhibitors,” Mol. 
Cell, vol. 57, no. 3, pp. 521–537, 2015. 
[159] R. L. K. Virchow, Cellular pathology as based upon physiological and 
pathological histology ... / by Rudolf Virchow. Translated from the 2d ed. of the 
original by Frank Chance. With notes and numerous emendations, principally 
from MS. notes of the author. Philadelphia : J. B. Lippincott, 1863. 
[160] S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, inflammation, and 
cancer.,” Cell, vol. 140, no. 6, pp. 883–99, Mar. 2010. 
[161] S. Wu et al., “A human colonic commensal promotes colon tumorigenesis via 
activation of T helper type 17 T cell responses,” Nat. Med., vol. 15, no. 9, pp. 
1016–1022, Sep. 2009. 
[162] H. Takahashi, H. Ogata, R. Nishigaki, D. H. Broide, and M. Karin, “Tobacco 
Smoke Promotes Lung Tumorigenesis by Triggering IKKβ- and JNK1-Dependent 
Inflammation,” Cancer Cell, vol. 17, no. 1, pp. 89–97, Jan. 2010. 
[163] S. I. Grivennikov and M. Karin, “Inflammation and oncogenesis: a vicious 
connection.,” Curr. Opin. Genet. Dev., vol. 20, no. 1, pp. 65–71, Feb. 2010. 
[164] M. Karin, “Nuclear factor-κB in cancer development and progression,” Nature, 
vol. 441, no. 7092, pp. 431–436, May 2006. 
[165] H. Yu, M. Kortylewski, and D. Pardoll, “Crosstalk between cancer and immune 
cells: role of STAT3 in the tumour microenvironment,” Nat. Rev. Immunol., vol. 
7, no. 1, pp. 41–51, Jan. 2007. 
[166] B. Ancrile, K.-H. Lim, and C. M. Counter, “Oncogenic Ras-induced secretion of 
IL6 is required for tumorigenesis,” Genes &amp; Dev., vol. 21, no. 14, pp. 1714–
 156 
1719, Jul. 2007. 
[167] F. R. Greten et al., “IKKβ Links Inflammation and Tumorigenesis in a Mouse 
Model of Colitis-Associated Cancer,” Cell, vol. 118, no. 3, pp. 285–296, Aug. 
2004. 
[168] S. Maeda, H. Kamata, J.-L. Luo, H. Leffert, and M. Karin, “IKKβ Couples 
Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that 
Promotes Chemical Hepatocarcinogenesis,” Cell, vol. 121, no. 7, pp. 977–990, 
Jul. 2005. 
[169] S. Grivennikov et al., “IL-6 and Stat3 Are Required for Survival of Intestinal 
Epithelial Cells and Development of Colitis-Associated Cancer,” Cancer Cell, 
vol. 15, no. 2, pp. 103–113, Feb. 2009. 
[170] J. Bollrath et al., “gp130-Mediated Stat3 Activation in Enterocytes Regulates 
Cell Survival and Cell-Cycle Progression during Colitis-Associated 
Tumorigenesis,” Cancer Cell, vol. 15, no. 2, pp. 91–102, Feb. 2009. 
[171] J. Wyckoff et al., “A Paracrine Loop between Tumor Cells and Macrophages Is 
Required for Tumor Cell Migration in Mammary Tumors,” Cancer Res., vol. 64, 
no. 19, pp. 7022–7029, Oct. 2004. 
[172] S. Goswami et al., “Macrophages Promote the Invasion of Breast Carcinoma 
Cells via a Colony-Stimulating Factor-1/Epidermal Growth Factor Paracrine 
Loop,” Cancer Res., vol. 65, no. 12, pp. 5278–5283, Jun. 2005. 
[173] I. Mishalian, R. Bayuh, L. Levy, L. Zolotarov, J. Michaeli, and Z. G. Fridlender, 
“Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties 
during tumor progression.,” Cancer Immunol. Immunother., vol. 62, no. 11, pp. 
1745–56, Nov. 2013. 
[174] T. Chanmee, P. Ontong, K. Konno, and N. Itano, “Tumor-Associated 
Macrophages as Major Players in the Tumor Microenvironment,” Cancers 
(Basel)., vol. 6, pp. 1670–1690, 2014. 
[175] S. J. Roberts et al., “Characterizing tumor-promoting T cells in chemically 
induced cutaneous carcinogenesis,” Proc. Natl. Acad. Sci., vol. 104, no. 16, pp. 
6770–6775, Apr. 2007. 
 157 
[176] D. G. DeNardo et al., “CD4+ T Cells Regulate Pulmonary Metastasis of 
Mammary Carcinomas by Enhancing Protumor Properties of Macrophages,” 
Cancer Cell, vol. 16, no. 2, pp. 91–102, Aug. 2009. 
[177] K. E. de Visser, L. V. Korets, and L. M. Coussens, “De novo carcinogenesis 
promoted by chronic inflammation is B lymphocyte dependent,” Cancer Cell, 
vol. 7, no. 5, pp. 411–423, May 2005. 
[178] S. Ostrand-Rosenberg and S. Rosenberg, “Immune surveillance: a balance 
between protumor and antitumor immunity,” Curr. Opin. Genet. Dev., vol. 18, 
pp. 11–18, 2008. 
[179] J. S. Flier, L. H. Underhill, and H. F. Dvorak, “Tumors: Wounds That Do Not 
Heal,” N. Engl. J. Med., vol. 315, no. 26, pp. 1650–1659, Dec. 1986. 
[180] K. Goetze, S. Walenta, M. Ksiazkiewicz, L. A. Kunz-Schughart, and W. Mueller-
Klieser, “Lactate enhances motility of tumor cells and inhibits monocyte 
migration and cytokine release,” Int. J. Oncol., vol. 39, no. 2, pp. 453–463, Aug. 
2011. 
[181] K. Fischer et al., “Inhibitory effect of tumor cell-derived lactic acid on human T 
cells.,” Blood, vol. 109, no. 9, pp. 3812–9, May 2007. 
[182] E. Gottfried et al., “Tumor-derived lactic acid modulates dendritic cell 
activation and antigen expression.,” Blood, vol. 107, no. 5, pp. 2013–21, Mar. 
2006. 
[183] C. J. Hall et al., “Immunoresponsive Gene 1 Augments Bactericidal Activity of 
Macrophage-Lineage Cells by Regulating β-Oxidation-Dependent 
Mitochondrial ROS Production,” Cell Metab., vol. 18, no. 2, pp. 265–278, 2013. 
[184] A. Sica, T. Schioppa, A. Mantovani, and P. Allavena, “Tumour-associated 
macrophages are a distinct M2 polarised population promoting tumour 
progression: Potential targets of anti-cancer therapy,” Eur. J. Cancer, vol. 42, 
no. 6, pp. 717–727, 2006. 
[185] R. Ostuni, F. Kratochvill, P. J. Murray, and G. Natoli, “Macrophages and cancer: 
from mechanisms to therapeutic implications,” Trends Immunol., vol. 36, pp. 
229–239, 2015. 
 158 
[186] T. L. Putoczki et al., “Interleukin-11 Is the Dominant IL-6 Family Cytokine during 
Gastrointestinal Tumorigenesis and Can Be Targeted Therapeutically,” Cancer 
Cell, vol. 24, no. 2, pp. 257–271, Aug. 2013. 
[187] M. Chittezhath et al., “Molecular Profiling Reveals a Tumor-Promoting 
Phenotype of Monocytes and Macrophages in Human Cancer Progression,” 
Immunity, vol. 41, no. 5, pp. 815–829, Nov. 2014. 
[188] Z. G. Fridlender et al., “Polarization of tumor-associated neutrophil phenotype 
by TGF-beta: ‘N1’ versus ‘N2’ TAN.,” Cancer Cell, vol. 16, no. 3, pp. 183–94, 
Sep. 2009. 
[189] J. Jablonska, S. Leschner, K. Westphal, S. Lienenklaus, and S. Weiss, 
“Neutrophils responsive to endogenous IFN-β regulate tumor angiogenesis 
and growth in a mouse tumor model,” J. Clin. Invest., vol. 120, no. 4, pp. 1151–
1164, Apr. 2010. 
[190] M. R. Galdiero, E. Bonavita, I. Barajon, C. Garlanda, A. Mantovani, and S. Jaillon, 
“Tumor associated macrophages and neutrophils in cancer.,” Immunobiology, 
vol. 218, no. 11, pp. 1402–10, Nov. 2013. 
[191] N. Gungor et al., “Genotoxic effects of neutrophils and hypochlorous acid,” 
Mutagenesis, vol. 25, no. 2, pp. 149–154, Mar. 2010. 
[192] Y. Feng, C. Santoriello, M. Mione, A. Hurlstone, and P. Martin, “Live imaging of 
innate immune cell sensing of transformed cells in zebrafish larvae: parallels 
between tumor initiation and wound inflammation.,” PLoS Biol., vol. 8, no. 12, 
p. e1000562, Jan. 2010. 
[193] Y. Feng, S. Renshaw, and P. Martin, “Live imaging of tumor initiation in 
zebrafish larvae reveals a trophic role for leukocyte-derived PGE₂.,” Curr. Biol., 
vol. 22, no. 13, pp. 1253–9, Jul. 2012. 
[194] G. Streisinger, C. Walker, N. Dower, D. Knauber, and F. Singer, “Production of 
clones of homozygous diploid zebra fish (Brachydanio rerio).,” Nature, 1981. 
[195] J. P. Briggs, “The zebrafish: a new model organism for integrative physiology.,” 
Am. J. Physiol. Regul. Integr. Comp. Physiol., 2002. 
[196] G. J. Lieschke and P. D. Currie, “Animal models of human disease: zebrafish 
 159 
swim into view,” Nat. Rev. Genet., vol. 8, no. 5, pp. 353–367, May 2007. 
[197] M. Westerfield, The zebrafish book: A guide for the laboratory use of zebrafish 
(Danio rerio)., 4th ed. Univ. of Oregon Press, 2000. 
[198] C. M. Bennett et al., “Myelopoiesis in the zebrafish, Danio rerio.,” Blood, vol. 
98, no. 3, pp. 643–51, 2001. 
[199] D. Traver et al., “The Zebrafish as a Model Organism to Study Development of 
the Immune System,” Adv. Immunol., vol. 81, pp. 254–330, 2003. 
[200] W. Driever et al., “A genetic screen for mutations affecting embryogenesis in 
zebrafish.,” Development, vol. 123, pp. 37–46, Dec. 1996. 
[201] P. Haffter et al., “The identification of genes with unique and essential 
functions in the development of the zebrafish, Danio rerio.,” Development, vol. 
123, pp. 1–36, Dec. 1996. 
[202] C. M. McCallum, L. Comai, E. A. Greene, and S. Henikoff, “Targeted screening 
for induced mutations,” Nat. Biotechnol., vol. 18, no. 4, pp. 455–457, Apr. 
2000. 
[203] A. Nasevicius and S. C. Ekker, “Effective targeted gene ‘knockdown’ in 
zebrafish,” Nat. Genet., vol. 26, no. 2, pp. 216–220, Oct. 2000. 
[204] K. Kawakami, “Transgenesis and gene trap methods in zebrafish by using the 
Tol2 transposable element.,” Methods Cell Biol., vol. 77, pp. 201–22, 2004. 
[205] R. T. Peterson, B. A. Link, J. E. Dowling, and S. L. Schreiber, “Small molecule 
developmental screens reveal the logic and timing of vertebrate 
development,” Proc. Natl. Acad. Sci., vol. 97, no. 24, pp. 12965–12969, Nov. 
2000. 
[206] R. T. Peterson et al., “Chemical suppression of a genetic mutation in a zebrafish 
model of aortic coarctation,” Nat. Biotechnol., vol. 22, no. 5, pp. 595–599, May 
2004. 
[207] H. M. Stern et al., “Small molecules that delay S phase suppress a zebrafish 
bmyb mutant.,” Nat. Chem. Biol., vol. 1, no. 7, pp. 366–70, Dec. 2005. 
[208] R. D. Murphey, H. M. Stern, C. T. Straub, and L. I. Zon, “A Chemical Genetic 
Screen for Cell Cycle Inhibitors in Zebrafish Embryos,” Chem. Biol. Drug Des., 
 160 
vol. 68, no. 4, pp. 213–219, Oct. 2006. 
[209] R. M. White et al., “DHODH modulates transcriptional elongation in the neural 
crest and melanoma,” Nature, vol. 471, no. 7339, pp. 518–522, Mar. 2011. 
[210] G. B. Pliss, M. A. Zabezhinski, A. S. Petrov, and V. V Khudoley, “Peculiarities of 
N-nitramines carcinogenic action.,” Arch. Geschwulstforsch., vol. 52, no. 8, pp. 
629–34, 1982. 
[211] R. White, K. Rose, and L. Zon, “Zebrafish cancer: the state of the art and the 
path forward,” Nat. Rev. Cancer, vol. 13, no. 9, pp. 624–636, Aug. 2013. 
[212] D. M. Langenau et al., “Myc-induced T cell leukemia in transgenic zebrafish.,” 
Science (80-. )., vol. 299, no. 5608, pp. 887–90, Feb. 2003. 
[213] E. E. Patton et al., “BRAF mutations are sufficient to promote nevi formation 
and cooperate with p53 in the genesis of melanoma.,” Curr. Biol., vol. 15, no. 
3, pp. 249–54, Feb. 2005. 
[214] M. Dovey, R. M. White, and L. I. Zon, “Oncogenic NRAS Cooperates with p53 
Loss to Generate Melanoma in Zebrafish,” Zebrafish, vol. 6, no. 4, pp. 397–404, 
Dec. 2009. 
[215] C. J. Ceol et al., “The histone methyltransferase SETDB1 is recurrently amplified 
in melanoma and accelerates its onset.,” Nature, vol. 471, no. 7339, pp. 513–
7, Mar. 2011. 
[216] C. K. Kaufman et al., “A zebrafish melanoma model reveals emergence of 
neural crest identity during melanoma initiation.,” Science, vol. 351, no. 6272, 
p. aad2197, Jan. 2016. 
[217] L. A. Rudner et al., “Shared acquired genomic changes in zebrafish and human 
T-ALL.,” Oncogene, vol. 30, no. 41, pp. 4289–96, Oct. 2011. 
[218] D. W. Laux, L. Kelly, I. Ribeiro, T. Ramezani, and Y. Feng, Live imaging the 
earliest host innate immune response to preneoplastic cells using a zebrafish 
inducible KalTA4-ERT2/UAS system, vol. 138. Elsevier Ltd, 2016. 
[219] N. Yamamoto et al., “Measurement of Glucose Uptake in Cultured Cells,” in 
Current Protocols in Pharmacology, vol. 55, no. 1, Hoboken, NJ, USA: John 
Wiley & Sons, Inc., 2011, p. 12.14.1-12.14.22. 
 161 
[220] I. Zaimenko, J. Lisec, U. Stein, and W. Brenner, “Approaches and techniques to 
characterize cancer metabolism in vitro and in vivo,” Biochim. Biophys. Acta - 
Rev. Cancer, vol. 1868, no. 2, pp. 412–419, 2017. 
[221] I. Agilent Technologies, “Seahorse XF e Extracellular Flux Analyzers: The 
World’s most advanced metabolic analyzers,” 2016. 
[222] I. Agilent Technologies, “Agilent Seahorse XF Cell Mito Stress Test Kit: A 
Complete Profile of Mitochondrial Function,” 2016. 
[223] I. Agilent Technologies, “Agilent Technologies Agilent Seahorse XF Glycolysis 
Stress Test Kit,” 2017. 
[224] M. O. Yuneva et al., “The metabolic profile of tumors depends on both the 
responsible genetic lesion and tissue type.,” Cell Metab., vol. 15, no. 2, pp. 
157–70, Feb. 2012. 
[225] H. Xie et al., “Targeting lactate dehydrogenase--a inhibits tumorigenesis and 
tumor progression in mouse models of lung cancer and impacts tumor-
initiating cells.,” Cell Metab., vol. 19, no. 5, pp. 795–809, May 2014. 
[226] K. Sellers et al., “Pyruvate carboxylase is critical for non–small-cell lung cancer 
proliferation,” J. Clin. Invest., vol. 125, no. 2, pp. 687–698, Feb. 2015. 
[227] S. Hayashi et al., “A novel application of metabolomics in vertebrate 
development,” Biochem. Biophys. Res. Commun., vol. 386, no. 1, pp. 268–272, 
Aug. 2009. 
[228] E. S. Ong, C. F. Chor, L. Zou, and C. N. Ong, “A multi-analytical approach for 
metabolomic profiling of zebrafish (Danio rerio) livers,” Mol. BioSyst., vol. 5, 
no. 3, pp. 288–298, Feb. 2009. 
[229] S.-M. Huang, F. Xu, S. H. Lam, Z. Gong, and C. N. Ong, “Metabolomics of 
developing zebrafish embryos using gas chromatography- and liquid 
chromatography-mass spectrometry,” Mol. Biosyst., vol. 9, no. 6, p. 1372, May 
2013. 
[230] V. Dunet, C. Rossier, A. Buck, R. Stupp, and J. O. Prior, “Performance of 18F-
fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary 
brain tumor: a systematic review and Metaanalysis.,” J. Nucl. Med., vol. 53, no. 
 162 
2, pp. 207–14, Feb. 2012. 
[231] A. Chalkidou, D. B. Landau, E. W. Odell, V. R. Cornelius, M. J. O’Doherty, and P. 
K. Marsden, “Correlation between Ki-67 immunohistochemistry and 18F-
fluorothymidine uptake in patients with cancer: A systematic review and meta-
analysis.,” Eur. J. Cancer, vol. 48, no. 18, pp. 3499–513, Dec. 2012. 
[232] H. Jadvar, “Positron emission tomography in imaging evaluation of staging, 
restaging, treatment response, and prognosis in prostate cancer,” Abdom. 
Radiol., vol. 41, no. 5, pp. 889–898, May 2016. 
[233] I. Grassi et al., “The clinical use of PET with (11)C-acetate.,” Am. J. Nucl. Med. 
Mol. Imaging, vol. 2, no. 1, pp. 33–47, 2012. 
[234] M. M. Santoro, “Zebrafish as a model to explore cell metabolism.,” Trends 
Endocrinol. Metab., vol. 25, no. 10, pp. 546–54, Oct. 2014. 
[235] V. V Belousov et al., “Genetically encoded fluorescent indicator for 
intracellular hydrogen peroxide,” Nat. Methods, vol. 3, no. 4, pp. 281–286, Apr. 
2006. 
[236] K. Santhakumar et al., “A Zebrafish Model to Study and Therapeutically 
Manipulate Hypoxia Signaling in Tumorigenesis,” Cancer Res., vol. 72, no. 16, 
pp. 4017–4027, Aug. 2012. 
[237] G. B. Waypa et al., “Hypoxia triggers subcellular compartmental redox 
signaling in vascular smooth muscle cells.,” Circ. Res., vol. 106, no. 3, pp. 526–
35, Feb. 2010. 
[238] A. San Martín, S. Ceballo, I. Ruminot, R. Lerchundi, W. B. Frommer, and L. F. 
Barros, “A Genetically Encoded FRET Lactate Sensor and Its Use To Detect the 
Warburg Effect in Single Cancer Cells,” PLoS One, vol. 8, no. 2, 2013. 
[239] A. San Martín et al., “Imaging mitochondrial flux in single cells with a FRET 
sensor for pyruvate.,” PLoS One, vol. 9, no. 1, p. e85780, Jan. 2014. 
[240] J. Berg, Y. P. Hung, and G. Yellen, “A genetically encoded fluorescent reporter 
of ATP:ADP ratio,” Nat. Methods, vol. 6, no. 2, pp. 161–6, Jan. 2009. 
[241] M. Tantama, J. Ramón Martínez-Franc¸ois, R. Mongeon, and G. Yellen, 
“Imaging energy status in live cells with a fluorescent biosensor of the 
 163 
intracellular ATP-to-ADP ratio,” Nat. Commun., vol. 4, p. 2550, 2013. 
[242] Y. P. Hung, J. G. Albeck, M. Tantama, and G. Yellen, “Imaging cytosolic NADH-
NAD(+) redox state with a genetically encoded fluorescent biosensor.,” Cell 
Metab., vol. 14, no. 4, pp. 545–54, Oct. 2011. 
[243] D. Balciunas et al., “Harnessing a High Cargo-Capacity Transposon for Genetic 
Applications in Vertebrates,” PLoS Genet., vol. 2, no. 11, p. e169, 2006. 
[244] C. Hall, M. V. Flores, T. Storm, K. Crosier, and P. Crosier, “The zebrafish 
lysozyme C promoter drives myeloid-specific expression in transgenic fish.,” 
BMC Dev. Biol., vol. 7, p. 42, 2007. 
[245] R. Marín-Juez, M. Rovira, D. Crespo, M. van der Vaart, H. P. Spaink, and J. V 
Planas, “GLUT2-mediated glucose uptake and availability are required for 
embryonic brain development in zebrafish.,” J. Cereb. blood flow Metab., vol. 
35, no. 1, pp. 74–85, Jan. 2015. 
[246] M. Distel, M. F. Wullimann, and R. W. Köster, “Optimized Gal4 genetics for 
permanent gene expression mapping in zebrafish.,” Proc. Natl. Acad. Sci. U. S. 
A., vol. 106, no. 32, pp. 13365–70, Aug. 2009. 
[247] Y. Takasaki, J. S. Deng, and E. M. Tan, “A nuclear antigen associated with cell 
proliferation and blast transformation.,” J. Exp. Med., vol. 154, no. 6, pp. 1899–
909, Dec. 1981. 
[248] R. Bravo, R. Frank, P. A. Blundell, and H. Macdonald-Bravo, “Cyclin/PCNA is the 
auxiliary protein of DNA polymerase-δ,” Nature, vol. 326, no. 6112, pp. 515–
517, Apr. 1987. 
[249] W. L. Richards, M. K. Song, H. Krutzsch, R. P. Evarts, E. Marsden, and S. S. 
Thorgeirsson, “Measurement of cell proliferation in microculture using 
hoechst 33342 for the rapid semiautomated microfluorimetric determination 
of chromatin DNA,” Exp. Cell Res., vol. 159, no. 1, pp. 235–246, 1985. 
[250] R. A. Blaheta, M. Franz, M. K. H. Auth, H. J. C. Wenisch, and B. H. Markus, “A 
rapid non-radioactive fluorescence assay for the measurement of both cell 
number and proliferation,” J. Immunol. Methods, vol. 142, no. 2, pp. 199–206, 
Sep. 1991. 
 164 
[251] A. Salic and T. J. Mitchison, “A chemical method for fast and sensitive detection 
of DNA synthesis in vivo,” Proc. Natl. Acad. Sci., vol. 105, no. 7, pp. 2415–2420, 
Feb. 2008. 
[252] M. van Engeland, L. J. Nieland, F. C. Ramaekers, B. Schutte, and C. P. 
Reutelingsperger, “Annexin V-affinity assay: a review on an apoptosis 
detection system based on phosphatidylserine exposure.,” Cytometry, vol. 31, 
no. 1, pp. 1–9, Jan. 1998. 
[253] Y. Gavrieli, Y. Sherman, and S. A. Ben-Sasson, “Identification of Programmed 
Cell Death In Situ via Specific Labeling of Nuclear DNA Fragmentation,” J. Cell 
Biol., vol. 119, no. 3, pp. 493–501, 1992. 
[254] J. Yuan, S. Shaham, S. Ledoux, H. M. Ellis, and H. R. Horvitz, “The C. elegans cell 
death gene ced-3 encodes a protein similar to mammalian interleukin-1β-
converting enzyme,” Cell, vol. 75, no. 4, pp. 641–652, Nov. 1993. 
[255] M. O. Hengartner, “The biochemistry of apoptosis,” Nature, vol. 407, no. 6805, 
pp. 770–776, Oct. 2000. 
[256] S. Elmore, “Apoptosis: A Review of Programmed Cell Death,” Toxicol. Pathol., 
vol. 35, pp. 495–516, 2007. 
[257] S. Mazumder, D. Plesca, and A. Almasan, “Caspase-3 Activation is a Critical 
Determinant of Genotoxic Stress-Induced Apoptosis,” in Apoptosis and Cancer, 
Totowa, NJ: Humana Press, 2008, pp. 13–21. 
[258] C. B. Kimmel, W. W. Ballard, S. R. Kimmel, B. Ullmann, and T. F. Schilling, 
“Stages of embryonic development of the zebrafish.,” Dev. Dyn., vol. 203, no. 
3, pp. 253–310, 1995. 
[259] H. S. Huitfeldt, A. Heyden, O. P. F. Clausen, E. V. Thrane, D. Roop, and S. H. 
Yuspa, “Altered regulation of growth and expression of differentiation-
associated keratins in benign mouse skin tumors,” Carcinogenesis, vol. 12, no. 
11, pp. 2063–2067, 1991. 
[260] T. Tamura, S. Said, W. Lu, and D. Neufeld, “Specificity of Tunel Method 
Depends on Duration of Fixation,” Biotech. Histochem., vol. 75, no. 4, pp. 197–
200, Jan. 2000. 
 165 
[261] N. Taguchi, N. Ishihara, A. Jofuku, T. Oka, and K. Mihara, “Mitotic 
phosphorylation of dynamin-related GTPase Drp1 participates in 
mitochondrial fission.,” J. Biol. Chem., vol. 282, no. 15, pp. 11521–9, Apr. 2007. 
[262] M. Liesa, M. Palacín, and A. Zorzano, “Mitochondrial Dynamics in Mammalian 
Health and Disease,” Physiol. Rev., vol. 89, no. 3, pp. 799–845, Jul. 2009. 
[263] D. Senft and Z. A. Ronai, “Regulators of mitochondrial dynamics in cancer,” 
Curr. Opin. Cell Biol., vol. 39, no. Table 1, pp. 43–52, 2016. 
[264] A. Cassidy-Stone et al., “Chemical inhibition of the mitochondrial division 
dynamin reveals its role in Bax/Bak-dependent mitochondrial outer 
membrane permeabilization.,” Dev. Cell, vol. 14, no. 2, pp. 193–204, Feb. 2008. 
[265] G. T. Hanson et al., “Investigating mitochondrial redox potential with redox-
sensitive green fluorescent protein indicators.,” J. Biol. Chem., vol. 279, no. 13, 
pp. 13044–53, Mar. 2004. 
[266] P. Niethammer, C. Grabher, A. T. Look, and T. J. Mitchison, “A tissue-scale 
gradient of hydrogen peroxide mediates rapid wound detection in zebrafish,” 
Nature, vol. 459, no. 7249, pp. 996–999, Jun. 2009. 
[267] F. Hirschhaeuser, U. G. A. Sattler, and W. Mueller-Klieser, “Lactate: a metabolic 
key player in cancer.,” Cancer Res., vol. 71, no. 22, pp. 6921–5, Nov. 2011. 
[268] B. M. Heckman-Stoddard, A. DeCensi, V. V. Sahasrabuddhe, and L. G. Ford, 
“Repurposing metformin for the prevention of cancer and cancer recurrence,” 
Diabetologia, vol. 60, no. 9, pp. 1639–1647, 2017. 
[269] B. J. Quinn, H. Kitagawa, R. M. Memmott, J. J. Gills, and P. A. Dennis, 
“Repositioning metformin for cancer prevention and treatment,” Trends 
Endocrinol. Metab., vol. 24, no. 9, pp. 469–480, 2013. 
[270] W. Pendergrass, N. Wolf, and M. Pool, “Efficacy of MitoTracker GreenTM and 
CMXRosamine to measure changes in mitochondrial membrane potentials in 
living cells and tissues,” Cytom. Part A, vol. 61, no. 2, pp. 162–169, Oct. 2004. 
[271] B. Xiao, X. Deng, W. Zhou, and E.-K. Tan, “Flow Cytometry-Based Assessment 
of Mitophagy Using MitoTracker,” Front. Cell. Neurosci., vol. 10, p. 76, Mar. 
2016. 
 166 
[272] K. D. Stackley, C. C. Beeson, J. J. Rahn, and S. S. L. Chan, “Bioenergetic profiling 
of zebrafish embryonic development,” PLoS One, vol. 6, no. 9, 2011. 
[273] Y. Gibert, S. L. McGee, and A. C. Ward, “Metabolic profile analysis of zebrafish 
embryos.,” J. Vis. Exp., no. 71, p. e4300, Jan. 2013. 
[274] S. S. Korshunov, V. P. Skulachev, and A. A. Starkov, “High protonic potential 
actuates a mechanism of production of reactive oxygen species in 
mitochondria,” FEBS Lett., vol. 416, no. 1, pp. 15–18, Oct. 1997. 
[275] J. E. Bestman, K. D. Stackley, J. J. Rahn, T. J. Williamson, and S. S. L. Chan, “The 
cellular and molecular progression of mitochondrial dysfunction induced by 
2,4-dinitrophenol in developing zebrafish embryos.,” Differentiation, vol. 89, 
no. 3–4, pp. 51–69, Jan. 2015. 
[276] B. . Hames and N. . Hooper, Instant Notes: Biochemistry, Second Edi. Oxford: 
Bios Scientific Publishers Ltd., 2000. 
[277] D. Fraher, A. Sanigorski, N. A. Mellett, P. J. Meikle, A. J. Sinclair, and Y. Gibert, 
“Zebrafish Embryonic Lipidomic Analysis Reveals that the Yolk Cell Is 
Metabolically Active in Processing Lipid,” Cell Rep., vol. 14, no. 6, pp. 1317–
1329, Feb. 2016. 
[278] K. E. Sant and A. R. Timme-Laragy, “Zebrafish as a Model for Toxicological 
Perturbation of Yolk and Nutrition in the Early Embryo,” Curr. Environ. Heal. 
Reports, vol. 5, no. 1, pp. 125–133, Feb. 2018. 
[279] P. G. Lloyd, C. D. Hardin, and M. Sturek, “Examining glucose transport in single 
vascular smooth muscle cells with a fluorescent glucose analog.,” Physiol. Res., 
vol. 48, no. 6, pp. 401–10, 1999. 
[280] C. Mosimann, C. K. Kaufman, P. Li, E. K. Pugach, O. J. Tamplin, and L. I. Zon, 
“Ubiquitous transgene expression and Cre-based recombination driven by the 
ubiquitin promoter in zebrafish.,” Development, vol. 138, no. 1, pp. 169–77, 
Jan. 2011. 
[281] T. Wilson and J. W. Hastings, “Bioluminescence,” Annu. Rev. Cell Dev. Biol., vol. 
14, no. 1, pp. 197–230, Nov. 1998. 
[282] S. Liu and S. D. Leach, “Zebrafish Models for Cancer,” Annu. Rev. Pathol. Mech. 
 167 
Dis, vol. 6, pp. 71–93, 2011. 
[283] M. C. Mione and N. S. Trede, “The zebrafish as a model for cancer.,” Dis. Model. 
Mech., vol. 3, no. 9–10, pp. 517–23, 2010. 
[284] C. M. Freisinger and A. Huttenlocher, “Live imaging and gene expression 
analysis in zebrafish identifies a link between neutrophils and epithelial to 
mesenchymal transition.,” PLoS One, vol. 9, no. 11, p. e112183, 2014. 
[285] C. Michailidou, M. Jones, P. Walker, J. Kamarashev, A. Kelly, and A. F. L. 
Hurlstone, “Dissecting the roles of Raf- and PI3K-signalling pathways in 
melanoma formation and progression in a zebrafish model.,” Dis. Model. 
Mech., vol. 2, no. 7–8, pp. 399–411, 2009. 
[286] S. Phane Berghmans et al., “tp53 mutant zebrafish develop malignant 
peripheral nerve sheath tumors,” PNAS, vol. 102, no. 2, pp. 407–412, 2005. 
[287] R. Di Micco et al., “Oncogene-induced senescence is a DNA damage response 
triggered by DNA hyper-replication,” Nature, vol. 444, no. 7119, pp. 638–642, 
Nov. 2006. 
 
 
 
